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INTRODUCTION AND OUTLINE OF THESIS 

INTRODUCTION 
Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that is 
due to excessive growth of both the glandular and stromal elements of the prostate 
gland. This is a very common condition in men over 40 years of age of all races 
and cultures and it may lead to troublesome lower urinary tract symptoms that 
usually result in referral to a urological clinic.' 
Previously, the therapeutic options for symptomatic benign prostatic 
enlargement mainly consisted of surgical resection of the prostate. The 
transurethral surgical approach (TURP) has dominated prostatic surgery because 
of the high success rate and low morbidity obtained in the hands of experienced 
urologists. Although it is an effective treatment for most men, it is by no means 
perfect. Approximately 20-25 percent of patients that underwent surgery do not 
have satisfactory long-term outcome with a reoperation rate up to about 15% over 
an 8 year observation period.2 3 Furthermore, there is some morbidity of this 
surgical intervention. The necessity for general or spinal anesthesia, possible blood 
transfusion (5- 10%) and infection, involves risks with a mortality rate that still 
amounts to about \%.A·5 Some degree of urinary incontinence is reported in 2-4% 
and the incidence of urethral strictures even amounts to 2-20% of patients.6,7 
Due to the aging population, the costs induced by the treatment of BPH 
represent a substantial part of health expenses in most countries.8 Because of these 
problems as well as the desire of many men to avoid surgery whenever possible, 
the management of symptomatic BPH is in transition. It now also includes medical 
management that essentially is palliative and reversible at the end of the 
treatment,9" and several procedural and minimally invasive procedures that aim 
at the definite removal of tissue.12"16 Efforts to dilate the prostatic tract by either 
balloon or stents have either been abandoned, or reserved for the unfit patient.17 '8 
The application of heat in prostatic disease has been advocated over a 
century.19 Heat is a physical agent whose biologic effects depend on the intensity, 
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duration and means of application. The majority of the interventional nonsurgical 
modalities that have emerged the last decade, apply the thermal energy to the 
prostate adenoma by either the rectal or urethral route. Different heat applicators 
have been used, varying from laser-devices to high intensity focused ultrasound 
and radiofrequency. Presently, the major drawback of these options still is the 
necessity for anesthesia. The use of microwave as a heat source, has been 
extensively investigated. Pioneer microwave research efforts in the early 1980's 
were focused on the use of hyperthermia by applying microwave heat rectally or 
urethrally. It eventually became apparent that with hyperthermia the aimed 
temperature of 45°C or less, wasn't effective and higher temperatures were 
required. This led to development of transurethral microwave thermotherapy that 
was designed to apply microwave energy deep within lateral prostatic lobes, whilst 
simultaneously cooling the urethral mucosa thus enabling an outpatient based 
anesthesia-free procedure.16 
The rational behind microwave thermotherapy 
Microwaves comprise the 300-3000 MHz range of the appropriate electromagnetic 
spectrum. The entire spectrum of electromagnetic waves (X-rays, visible light, 
infrared) can interact with living matter, but the mechanisms of interactions are not 
the same on the entire frequency range. The interaction with microwaves results 
in the heating of biological tissue. 
As microwaves propagate through biological tissue, energy is transferred to 
heat via electromagnetic field oscillation of free charges (electrons and ions) and 
by polarization of small molecules (mainly Hfi). The resulting molecular kinetic 
energy raises the temperature of the tissue and causes heating. The penetration of 
microwaves is greater in low-water content tissue (fat) than in high-water content 
tissue (muscle). Moreover, the higher the frequency, the less the penetration. 
Consequently, the depth of the penetration is dependent on the frequency and the 
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predominant type of targeted tissues, and at any time given frequency, penetration 
also varies with the temperature. Unfortunately, the waves are refracted, reflected, 
and dispersed when met with tissue inhomogeneities. Furthermore, tissue 
temperatures in a microwave field depend, not only on the energy extracted, but 
also on the thermal conduction and convection related to tissue perfusion. 
With thermotherapy the transurethral route was chosen to deliver the 
microwave energy through a flexible applicator. A frequency of 1296 MHz was 
chosen, since the isothermic field shows a concentric heat distribution more or less 
following the anatomical borders of the transition zone of the prostate and not 
reaching the maximum temperature in the rectal mucosa. The goal of heating is to 
destroy tissue by achieving temperatures that exceed the cytotoxic threshold and 
induces cell death. The cytotoxic thermal threshold for prostatic adenomatous 
tissue is 45°C for 30 minutes.16 However, the threshold depends on the cell type 
and thus when heterogenous tissue is treated, not all cells within the treated area 
will die. Furthermore, small capillaries are thrombosed, whereas larger vessels are 
spared because they are cooled by blood flow. 
In order to destroy intraprostatic tissue at a depth of 10 to 15 mm from the 
urethra, the required power would raise the temperature at the urethral level to 75° 
to 80° С (figure 1 A). Therefore, to avoid heating of the urethral mucosa, which is 
rich in pain receptors, the urethral temperature should be no more than 45°C, 
which is the thermal pain threshold, the urethra is cooled. Whereas microwave 
heating is depending on radiation penetrating tissue, cooling is based on 
conductivity which has a limited action. These two principles, radiative heating 
and conductive cooling, result in a temperature curve with a steep ascending slope 
and a progressive 'descending' slope (figure IB). In this manner, deep within the 
prostate temperatures exceed the cell toxicity threshold with consequent tissue 
destruction, whereas the urethral mucosa remains spared. And in this way, the 
urethral temperatures maintain below the thermal pain threshold which enables the 
treatment to be performed without the need for anesthesia. 
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Figure 1. Transurethral microwave therapy (TUMT) concept (x axis: distance in cm from 
antenna in the urethra; y-axis: temperature in °C. A) Microwave heating pattern 
shows the energy needed to induce deep tissue necrosis would raise 
temperature to 70-80°C in the urethra. B) Combination of deep radiative heating 
and superficial conductive heating leads to an asymmetrical temperature profile, 
with a steep ascending slope and a progressive descending slope. 
30 mm 40 mm 
Radiative Heating 
Resulting 
Thermotherapeutic 
Profile 
Basal Temperature 
Conductive Cooling 
20 mm 30 mm 40 mm 50 mm 
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(Graphs courtesy of Vincent Cabane) 
Figure 2. The Prostatron device with treatment couch and control module 
Material and methods 
The Prostatron device 
The Prostatron is an integrated unit consisting of a microwave generator, a urethral 
cooling system, a fiberoptic temperature-monitoring system and a treatment couch 
(figure 2). The Prostatron is controlled by a dedicated computer software system 
(Prostasoft version 2.0: lower energy protocol; version 2.5: high energy protocol) 
operated from the separate control module. The device is used in conjunction with 
a disposable transurethral applicator and rectal thermometry probe (figure 3). The 
microwave antenna is mounted within a flexible 20F urethral applicator with a 
Foley balloon self-retaining device. The treatment applicator contains two 
channels for the circulation of the coolant. The tip of the thermosensor is 
positioned beneath the surface of the catheter to measure the applicator surface 
temperature at the hottest point of the microwave field. The antenna is positioned 
15 
Figure 3. Microwave transurethral catheter delivery system with rectal temperature probe 
in a precise relation to the Foley balloon so that the predictable microwave field 
can treat the greatest volume of the prostate without compromising the external 
sphincter. 
The integral thermometry system is of the optical fiber type, designed to 
measure temperature accurately within a microwave field, and is consistently 
accurate to 0.1 °C. In addition to the urethral thermosensor, three further fibers are 
mounted on a rectal probe to monitor the temperature of the anterior rectal wall. 
The rectal thermosensors are placed at 80, 90, and 100 mm from the anal verge, 
positions which have been shown to indicate the maximum rectal wall 
temperature most reliably during treatment. 
The cooling system is comprised of both a refrigeration and a heating unit 
providing precise control of applicator temperature during treatment. The coolant 
is circulated at a constant rate, although the temperature can be varied from 20° 
to 40°C. The microprocessor controls the power output of the Prostatron in 
response to preset parameters of achieved temperature within the rectal and 
urethral thermosensors. Multiple safely devices are incorporated to prevent the 
excessive or misplaced delivery of energy, and the treatment remains under the 
physician's control at all times. The treatment profile with temperature readings 
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from all four sensors (1 urethral and 3 rectal) and energy output is displayed on 
a video monitor and recorded by a computer for subsequent analysis. 
The technique 
The patient is placed on the treatment couch in supine position. After disinfecting 
the penis and applying lidocaine jelly transurethrally, the bladder is emptied with 
a 14 Ch Lofric catheter and refilled with 50 ml of saline. The sterilized treatment 
catheter is then inserted and the balloon inflated with 20 ml of saline and the 
catheter is withdrawn until the balloon is gently resting at the bladder neck. With 
the patient positioned in the left lateral position, the rectal temperature probe is 
then inserted with the temperature sensors directed towards the prostate. 
After checking the catheter's correct position by abdominal ultrasound, the 
catheter module is connected to the Prostatron and the machine is switched on. 
After calibration of the temperature sensors, the physician starts the microwave 
power application at 20 W. The power level is increased every 2 minutes to a 
maximum of 60 W with Prostasoft 2.0 and 70 W with Prostasoft 2.5. The coolant 
temperature is kept at 20°C until the maximum power is achieved or after 20 
minutes. Thereafter, the coolant temperature is increased to a maximum of 
44.5°C. If the temperature in the urethral applicator sensor exceeds 44.5°C, the 
microwave power is stopped until it cools to 44°C. The rectal alarm is set at 
42.5°C with Prostasoft 2.0 and at 43.5°C with Prostasoft 2.5. The treatment is 
continued for 60 minutes from the start of the microwave application. At the 
conclusion of the treatment, the urethral and rectal probes are removed. With the 
Prostasoft 2.0 protocol, patients were asked to remain in the department until 
satisfactory voiding had been established. In case of urinary retention or with the 
Prostasoft 2.5 protocol, patients received a transurethral catheter and were set up 
with a leg-bag and discharged home. Depending on the protocol, patients were 
usually seen for outpatient control one week after treatment. 
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Symptom scores 
The first TUMT treatments were performed in 1990. At that time the most 
commonly used symptom score was the Madsen-Iversen symptom score.20 In an 
attempt to standardize the preoperative evaluation of patients with no absolute 
indication for surgery, Madsen and Iversen developed a point system in which the 
various symptoms and objective findings are graded according to severity. This 
physician guided questionnaire grades the quality of the urinary stream, straining 
to void, hesitancy, intermittency, sensation of bladder emptying, stress 
incontinence or postmicturition dribbling, and symptoms of urgency, frequency 
and nocturia. The symptoms are graded on a scale of 0-4 and scores are tabulated 
(Table 1). The total score can vary between 0 - 25 points. A Madsen-Iversen score 
of 8 or more has been the entry level for all the studies. 
Table 1 Madsen-Iversen Symptom score sheet 
Symptom 
Stream 
Voiding 
Hesitancy 
Intermittency 
Bladder 
emptying 
Incontinence 
Urge 
Nocturia 
Diuria 
0 
Normal 
No strain 
None 
None 
Do not know 
or complete 
None 
None 
0 - 1 
q > 3h 
1 
Variable 
-
-
-
Variable 
-
Mild 
2 
q2-3h 
2 
-
Abdominal strain 
-
-
Incomplete 
Yes (including 
terminal dribbling) 
Moderate 
3 - 4 
q1-2h 
3 
Weak 
-
Yes 
Yes 
Single 
retention 
-
Severe 
>4 
q<1h 
4 
Dribbling 
-
-
-
Repeated 
retention 
-
-
-
-
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OUTLINE OF THESIS 
All treatments for lower urinary tract symptoms and benign prostatic 
enlargement contain possible 'placebo' effects. In chapter 1, the results of a 
randomized placebo controlled study of transurethral microwave thermotherapy 
(TUMT) versus Sham are presented. It reports on three months data of one center, 
and the combined data at 1 year follow-up of two European centers. 
The clinical results of transurethral microwave thermotherapy show a clear 
separation between patients who respond favorably to TUMT in both subjective 
and objective parameters and patients who do not respond at all. Chapter 2 
reports on a multi center international study that enlightens the differences in 
treatment outcome between responders and nonresponders to thermotherapy. In 
seventeen centers, 292 patients were included in the study retrospectively. The 
baseline clinical variables were correlated with variables derived from the 
treatment profiles. 
The durability and long-term followup results of thermotherapy are 
presented in chapter 3. A total of 305 patients who underwent TUMT at two 
different centers, was analyzed retrospectively. Improvement in subjective and 
objective variables are noted over a three-year followup period. Furthermore, the 
fate of the patients in case of retreatment by either medical therapy or invasive 
intervention and possible side-effects on short and long term are also discussed. 
Although symptomatic improvement after TUMT is very comparable to 
that achieved with a surgical resection of the prostate, the objective improvement 
was less pronounced. Chapter 4 reports on the initial results of a phase II study 
in patients treated with high energy thermotherapy. Both multi center data on I 16 
patients, and one year followup data on 85 patients are presented. Not only the 
common study variables as symptom scores and uroflowmetry variables, but also 
urodynamics with pressure-flow study variables are used in these two studies. 
Significant urodynamic changes after lower energy thermotherapy have 
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been reported in earlier studies. On the other hand the reduction of bladder outlet 
obstruction was not comparable to that achieved after a surgical resection of the 
prostate. Chapter 5 documents the urodynamic changes of pressure-flow study 
parameters after high energy thermotherapy. Data of 120 patients are analyzed. 
Furthermore, possible selection criteria to enhance treatment outcome are 
identified. 
Finally, in chapter 6 the current status of thermotherapy in the complete 
armamentarium of treatment options for patients with lower urinary tract 
symptoms and benign prostatic enlargement is reviewed. 
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Chapter 1 
TUMT VERSUS SHAM 
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FMJ Debruyne. 
Transurethral Microwave Thermotherapy (TUMT) in benign prostatic 
hyperplasia: Placebo versus TUMT. 
Urology, 40: 58-63,1994 
MJAM de Wildt, M Hubregtse, CW Ogden, SStC Carter, FMJ Debruyne and 
JJMCH de la Rosette. 
A 12-month study of the placebo effect in transurethral microwave 
thermotherapy. 
British Journal of Urology, 77:221-227, 1996 

PLACEBO VERSUS TUMT 
SUMMARY 
A prospective, randomized placebo-controlled study was designed to exclude a 
placebo response in transurethral microwave thermotherapy (TUMT). During a 
sham procedure, the microwave applicator was installed in the urethra as in the 
real TUMT treatment and a complete procedure was simulated by the microwave 
delivery system (Prostatron). Any patient who entered this study had the option 
to request a second real TUMT treatment if, 3 months after the initial procedure 
his condition had not improved. A total of 48 patients were available for 
evaluation at 3 months and 28 at 6 months. The TUMT group had an average 
decrease of 7.3 points (from 13.2 to 5.9) in the Madsen symptom score, an average 
increase in flowrate of 3.4 ml/s (9.6 to 13.0), and an increase in voiding 
percentage of 9.6% (81.7 to 91.3). All improvements were statistically significant. 
In the sham group, the average Madsen score decreased from 12.1 to 8.2 points, 
the average flowrate decreased from 9.7 to 9.5 ml/s, and the voiding percentage 
increased from 80.8% to 84.3%. Only the change in symptom score was signifi-
cant. In both groups, observations at the 3-month follow-up were similar to those 
after 6 and 12 months. Patients who had TUMT after sham treatment showed 
similar significant changes in symptom score and peak flow as observed in the 
original TUMT group. Patients who did not respond favorably to a first TUMT 
did not experience improvement after a second TUMT. A placebo effect, although 
minimal, exists. This placebo response, however, accounts for little of the 
observed benefit of TUMT. 
26 
INTRODUCTION 
It is estimated that eventually one third of all men will require treatment for relief 
of symptoms due to benign prostatic hyperplasia (BPH) .' Surgical treatment of 
the prostate is effective and relatively safe. Hospitalization and anesthesia are 
necessary. Although the mortality rate is low,2 morbidity is considerable,3"6 and 
has prompted a search for a less morbid but equally effective treatment.7-8 
Several minimally invasive treatments for patients with complaints related to BPH 
have recently been introduced.9"" The application of heat to the prostate has been 
believed to be beneficial since the earliest days of medicine. Many ingenious 
methods of heating the prostate have been described since the mid-19th century.12 
Only limited success was obtained because of the superficial nature of prostatic 
heating obtained by conduction from the urethral or rectal surface. Transurethral 
microwave thermotherapy (TUMT) uses a combination of transurethral^ 
administered radiating heat energy and conductive cooling administered via the 
urethra. This treatment results in high-power microwave application deep in the 
lateral lobes, leading to irreversible cell damage of prostatic tissue without 
damaging the urethra. Early results of TUMT seem very promising, although a 
placebo effect has not yet been excluded.13 We conducted a randomized, double-
blind, placebo-controlled study In this article we will describe the results of a 
TUMT-sham study. 
MATERIAL AND METHODS 
From June 1991 to December 1992, 50 men aged 50 to 79 years (average, 63.6) 
with symptoms of BPH were randomized to receive TUMT or sham treatment. 
The major inclusion and exclusion criteria for treatment are shown in Table 1. For 
this study we used the Prostasoft 2.0 version. Screening included a general history, 
27 
complete physical examination, estimations of full blood count, urea, creatinine, 
urine microscopy, and culture. Urine cytology and prostate-specific antigen (PSA) 
levels were always measured in order to exclude coexisting malignancy The 
severity of symptoms was scored according to the Madsen FDA symptom score.14 
Uroflowmetry (peak flow Qmax) was performed twice with a minimum voided 
volume of 100 ml. Residual urine was measured with transabdominal ultrasound. 
We also computed the voiding percentage ([voided volume/bladder volume] χ 
100), as a measure of voiding efficiency A transrectal ultrasound of the prostate 
(TRUS) was performed to measure the volume of the prostate (stepwise 
measurement according to Hastak et al.,15 and to determine the prostate configu­
ration. Flexible urethrocystoscopy was used to verify patency of the urethra, and 
also to look for an enlargement of the middle lobe and for signs of malignancy. 
A minimum prostatic urethra length of 3 5 cm was required in order to be able to 
give treatment without risk of damage to the urethral sphincter by the microwave 
energy. All patients with an abnormal rectal examination, PSA values more than 
10 ng/ml (Hybritech), and/or abnormal TRUS underwent biopsy. 
Table 1 Inclusion and exclusion entena for TUMT treatment 
Inclusion Criteria Exclusion Criteria 
Prostate volume > 30 cm3 Prostatic carcinoma 
Length of prostatic urethra > 35 Bacterial prostatitis 
Age > 45 years Urethral stricture 
Duration of symptoms > 3 months Neurogenic bladder dysfunction 
Madsen symptom score > 8 points Urinary tract infection 
Peak uroflow < 15 ml/s Use of drugs influencing bladder 
History of TURP or TUIP 
Diabetes mellitus 
Isolated enlargement of the middle lobe 
Bladder residual urine > 250 ml 
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Patients were randomized after informed consent had been obtained. The 
procedure for the real TUMT treatment has been described extensively 
elsewhere.1'If' If the patient was randomized to receive sham treatment, the same 
procedure was performed, but no microwave energy was applied. A customized 
sham program was run on the computer to give a simulated treatment display on 
the visual display unit. 
At the end of the outpatient session, patients were asked to remain in the 
department until satisfactory voiding had been established. In the event of urinary 
retention a urethral catheter was inserted for 1 week. Patients were seen 1,6, 12, 
26, and 52 weeks after treatment. If the patients did not experience improvement 
at 3 months, a second real TUMT was administered if requested. 
Statistical analysis within each group was done with the Student's t-test (a = 0.05) 
while the Wilcoxon's signed rank test (a = 0.05) was used for comparison between 
the groups. For evaluation of the correlation between uroflow and symptom score, 
the Spearman test was used. 
RESULTS 
The average age of the TUMT group was 64 years (range, 50 to 79) and for the 
sham group 63 years (range, 52 to 78). The average prostate volume, as measured 
with TRUS, was 51 cm1 for the TUMT as well as the sham group. Fifteen patients 
received a second TUMT procedure: 11 patients in the SHAM group and 4 
patients in the TUMT group. 
There was no statistical difference between the two groups for any given 
parameter at baseline (Table 2). Forty-eight patients were available at 12 weeks 
for assessment and 28 at 24 weeks. One patient was lost to follow-up and 1 patient 
was treated by TURP. 
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Table 2 Baseline characteristics 
Mean ± SD 
Age (yr) 
Madsen score 
Prostatic volume 
Voided volume (ml) 
Residual urine (ml) 
Voiding% 
PSA (ng/ml) 
TUMT (n=25) 
64.1 ±6.0 
1 3 2 ± 3 4 
51.1 ±15.4 
270 ±124 
56.4 ± 37 7 
81 7 ±12.3 
54 ±4.5 
Sham (n=25) 
62.7 ± 5.9 
12.1 ±2.9 
51.0 ±18.8 
260 ±124 
64.6 ±51 2 
80.8 ±12.7 
4.5 ±3.5 
A statistical analysis of the difference between the two groups can only be 
made at 12 weeks, because, thereafter, patients in either group were offered 
retreatment with definitive TUMT. The number of patients in the retreatment 
groups is too small for analysis before 1 year. 
Table 3 shows the subjective and objective changes after treatment. For the 
TUMT group, a significant reduction in Madsen symptom score was shown from 
the average of 13.2 to 5.9 after 12 weeks (P = 0.0001), to 3.2 after 26 weeks and 
3.3 after 52 weeks. At 1 year follow-up, 92% still had a reduction in the severity 
of symptoms of more than 50%. In the sham group, the reduction of the symptoms 
was less pronounced, with changes from 12.1 at the onset to 8.2 after 12 weeks, 
6.8 after 26 weeks, and 9.1 after 52 weeks. Statistical evaluation after 12 weeks 
shows a significant reduction of symptom score (p = 0.001). After I year, 38% in 
the sham group still had a reduction of more than 50% in the severity of 
symptoms. Uroflowmetric results showed no improvement in the sham group, but 
in the TUMT group the average improvement after 3 months was 3.4 ml/s, which 
is statistically significant (p = 0.004). The voiding percentage improved in both 
groups, but this improvement was statistically significant (p = 0.004) only in the 
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TUMT group. 
Comparison between the sham and the TUMT group after 12 weeks showed 
a statistically significant difference with regard to symptom score improvement 
(p = 0.025) and peak flow (p = 0.019), in favor of the TUMT group. The patients 
who had a TUMT treatment after sham showed similar results compared to the 
initial TUMT group (Table 4). However, in the four patients who had a second real 
TUMT after their first one, no improvement 
Table 3. Main follow-up indices after sham treatment or TUMT 
Sham 
Qmax 
Symptom 
Voiding% 
TUMT 
Qmax 
Symptom 
Voiding% 
η 
mean 
Ρ 
mean 
Ρ 
mean 
Ρ 
η 
mean 
Ρ 
mean 
Ρ 
mean 
Ρ 
0 
25 
9.7 
12.1 
0.0001 
80.8 
0 06 
25 
9.6 
0.015 
132 
0.0001 
81 7 
0.07 
6 
23 
10.0 
0 61 
7.7 
0 0010 
84.6 
0 07 
24 
11 9 
0.004 
6 2 
0 0001 
88.7 
0.004 
Week 
12 
24 
9 5 
0 73 
82 
84.3 
24 
130 
5.9 
91 3 
26 
11 
101 
6.8 
87.6 
17 
15.3 
3 2 
93.0 
52 
7 
11.3 
9.1 
90.0 
12 
140 
3.3 
86.7 
was seen. The average prostate volume, as measured with TRUS, was 51 cm3 
before treatment, in the TUMT group and the sham group. No relation was found 
between the prostate volume and the obtained subjective and objective results. 
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As shown in Table 2, PSA serum concentrations were normal before treatment 
When measured 1 week after treatment, there was an elevation of the average PSA 
value to more than 25 ng/ml (range, 1 0 to 93.0). After 3 months, the PSA level 
returned to normal (Figs. 1 and 2) 
Table 4 Main follow-up indices of TUMT after pnor sham (sham-TUMT) 
and TUMT after pnor TUMT (TUMT-TUMT) treatment 
Sham-TUMT 
Qmax 
Symptom 
Voiding% 
TUMT-TUMT 
Qmax 
Symptom 
Voiding% 
η 
mean 
Ρ 
mean 
Ρ 
mean 
Ρ 
η 
mean 
mean 
mean 
0 
11 
8 9 
129 
82 4 
4 
8 4 
130 
89 7 
6 
11 
13 1 
0 0019 
6 5 
0 0003 
83 5 
0 85 
4 
9 3 
6 5 
93 9 
Week 
12 
11 
148 
0 003 
5 6 
0 0019 
84 7 
0 58 
4 
7 2 
7 8 
84 8 
26 
8 
15 1 
6 4 
88 9 
3 
8 3 
8 7 
80 0 
52 
0 
-
-
-
1 
8 0 
9 0 
80 8 
The predominant complication in the TUMT group was immediate post-treatment 
retention of urine in 20%. In the sham group all but one patient passed urine freely 
before leaving the department. Patients with retention were treated with a 
transurethral catheter for 1 week. All patients were free of a catheter by 6 weeks. 
Most patients had some hematuria for up to 3 days; there was, however, no 
difference between the groups. 
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Figure 1. Changes in PSA level after sham treatment and TUMT 
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Figure 2. Changes in PSA level after second TUMT 
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DISCUSSION 
Very promising changes in objective and subjective parameters after TUMT 
treatment were presented by Devonec to the American Urological Association 
(AUA) in 1990." Other studies have shown a significant and sustained 
response.13'21"23 However, symptoms in patients with BPH frequently improve 
without any explicit underlying mechanism of explanation.1819 There also may be 
an important placebo effect in device treatments, as has been shown in 
pharmacologic studies.20 It is also well known that catheterization in itself may 
have a (temporary) beneficial effect on prostatic symptoms.24 It has been 
suggested that this catheterization in itself may contribute substantially to the 
TUMT effect. The objective of this study was to evaluate the effect of TUMT 
using therapeutic temperatures within the prostate, and to compare the effects with 
a simulated TUMT treatment (sham). 
Several controlled studies have been undertaken to describe the (placebo) effect 
of TUMT treatment."16·21 In our study there was, as in the study of Ogden et al,25 
a significant increase in flowrate and reduction of symptom scores in the TUMT 
group, as well as a marked increase in the voiding percentage. However, in our 
study, the sham group also had a significant change in average symptom score 
without significant changes in peak flowrate or voiding percentage. The results of 
flowrate changes are compared to the changes in symptom score for each 
individual and shown in Figure 3. In contrast to the results of Ogden et al.,25 a 
considerable placebo effect is seen in this study for the subjective parameters. 
Also, on an individual basis, an improvement in peak flowrate may be seen in the 
sham group. Overall, however, there is a more significant improvement of changes 
in peak flowrate and symptom score in the TUMT group. The value of the voiding 
percentage seems to be of more importance than the individual values of voided 
volume or postmicturition residual urine, and represents the index of voiding 
efficacy.26 For patients receiving TUMT treatment, it is clear that the efficiency 
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of bladder emptying has improved, resulting in a decrease in frequency of 
micturition. The decrease in frequency of micturition will be reflected in the 
decrease in the symptom score. After sham treatment, the voiding percentage 
improves, although not significantly. Although there was a statistically significant 
improvement in symptom scores in both the TUMT and the sham patients, 
comparison between the two groups showed a statistically significant difference 
in favor of the TUMT group. Thus, TUMT gives a small placebo effect reflected 
in the subjective parameters. 
To our surprise, only a minor but not statistically significant correlation 
(Spearman correlation coefficient 0.38, ρ = 0.07) could be found between the 
improvement of the subjective and objective parameters for the TUMT group 
(Fig. 3). In the sham group there was no correlation (Spearman correlation 
coefficient -0.04, ρ = 0.86). We do not have any clear explanation for this finding. 
Perhaps the items of the Madsen symptom score do not correlate that well with the 
objective parameters. This may result in a patient with a good subjective 
improvement but without a significant objective result and vice versa. 
In comparing the results of treatment after 1 year of follow-up, 92% of the patients 
in the TUMT group, compared with 38% of the remaining patients in the sham 
group, still had a reduction in the severity of symptoms of more than 50%. Almost 
half of the patients treated with sham, however, opted for a second treatment 
compared with only 4 of the 25 patients in the TUMT group. Because of this 
second TUMT treatment a selection in both groups was made after 3 months. This 
results in a subgroup of patients with a "better" effect after sham treatment. 
Because of this selection, the results of these remaining patients in the sham group 
should improve. The general trend, however, remains unchanged and the 38% of 
patients with a reduction of severity of symptoms of more than 50% is, therefore, 
overestimated. Reduction of prostate volume by TUMT, if present at all, is 
limited. No significant reduction has been shown in earlier reports,16 and it is 
interesting to note that although rather bigger prostates have been treated in this 
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study the results are similar.25 We noticed a marked change in PSA level after 
TUMT, which has not been seen in the sham group (Fig. 1 ). The change in PSA 
value may be an indication of the effect of the treatment on prostatic tissue, since 
a second TUMT after an earlier sham treatment shows the same change in PSA 
levels as seen in the initial TUMT group (Fig. 2). In the four patients who had a 
second TUMT after TUMT, in both sessions almost no changes in PSA levels 
were noticed. Thus, there might be a correlation between the success of treatment 
and the detection of any PSA elevation after TUMT. It is apparent from the sham 
study that elevation of PSA and the incidence of post-treatment retention are 
uniquely associated with the application of microwave power and presumably 
consequent prostatic heating. It is possible that failure of TUMT in certain persons 
may be related to the morphologic characteristics of the prostate. A further 
histologic study of the prostate before treatment is needed to understand the 
relationship between tissue morphology and both a successful clinical outcome 
and post-treatment elevation of the PSA level. Until now there has been no report 
of such a correlation. 
CONCLUSION 
After TUMT there was a significant improvement in the objective (peak flowrate 
and voiding percentage) and subjective (symptom score) parameters. A subjective 
improvement is also noticed after sham treatment, but this was significantly less 
than after TUMT. There was no significant improvement seen in objective 
parameters after sham treatment. We may conclude that a minimal placebo effect 
exists. However, it accounts for little of the observed benefit of TUMT. 
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Figure 3. Correlation between improvement in peak flow and improvement in 
symptom score at 12 weeks after TUMTorsham treatment. 
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A 12 MONTH STUDY OF THE PLACEBO EFFECT 
SUMMARY 
To determine the placebo effect of transurethral microwave thermotherapy 
(TUMT) in the treatment of benign prostatic enlargement (ΒΡΕ), a prospective, 
randomized sham-controlled study in 93 patients (mean age 65 years, range 50-
88) was conducted at two centres comparing TUMT or sham treatment. Patients 
randomized to receive a sham treatment underwent the same initial procedure as 
for TUMT, but the complete procedure simulated on the visual display with no 
application of microwave energy. If the patients condition had not improved after 
3 months, a second genuine TUMT treatment was given at the patient's request. 
After 3 months there were significant clinical and statistical differences in efficacy 
between the groups: 62% and 18% of patients had a > 50% improvement in 
symptom score in the treated and sham groups, respectively (p=0.001). The 
corresponding changes inflow rate were 36% and 11% (p=0.002), respectively. 
After 1 year, 63 patients were divided into those that had TUMT initially and those 
that had sham initially but subsequently had TUMT and those whose sham 
procedure had led to sufficient clinical improvement to require no further 
treatment. The two treatment groups had a significant improvement over the sham 
group. The benefit from TUMT cannot be due to a placebo effect alone. 
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INTRODUCTION 
Several minimally invasive treatments for patients with symptomatic benign 
prostatic enlargement (ΒΡΕ) have been introduced recently. Some rely on 
mechanical disruption or distraction of the prostatic urethra, e.g. balloon dilatation 
or stenting ,1"3 but prostatic heating appears to be the most promising alternative. 
Heat can be delivered selectively to the prostate using different sources, e.g. high 
intensity focused ultrasound (HIFU), radiofrequency (transurethral needle 
ablation, TUNA), endoscopic lasers and microwave devices.4"8 So far, the 
microwave techniques have been the most extensively investigated. There are two 
basic concepts; one is hyperthermia, where the prostatic temperature is not 
allowed to exceed 45°С and the other is thermotherapy where the target 
temperature is greater than 45°C.9"12 Initially, research was concentrated on the use 
of hyperthermia delivered with either a transurethral or transrectal applicator. 
Hyperthermia was evaluated against sham treatment in a multicentre study in 
which five different machines (three transrectal and two transurethral) were 
tested13 and which concluded that transrectal hyperthermia was probably 
ineffective in the treatment of ΒΡΕ, and thus should not be recommended.14 
Recently, many researchers have used higher temperature microwave 
treatments or thermotherapy. The treatments deliver high power microwave 
energy deep within the lateral prostatic lobes, causing irreversible cell damage to 
prostatic tissue without damaging the urethra. Results of transurethral microwave 
thermotherapy (TUMT) are very promising, although the degree and significance 
of the placebo effect remains controversial.15 Reports from two other groups have 
suggested that the response to TUMT is significantly greater than due to any effect 
of placebo or instrumentation.16'7 A recent report by Nawrocki et al. casts doubt 
on the validity of these conclusions.18 
In this paper we present the long term results of a randomized placebo 
controlled study conducted in two centres. Moreover, we give an overview of the 
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published placebo controlled studies on TUMT and discuss the extent of the 
placebo effect in TUMT in treatment of symptomatic bladder outlet obstruction 
due to ΒΡΕ. 
PATIENTS AND METHODS 
From June 1991 to December 1992, ninety three men (mean age 65 years, range 
50 - 88) were recruited into the study. For entry into the study all patients had to 
be older than 45 and complaining of symptoms of bladder outlet obstruction for 
more than three months, have a Madsen symptom score of greater than 8 and two 
free flow rates of 15 ml/s or less on two voids of greater than 150 ml. The 
presence of ΒΡΕ was confirmed by transrectal ultrasonography (TRUS), the 
measurement of prostate specific antigen and, where necessary, by prostatic 
biopsy. Exclusion criteria were: Prostate cancer, prostatitis, urethral stricture, 
intravesical pathology (stones, neoplasm), neurogenic bladder dysfunction, urinary 
tract infection, isolated enlargement of the middle lobe, a residual urine volume 
of 300 ml or more, use of drugs influencing bladder or prostate function, previous 
transurethral resection of the prostate (TURP), a metallic pelvic implant, disorders 
of blood flow or coagulation, diabetes mellitus and mental incapacity or inability 
to give informed consent. 
The assessment before treatment consisted of a general history and complete 
physical examination. Serum creatinine, urea, and electrolytes and full blood count 
were measured, and urine was sent for microbiological and cytological analysis. 
The severity of symptoms was expressed in a Madsen symptom score.19 Flow rates 
were corrected for artefacts by two independent observers (M. H. and M. de W.) 
using the 2-second method20, with no knowledge of the patient's treatment. The 
voided volume was correlated with the post-void residual volume (PVR) to give 
a 'voiding fraction', using formula: voiding fraction=voided volume/(voided 
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volume + PVR).21 TRUS was performed to measure the dimensions and 
configuration of the prostate and prostatic volume calculated using the formula of 
Stamey and Terris.22 
The procedures for TUMT treatment have been described previously.8 When a 
patient was randomized for the placebo (Sham) treatment, the whole procedure 
was simulated but without applying microwave energy. During both active and 
SHAM procedures, a real-time treatment profile was displayed on the computer 
screen and explained to the patient. The sequence of temperature calibration and 
checks were identical in both groups. At the end of the session patients were asked 
to remain in the department until satisfactory voiding had been established. In case 
of retention, a urethral catheter was placed for one week. The baseline tests were 
repeated at 1, 12 and 52 weeks after treatment. As far as possible the patient and 
the investigator were kept unaware as to the treatment administered. When a 
patient noticed no improvement after three months, whether he had previously 
received a sham or active treatment, a second genuine TUMT was performed on 
request. 
Statistical analysis within each group was done with the Student t test (with 
significance defined as ρ < 0.05) while the Wilcoxon signed rank test and the 
Kruskal-Wallis test were used for comparisons between groups. The Chi-squared 
test was used to assess the significance of the differences in response rates 
between the groups. 
RESULTS 
There were no statistical differences between either the Sham or TUMT group 
(Table 1). Patients from the London centre were sigificantly older, had more 
symptoms particularly obstructive ones, and a greater residual urine volume than 
those at Nijmegen. 
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Table 1. Differences in baseline venables between the centres and in each treatment 
Centre 
Charing Cross 
Mean 
SD 
Nijmegen 
Mean 
SD 
p-value 
Treatment (no 
Sham (46) 
Mean 
SD 
TUMT(47) 
Mean 
SD 
TUMT after 
Sham (27) 
Mean 
SD 
p-value 
Age 
(yrs) 
67.2 
8.1 
63.4 
60 
0.016 
Pat.) 
63.9 
6.0 
66.3 
8 1 
65.8 
6.1 
0.197 
Prostate 
vol. (ml) 
46 3 
18.1 
50 8 
18.2 
0116 
49.0 
20 0 
48.6 
166 
52.0 
23.9 
0.503 
Madsen 
score 
14.2 
3.2 
126 
3.2 
0.036 
129 
3.1 
13.7 
3.4 
13.6 
2.8 
0.435 
Peak-flow 
(ml/s) 
9.1 
2.4 
9.6 
2.7 
0.269 
9.6 
2.7 
9.2 
2.5 
9.0 
33 
0.385 
PVR* 
(ml) 
132 5 
72.8 
55.2 
46 8 
<0.00 
84.7 
66.1 
93 9 
75.4 
110.0 
80.4 
0.259 
Voided 
fraction(%) 
67 3 
15.8 
83 0 
128 
<0 001 
77.3 
15.7 
74.9 
16.6 
70.6 
17.8 
0.938 
PVR, Post Void Residual 
There were marginal differences between the entry study groups and those that 
had a re-treatment TUMT after Sham. Eighty-eight patients were available for 
assessment at 3 months and 63 at 1 year. The fate of the other patients is given in 
Table 2. The period of follow-up for each group is given as the time after the last 
treatment session, whether first or second TUMT or SHAM, rather than from the 
beginning of the study. 
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Table 2. The number of patients in all groups and the treatments and losses 
during follow-up 
Follow-up Baseline 
Number of patients (months) 
3 
43 
2 
1 
45 
2 
26 
1 
4 
6 
18 
2 
23 
36 
1 
3 
4 
1 
23 
3 
4 
12 
13 
1 
4 
33 
1 
2 
15 
6 
1 
1 
2 
2 
Sham 46 
Lost to follow-up 
Second TUMT 
Other* 
TUMT 47 
TURP 
Lost to follow-up 
Second TUMT 
Deatht 
TUMT after Sham 27 
Lost to follow-up 
Laser 
Othert-
Deatht 
TUMT after TUMT 4 
Lost to follow-up 
' Technical failure, t Not treatment related. $ a1-blocker treatment 
The 46 patients who received Sham treatment experienced a significant 
improvement in symptoms at 3 months, with the initial Madsen score of 12.9 ± 3.1 
decreasing to 10.4 ± 4.7. However, there was no significant change in the peak 
flow rate (Table 3). Thirteen patients were sufficiently content with their 
symptoms that no further intervention was required by 1 year, representing the 
best possible outcome of the Sham treatment or the maximum placebo effect. Only 
the symptom score had improved significantly from baseline. The main 
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complication was the rate of retention. After the genuine TUMT treatment, 10 
patients (21%) needed a transurethral catheter, whereas in the Sham group only 
one patient was unable to pass urine freely. 
Following either TUMT or TUMT after Sham, there is a statistically 
significant improvement in both Madsen score and flow rate over baseline, at both 
3 months and one year. Comparison with the SHAM group at 3 months showed 
a significant difference in outcome for each of the variables. At 1 year, the patients 
treated by TUMT continued to have a statistically significant improvement over 
the remaining patients from the Sham group in both Madsen score and flow rate. 
There were no significant differences at 1 year for PVR or voiding fraction 
amongst the three groups. 
Stratification of the three groups by the outcome at 3 months, defined by the 
criteria for success suggested in the Food and Drug Administration (FDA) 
guidelines is shown in Table 4. There were more successful patients among those 
receiving TUMT than among those receiving Sham when assessed by both 
Madsen score and peak flow rate, but the difference was not as striking using the 
change in PVR as a criterion of success. 
DISCUSSION 
The placebo phenomenon is difficult to define and the terminology in treatments 
using devices is still a matter of debate. Traditionally, placebo trials are associated 
with drug studies and the benefits which a patient may experience while taking a 
placebo are often assumed to result only from the psychological improvement 
obtained by contact with those involved in the trial, or better education in health 
matters. However there may also be improvement due to the natural resolution of 
the disease process or as a result of the interventions required during the study. 
Placebo studies do not address fully the problem that the natural history of disease 
is necessarily brief, because there are ethical constraints against withholding 
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Table 3. Main follow-up indices in the sham, TUMT and TUMT after sham groups at 
baseline, 12 and 52 weeks 
Baseline Follow-up at 12 weeks Follow-up at 52 weeks 
Mean 95%CI Mean 95%CI p-value Mean 95%CI p-value 
Madsen score 
Sham 12 9 
TUMT 13 7 
TUMT after Sham 13 6 
Peak flow (ml/s) 
Sham 9 6 
TUMT 9 2 
TUMT after Sham 9 0 
PVR* (ml) 
Sham 84 7 
TUMT 93 9 
TUMT after Sham 110 0 
Voided fraction (%) 
Sham 77 3 
TUMT 74 9 
TUMT after Sham 70 6 
*PVR, Post-void residual 
treatment for a prolonged period. The spontaneous changes occurring with time 
in any disease process are best observed by comparing an active treatment to an 
arm with no treatment arm, randomly and prospectively. A spontaneous 
improvement in a patient's condition may seem to occur as the result of the study, 
e.g. an improved urine flow after more experience or from repeated catherization 
in studies of ΒΡΕ. In device-based therapies, the intervention required to prevent 
the patient knowing wich treatment has been received may have a previously 
unsuspected therapeutic benefit, e.g. the insertion of a urethral applicator during 
thermotherapy. One of the critical issues for the evaluation of devices for the 
1 1 9 , 1 3 9 104 8 9 , 1 1 8 
12 7,14 7 4 7 3 6,59 
12 4,14 8 5 4 3 6,7.2 
8 8 , 1 0 4 9 7 8 7 , 1 0 7 
8 4 , 9 9 134 117,153 
7 6 , 1 0 4 1 3 4 11 1,157 
64 0,105 1 104 1 74 7,133 
71 8,1160 342 194,468 
76 9,143 2 67.1 37 7,91 1 
72 4,82 1 75 4 69 6,81 3 
70 1,79 8 89 5 85 2,93 7 
63 3,77 8 810 73 8,88 2 
0 003 8 2 5 5,110 0 011 
<0 001 4 2 3 0,53 <0001 
<0 001 7 0 3 8,10 2 0 005 
0 846 10 5 7 9,13 1 0 657 
<0001 134 116,15 1 <0 001 
<0 001 12 8 9 8,5 8 0 033 
0 428 56 3 16 9,95 7 0 433 
<0 001 49 7 33 0,66 3 0 002 
0 012 57 3 23 4,91.1 0 133 
0 936 83 5 73 8,93 2 0 814 
<0 001 84 5 79 3,89.7 <0 001 
0 015 84 5 77 1,92 0 0 116 
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Table 4 The proportional improvement in the mam indices at 3 months of follow-up 
percentages are based on intention to treat 
Madsen score 
Sham 
TUMT 
TUMT after Sham 
Peak flow (ml/s) 
Sham 
TUMT 
TUMT after Sham 
PVR* (ml) 
Sham 
TUMT 
TUMT after Sham 
< 
26 
10 
9 
31 
23 
13 
31 
18 
14 
Im 
25% 
58% 
2 1 % 
33% 
69% 
49% 
48% 
69% 
38% 
52% 
iprovement from baseline parameter (%) 
> 25% 
11 
8 
5 
9 
7 
2 
4 
6 
6 
< 50% 
24% 
17% 
19% 
20% 
15% 
7% 
9% 
13% 
22% 
8 
29 
13 
5 
17 
12 
10 
23 
7 
> 50% 
18% 
62% 
p=0 002 
48% 
p<0 001 
11% 
36% 
p<0.002 
44% 
p<0 001 
22% 
49% 
p=0.002 
26% 
p=0 449 
> 
4 
14 
9 
4 
12 
7 
8 
21 
5 
75% 
9% 
30% 
33% 
9% 
26% 
26% 
18% 
45% 
19% 
*PVR, Post Void Residual 
treatment of symptomatic ΒΡΕ is whether the placebo response seen with drug 
studies can be expected with any treatment, be it a device or even surgery. 
The results from the present study suggest that there was indeed a significant 
placebo/instrumental response in patients undergoing sham treatment. The two 
other comparisons of TUMT and sham treatment,'6 '7 also showed similar changes 
in Madsen score in both the TUMT and sham arms (Fig. la). There are some 
differences in the peak flow rate changes, in that the study by Perrin and 
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Devonec17 showed a small decline in peak flow at 3 months and the study by Blute 
et al.,16 demonstrated a larger improvement than in the present study (Fig lb). The 
study of Bdesha et al., using a transurethral microwave device without cooling 
differs from other studies in that they found a 16% improvement in symptoms and 
a deterioration in peak flow rate and PVR in the sham arm.23 This result is 
comparable to the 19% symptomatic improvement in the current study. One of the 
best controlled drug studies in patients with symptomatic ΒΡΕ is that by the 
International Finasteride study group,24 which had a placebo arm followed for up 
to 1 year and comprising 154 patients. The mean change in symptom score was a 
decrease in symptom score of 2.6 points from a baseline of 19.2 (13.5%) on a 
modified Boyarski score with a maximum of 36. The increase in flow rate was 
minimal with an improvement of only 0.4 ml/s from a baseline of 8.6 ml/s in the 
placebo-treated patients. Jardin et al. reviewed the placebo response in studies of 
alpha- blocking agents and reported a change in flow rate from -2.7 to +2.3 ml/s.25 
The placebo response found in TU MT studies is greater than that in many drug 
studies. Previous studies comparing TUMT to sham agree that there is a greater 
benefit from thermotherapy.1617 Both the centres participating in the present study 
reported results at three month individually; there was a significant difference 
between the outcome of sham and TUMT.2627 However, the study based in London 
demonstrated little effect of placebo because a few patients in the sham-treated 
arm deteriorated significantly during the 3-months follow-up, thereby skewing the 
data. By pooling the data from the two studies, which were carried out according 
to the same protocol, the evidence for a placebo effect is strengthened. Only one 
study has concluded that the majority of the effect of TUMT is due to a placebo 
response, but the results lack credibility as they were from a non-randomized, 
unblinded study.15 Both the study of thermotherapy by Bdesha et al.,17 and the 
French multicentre study of hyperthermia devices,14 showed no difference in 
flowrate changes between sham and treatment, but it is presumed that this is due 
to the small increase in flow rate seen with transurethral microwave energy 
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Figure 1a. Changes in mean Madsen symptom score. 
Dotted line, Sham. Black line, TUMTA=[13], B=[16],C=Present study 
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application at lower power and without simultaneous cooling of the applicator.1·1·23 
The similarity of improvement of symptom score in a non-irrigated method of 
thermotherapy, e.g. by Bdesha et al.2·1 with that in the present study is interesting. 
To date, there is only one paper reporting subsequent treatment of those receiving 
sham treatment, and a 1- year follow-up which showed similar results to the 
present study.28 However, that study comprised few patients and the microwave 
therapy was more in the range of hyperthermia than in that of thermal therapy. A 
study of a three-way randomization between sham, TUMT and watchful waiting 
(WW) comprising 120 patients in total,15 reported that the WW group showed no 
clinically relevant deterioration or improvement. The sham-treated group had a 
symptomatic improvement of 45% comparable to TUMT (50%). There was little 
clinically relevant improvement of objective variables in the TUMT group and no 
relevant improvement in the sham-treated group. However, in that study, the 
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Figure 1 b. Changes in mean peak flow rate (ml/s). 
Dotted line, Sham. Black line, TUMT. A=[13], B=[16], C=Present study 
0) 
I 
X 
(6 
ε 
σ 
13 г 
12 • 
11 
10 
baseline 3 months 
patients were selected if they had severe obstruction, as defined by pressure-flow 
studies and may not represent a similar population to that in the present study (P 
Nawrocki - personal communication). There is evidence to suggest that TUMT has 
a much less effect on patients with more severe obstruction.29 
The conclusion from these comparisons of TUMT and sham treatment must 
be that there is an effect of heat on bladder outlet function in the older man and 
that only a small part of the clinical benefit can be accounted for by the effect of 
placebo or instrumentation. This conclusion is further supported by the analysis 
of those patients who have transferred from sham to TUMT treatment. 
Presumably, these men are not susceptible to a placebo effect and yet the changes 
after treatment are still very significant albeit a little less than occurred in the 
original treatment group. The difference in outcome between TUMT and TUMT 
after sham probably results from the exclusion of those responding to the placebo 
53 
and thus may be considered to represent the therapeutic effect of TUMT. 
The most cogent argument for a greater benefit from TUMT than from sham 
treatment is that from the analysis of the rates of response based on the percentage 
intention-to-treat. The FDA proposed that response should be examined as a 
percentage change in each individual criteria, as well as in combination; this gives 
an agreed framework by which to compare the outcome following what are often 
very different treatments.30 After sham treatment, only 11% of men have >50% of 
change in peak flow rate, compared to 36% of men after TUMT. The difference 
is more striking when comparing the effect on symptom score, with only 18% of 
patients receiving sham treatment attaining a satisfactory improvement (i.e. > 
50%) as opposed to 62% of those receiving TUMT. 
The present study shows that the difference between sham treatment and 
TUMT persisted for at least 1 year. Only 10 of the 74 patients who were treated 
by TUMT required any further intervention within one year and of those, only 4 
required TURP, the others being treated by either repeated TUMT or other 
minimal invasive therapy. 
We feel strongly that the evidence for a beneficial effect of heating at 
'thermotherapy' temperatures is conclusive and that further randomized sham 
studies would be unethical. The burden of these types of investigation upon the 
patient is substantial and should not needlessly be repeated. Now the most 
important question is how the improvement in voiding is obtained in the absence 
of any significant loss of prostatic volume. It is clear that the mechanism of action 
of TUMT is substantially different to the reduction in volume and the formation 
of a cavity that is obtained with TURP and thus provides an exciting opportunity 
to provide a genuinely novel treatment for patients with symptomatic ΒΡΕ. 
TUMT using this heating level (Prostasoft version 2.0) is particularly suitable for 
treatment of earlier and less severe disease in the younger man who wishes to 
avoid disturbance of sexual function or in the elderly with many comorbid 
conditions preventing safe resection. It is also important that a proportion of 
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patients respond more to TUMT than do others, possibly because the required 
threshold temperature of 45° С is not achieved M Furthermore, sophisticated 
methods to select patients are required to make better use of the advantages ot this 
minimally invasive therapy 
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Chapter 2 
RESPONDERS AND NONRESPONDERS TO 
THERMOTHERAPY 
Based on 
MJAM de Wildt, A Tubaro, К Hofner, SStC Carter, JJMCH de la Rosette, 
M Devonec 
Responder*, and nonresponders to transurethral microwave 
thermolherapy a multicenter retrospective analysis 
J Urol 154 1775-1778, 1995 
SUMMARY 
We attempted to identify any parameter could possibly lead to a successful 
treatment outcome after transurethral microwave thermotherapy Clinical 
parameters and treatment profiles of 292 patients were analyzed in a retrospective 
multicenter manner Responders and nonresponders were identified according to 
a given definition No statistically significant differences in baseline 
characteristics were found Responders showed a 76% symptomatic improvement 
rate to 27% in nonresponders, and an 82% improvement rate in peakflow to a 5% 
decrease m nonresponders Responders also showed an significantly greater 
increase m posttreatment PSA level and a significantly greater amount of energy 
released during treatment No baseline clinical parameter is capable of predicting 
treatment outcome 
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INTRODUCTION 
Microwave heating of the prostate is a fascinating approach to the treatment of 
voiding disturbances in patients with benign prostatic hyperplasia (BPH).121 There 
are 2 basic concepts: hyperthermia in which the prostatic temperature is not 
allowed to exceed 45°C, and thermotherapy in which the target temperature is 
greater than 45°C.45 A recent multicenter study showed that hyperthermia seems 
likely to be ineffective in the treatment of BPH and thus not to be recommended.6 
Thermotherapy applies high power microwave energy deep within the 
lateral prostatic lobes. The results of transurethral microwave thermotherapy arc 
promising. It is presumed that clinical benefit is achieved by a small decrease in 
adenoma volume and the destruction of certain specific cell types that have some 
part in the development of bladder outlet obstruction. The clinical improvement 
has been shown not to be due to a placebo effect or the result of the associated 
urethral instrumentation in randomized trials of transurethral microwave 
thermotherapy versus a Sham procedure.3 7 However, the criteria currently used for 
inclusion do not prevent a high variability in terms of clinical response to 
transurethral microwave thermotherapy, and treatment outcome is difficult to 
forecast in the individual patient. 
Clinical experience has shown that significant improvement of subjective 
and objective parameters of disease severity is achieved in a subgroup of treated 
patients.358 Patient parameters at entry and treatment parameters have been 
investigated in different series for possible correlation with treatment outcome. For 
patient selection, the specific type and grade of obstruction at screening was 
correlated significantly with the response rate in a multicenter European study У 
Analysis of different treatment parameters that are currently monitored during 
microwave treatment to date has failed to identify any difference between 
treatments leading to successful outcome and those producing no change for the 
individual patient. More recently, analysis of patients undergoing invasive 
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thermometry of the prostate during treatment suggested a significant correlation 
between the amount of heat induced within the gland and flow rate improvement.10 
We investigated further patient treatment profiles to identify any parameter 
that could possibly lead to a successful treatment outcome. Digital records of the 
microwave treatments from a large series of patients undergoing microwave 
therapy at 17 different prostate centers worldwide constitute the material for the 
study. 
PATIENTS AND METHODS 
Data from BPH patients undergoing microwave thermotherapy at 17 different 
hospitals were collected. The same instrument and treatment software were used 
at the various centers, and treatments were performed according to a common 
study protocol. Treatment was given on an ambulatory basis and has been 
described in detail previously." A representation of a treatment session, the 
position of catheter and rectal probe, and a treatment profile are demonstrated in 
figure 1. During the transurethral microwave thermotherapy the microwave energy 
is emitted to the prostate resulting in heat. To prevent damage to urethral mucosa 
or rectal wall, 1 thermal sensor is positioned in the treatment device and 3 sensors 
in the rectal probe to check the urethral and rectal wall temperature. When the 
maximum allowed temperature is detected by one of 1 these sensors an alarm 
automatically interrupts the treatment. Therapy is resumed when the temperature 
decreases to a certain level. 
Screening consisted of a patient history with the Madsen-I versen symptom 
score, physical examination with digital rectal examination of the prostate, 
hematology and blood chemistry studies, including prostate specific antigen (PSA) 
measurements, electro-cardiography, chest X-ray, kidney and bladder ultrasound 
imaging or excretory urography, transrectal ultrasound of the prostate, uroflow-
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Figure 1. Position of 3 rectal temperature sensors and urethral sensor in catheter. Curves 
represent temperature readings of each sensor. Dotted line is urethral curve and 
3 continues lines are rectal temperature curves. Graph boxes represent amount 
of energy generated (watts) 
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metry (twice) with measurements of post-void residual volume using ultrasound. 
All patients studied were candidates for transurethral resection of the prostate and 
had a Madsen-Iversen symptom score of 8 or more, a maximum flow-rate of 15 
ml/s or less and post-void residual of 250 ml or less. Patients were excluded from 
the trial in case of an obstructive prostatic middle lobe, complications of BPH, 
suspicion of prostate cancer, presence of any condition that could interfere with 
bladder dynamics and patient compliance to the protocol. 
Each center was asked to provide case record forms and copies of the 
treatment computer files of at least 10 responders and 10 nonresponders to 
microwave thermotherapy. Responders were identified by a Madsen-Iversen 
symptom score of 3 or less, or 50% or greater decrease at month 6, a maximum 
flow rate of 15 ml/s or more, or 50 % or greater improvement and a post-void 
residual of 50 ml or less or 50 % or greater improvement at 6 months. 
Nonresponders were identified by a Madsen-Iversen symptom score of 8 or more, 
or 50 % or less improvement, a maximum flow rate of 10 ml/s or less, or 20% or 
less improvement and a post-void residual of 200 ml or more or 50% or less 
decrease at 6 months. At each center data were derived from consecutive series of 
patients satisfying the described criteria. 
Follow up visits, including symptom evaluation by Madsen-Iversen 
symptom score, flow rate measurements by free flow uroflowmetry and residual 
urine measurement by ultrasound, were scheduled at 1, 3 and 6 months after 
treatment. Blood samples were collected in selected sites at day 1, week 1, and 12 
weeks after thermotherapy. Quality data control included survey of the received 
case record forms and treatment files. Only patients with complete data bases were 
considered évaluable for analysis. Data collected from case record forms and 
retrieved from treatment files were entered in a computer and analyzed by a 
statistical program. 
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RESULTS 
Of 292 patients évaluable 136 were responders and 156 were nonresponders. 
Analysis of patient parameters at screening showed no significant difference 
among responders and nonresponders (Table 1). 
Table 1. Patient characteristics 
Mean ± SD 
Age (yrs) 
Prostate volume (cm3) 
Madsen score 
Maximum flow rate (ml/s) 
Post-void residual vol. (ml) 
PSA (ng/ml) 
Responders 
66.8 ± 7.9 
45.0 ±18.0 
13.7 ±4.0 
8.8 ±3.7 
96.0 ±158.0 
4.1 ±4.3 
Nonresponders 
66.4 ±8.3 
44.0 ±18.0 
13.3 ±4.3 
8.3 ± 3.3 
78.0 ± 80.0 
4.2 ±3.3 
Changes in Madsen-Iversen symptom score, maximum flow rate and post-void 
residual are presented in figure 2. Responders showed an average improvement of 
76% for Madsen-Iversen symptom score and an increase in maximum flow-rate of 
82%, with a decrease of 37% of post-void residual volume (Table 2). Non-respon-
ders had an average decrease of 27% for symptom score, an actual decrease in 
flow-rate of 5% and only a decrease of 14% for post-void residual volume. 
Screening plasma levels of PSA were found to be comparable among the 2 groups. 
Heat produced by microwave thermotherapy in the prostate gland is responsible 
for the observed increase of PSA. Interestingly, at week 1 significantly higher 
values were measured in responders (+371 %), when compared with nonrespon-
ders (+176 %). PSA values at 3 months were again comparable between the two 
groups and did not differ significantly from baseline (Figure 3). 
Different parameters derived from digital records of the microwave treatments 
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Table 2. Values at baseline and at 6 months 
Mean ± SD 
Baseline 6 Months 
Responders 
Madsen score 13.7 ±4.0 3.2 ±3.3 
Maximum flow rate (ml/s) 8.8 ± 3.7 16.0 ±5.7 
Post-void residual (ml) 96.0 ± 158 35.0 ± 50.0 
Nonresponders 
Madsen score 13.9 ±4.2 9.6 ±4.0 
Maximum flow-rate (ml/s) 8.3 ± 3.3 7.9 ± 3.0 
Post-void residual (ml) 78.0 ± 80.0 67.0 ± 77.0 
were analyzed (Figure 4). The amount of energy released during treatment, 
measured as total energy dose, average dose, and the maximum power output was 
found to be significantly different in the 2 groups. The higher amount of energy 
released in the responder group resulted in a higher temperature at the level of the 
urethra. 
The number of urethral alarms was greater in responders versus nonresponders but 
the difference was not significant (Figure 5). 
Notwithstanding a higher energy release in responders, temperatures 
recorded at the level of the rectal wall were comparable in the two groups; 
nevertheless fewer rectal alarms was observed in responders when compared to 
nonresponders 
DISCUSSION 
Variance analysis of data obtained has shown how our patient population did not 
differ significantly among the various sites and it is comparable with the BPH 
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Figure 2. Difference in symptom score, post-void residual volume (PVR) and maximum 
flow rate (Qmax) between responders and nonresponders at baseline (Pre), 3, 
6 and 12 months after treatment. 
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population enrolled in previous studies. The use of 2 discrete populations of 
responders and nonresponders instead of one single group was designed to achieve 
a balance between the two groups which is otherwise dependant on patient 
selection in the individual sites. Moreover, it is easier to perform such an analysis 
determining treatment parameters that predict outcome of treatment. 
The outcome of thermotherapy has been shown to be variable between different 
sites in previous studies.3·5·7·8·12 To identify selection criteria that could possibly 
predict successful treatment outcome, a large series of patients was evaluated 
according to the response of treatment. Responders and nonresponders 
characteristics at screening were not statistically different, which further supports 
a previous supposition from our group that currently only baseline urodynamic 
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Figure 3. Changes in PSA level (ng/ml) between responders and nonresponders at 
baseline, 1 day, 7 days and 3 months after treatment. 
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parameters can predict clinical outcome from microwave treatment.9 Provided the 
2 groups of patients were comparable at baseline, a different microwave treatment 
profile could have been responsible for the different outcome in the 2 populations. 
The treatment profile reflects the energy delivered to the prostate and depends on 
the number of the rectal and urethral alarms (Figure 1). The alarms result in a safe 
treatment but they may limit the emission of microwave energy. In view of the 
results achieved with higher energy levels we think that the safety of treatment 
obviously interferes with efficacy. One can not have high temperatures within the 
prostate using low power levels.10 We know that the amount of heat produced 
within the prostate is correlated with objective clinical outcome but such para-
meters are not available in this series. Nevertheless, we still have an indirect 
measure of intraprostatic temperatures which is given by the elevation of PSA in 
the days following transurethral microwave thermotherapy. We do not know 
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Figure 4. Difference in maximum (max) power, average power and total administered 
amount of energy between responders and nonresponders. 
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wether epithelial cell damage is of any importance in clinical response to micro-
wave therapy but is certainly one of the three major cellular components of BPH. 
Interestingly, the variation of the PSA level within 1 week after treatment was 
significantly different in the 2 groups. Variation among the individual patients is 
high and it reflects the different response of the individual prostate to microwave 
treatment, which we observed in previous studies. The kinetics of the PSA 
increase is outside the objectives of our study but they certainly deserve attention 
in the future. The concept was confirmed in a recently conducted placebo 
controlled study.3 
The key questions are why some patients achieve higher intraprostatic 
temperature than others and whether this is dependent on differing tissue 
architecture blood supply in some prostates. Answering such questions will 
significantly influence patients selection and the design of new treatment software 
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Figure 5. Difference in number of rectal and urethral alarms between responders and 
nonresponders. 
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in the future. Analysis of different treatment parameters has shown that the amount 
of energy released during treatment differs significantly in the 2 groups and more 
energy was delivered in responders when compared to nonresponders. The 
observation is confirmed by the evaluation of 3 separate parameters, maximum 
power output during treatment, and total and average energy doses. Interestingly, 
the energy applied cannot be related to prostate size. 
What happened to this higher amount of energy released into the prostate 
of patients who did well? A higher energy dose produced a higher urethral 
temperature, which is not evident when examining the peak urethral temperature 
achieved during treatment but it was clear if we note the maximum urethral 
temperature sustained for at least 3 minutes. A higher urethral temperature has, of 
course, triggered a greater number of urethral alarms, although the difference be­
tween the 2 groups was not significant because of the high variability of this 
parameter in different treatments (0 to 150). Transient interruption of microwave 
emission seems not to be detrimental to treatment outcome or the total energy 
dose. Therefore, where is all this energy going? The flux of energy emitted by the 
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microwave antenna passes through the prostate from the urethra to the rectum. As 
the irradiative energy is absorbed by tissue it is transformed into heat energy and 
the temperature increases. When temperatures increase, vasodilatation occurs 
creating a heat sink which may carry away significant amounts of heat. If 
irradiative energy is largely absorbed by prostatic tissues then rectal temperature 
cannot increase (by lack of energy) and, consequently, we expect a fewer rectal 
alarms. Interestingly, this is what happened in the responder group; lower 
temperatures were measured in the rectal wall of these patients and a fewer alarms 
were recorded. 
A higher energy dose with lower rectal temperature may be dependent on 
2 different phenomena: either a higher energy absorption by the prostate tissue 
with a high intraprostatic temperature or a higher energy dissipation from a major 
blood supply with little temperature rise within the gland. Because patients with 
a higher energy deposition and lower rectal temperatures have a more successful 
treatment outcome, better energy deposition is more likely to be responsible for the 
lower number of rectal alarms observed in responders. 
CONCLUSIONS 
None of the baseline parameters used within our study was able to define the ideal 
patient for and predict the result of treatment. Changes in PSA levels and energy 
absorption of the prostate merely reflect the heterogeneity of the disease and 
variability of outcome to this treatment modality. Tissue architecture of the 
prostate gland and its relative blood supply might have a role in determining the 
outcome of microwave heating.12 Investigation of possible correlations among 
these parameters might be important to understand the mechanism of therapeutic 
effect of microwave heating on BPH, resulting in more efficient heat induction of 
the prostate. 
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SUMMARY 
A retrospective study was conducted to investigate the long term outcome of 
patients treated with lower energy Transurethral Microwave Thermotherapy 
(TUMT). Three hundred and five patients with lower urinary tract symptoms and 
benign prostatic enlargement underwent TUMT according to a similar protocol 
at two centers. After three years followup, 133 patients who had only been treated 
with TUMT were available. Over this period of observation a significant 
symptomatic improvement over baseline and improvement in maximum flow of 
2.6 ml/s was seen. Hundred and twenty-five patients were retreated with either 
invasive or medical treatment. After three years followup, lower energy TUMT 
shows significant and durable improvement of baseline parameters in 52% of 
patients. 
76 
INTRODUCTION 
In the last decade many different alternatives to a surgical resection of the prostate 
in patients with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic 
Enlargement (ΒΡΕ) have been introduced. These include the use of different oral 
medications, such as 5oc-reductase inhibitors and αϊ-adrenergic antagonists, as 
well as several minimally invasive approaches ' 2 . Although a surgical resection is 
effective in relieving bladder outlet obstruction with a consequent reduction in 
symptoms, the popularity of these alternative therapeutic options in the treatment 
of ΒΡΕ is based on the potential reduction in morbidity and costs. The use of heat 
applied by different generators (e.g., ultrasound, radio-frequency, laser and 
microwave-devices), appears to be the most promising alternative w . 
Transurethral Microwave Thermotherapy (TUMT) offers great potential as an 
outpatient anesthesia-free single session procedure. Presently, of the many 
different thermotherapy-devices, the Prostatron (Technomed, Lyon, France) has 
received the most attention and has been investigated extensively with more than 
25.000 treatments performed worldwide. Several studies of this device report 
substantial and significant subjective improvement. An overall improvement of 
about 70% in symptom scores, using the Madsen-1 versen Symptom Score 
(MSS), compared with baseline is usually noted. The improvement in urinary 
performance is also encouraging, with an improvement in maximum flow (Qmax) 
of around 2-3 ml/s (representing about 35%) over baseline and a similar reduction 
in Post Void Residual volume (PVR) of around 35% '\ The mechanism of action 
may be related to thermal damage of prostate tissue and not to the effect of urethral 
manipulation as shown by several randomized studies of TUMT versus sham 7Й. 
More important, a study of TUMT versus TURP by Dahlstrand et al., has shown 
that the symptomatic improvement after TUMT is statistically identical to 
improvement in patients treated with TURP 9. However, the effect on 
uroflowmetry parameters in TUMT patients is less pronounced when compared 
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with TURP patients. Both subjective as objective parameters remained stable over 
3 years period of observation 6. 
The authors have a large experience with the Prostatron device. Since the end of 
1990, treatments with the lower-energy protocol (Prostasoft® version 2.0) have 
been performed. We conducted a retrospective study in patients treated with this 
protocol at two different centers to discover the results of treatment over a long 
period of followup. 
MATERIAL AND METHODS 
From December 1990 to December 1992, Three hundred and five men with LUTS 
and ΒΡΕ were treated with the Prostatron device. Pretreatment assessment 
included patient history (with Madsen-Iversen symptom scores) l0, physical 
examination (with digital rectal examination), urinalysis and urine culture, 
transrectal ultrasound of the prostate with calculation of the prostate volume using 
the formula of Stamey and Terris ", and uroflowmetry with measurement of PVR 
by abdominal ultrasound of the bladder using the ellipsoid technique. 
The great majority of these patients were included in a range of prospective trials 
that were conducted according to more or less similar protocols. Criteria to enter 
the study were an age of more than 45 years, LUTS for more than 3 months, a 
Madsen symptom score of 8 or more, a urinary maximum flow of 15 ml/s or less, 
and a Post Void Residual volume of 350 ml or less. Exclusion criteria were urinary 
retention, prostate carcinoma, acute or chronic prostatitis, urethral stricture, 
intravesical pathology (stones, neoplasm), neurogenic bladder dysfunction, urinary 
tract infection, isolated enlargement of the middle lobe, use of drugs influencing 
bladder or prostate function, disorders of blood flow or coagulation and diabetes 
mellitus. The TUMT treatment in general has been described before 12. After 
treatment, patients were asked to remain in the department until satisfactory 
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voiding had been established. In case of retention, a urethral catheter was placed 
usually for one week. All patients were treated at least 3 years ago. Data on 
symptom scores and uroflowmetry results were analyzed retrospectively at 
baseline, 12, 24 and 36 months after treatment. The maximum flow was corrected 
for artefacts by two independent observers using the 'two second method' '3. The 
voided volume was correlated with the Post Void Residual volume (PVR) to give 
a 'voiding fraction', using the formula: voiding fraction (%)= voided volume / 
(voided volume + PVR)14. In case of further treatment by either surgical or medical 
intervention, the date and type of treatment were noted. When a patient did not 
return for further followup and no record of the patient's fate was in the patient's 
file, a detailed questionnaire with an enclosed Madsen symptom score was sent to 
the patient. If the Madsen symptom score was missing at the three-year visit to the 
outpatient clinic, a Madsen symptom score was obtained by telephone interview. 
A patient was considered lost to followup if no knowledge was available of his 
fate after his last visit to the outpatient clinic, despite several attempts to contact 
him by either mail or telephone. If a patient was not satisfied with the result of the 
TUMT treatment and therefore changed to medication for his lower urinary tract 
symptoms (either 5a- reductase, α-blocker or anticholinergics) or underwent an 
operation, the uroflowmetry or symptom score data were not taken into 
consideration in evaluation of the followup. Finally, post treatment morbidity was 
noted if the patient experienced urinary incontinence, a urethral stricture or other 
treatment related complaints. 
RESULTS 
Of the total 305 patients, 73 patients were treated in the London center and 232 in 
Nijmegen. The English patients at average had smaller prostates, voided with 
larger volumes and had a larger post void residual volume and consequently 
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smaller voiding fraction. All other parameters used in the study were equally 
distributed and statistically similar (table 1) For the total group the mean age at 
baseline was 65.3 ± 7.3 years (range 45 - 87). 
Table 1 Baseline charade π sties for the two centers 
Age (yrs) 
Prostate volume (cm3) 
Madsen score 
Uroflowmetry 
Qmax (ml/s) 
Voided volume (ml) 
Post-void residual (ml) 
Voiding fraction (%) 
Mean ± SD 
Nijmegen 
η = 232 
64 9 ± 7 2 
49 9 ± 19 7 
1 2 7 ± 3 5 
9 0 ± 2 8 
223 ±113 
65 ±68 
79 ±18 
London 
η = 73 
66 8 ± 7 5 
43 6 ± 23 4 
1 3 5 ± 3 4 
9 4 ± 2 7 
258 ±121 
139 ±98 
68 ±19 
p-value 
0 051 
0 031* 
0 070 
0 375 
0 045* 
<0 001* 
<0 001* 
* Significant difference using Student-T test (a = 0 05) 
Table 2 Number of patients, additional treatments and losses in the followup 
TUMT only 
Medication 
Invasive procedure after 
prior use of medication 
Invasive procedure 
Death 
Lost to followup 
Missed visit 
Baseline 
305 
Number of patients 
1 year 
233 
18 
2 
22 
1 
17 
12 
2 years 
112 
11 
9 
23 
2 
19 
69 
3 years 
133 
16 
5 
19 
3 
5 
-
Total 
133 
45 
16 
64 
6 
41 
-
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The average prostate volume was 48.6 ± 20.7 cm1 (range 15 - 133). After three 
years followup 133 patients who had no additional treatment by either medication 
or an invasive procedure were available. The fate of the other patients is given in 
table 2. In total 140 letters were sent to the patients of which 99 were returned. 
The remaining 41 were considered lost to followup. If no data at one and/or two-
year followup was available and the patient returned for further followup after 
three years or when he filled out the mailed questionnaire, he was considered a 
missed visit at one and/or 2-year followup. 
Table 3 Followup paired data of baseline parameters of patients treated with TUMT 
without additional treatment 
Madsen Symptom 
Score 
N= 
Mean score 
Uroflowmetry 
N= 
Qmax (ml/s) 
Voided Volume(ml) 
Post Void Res (ml) 
Voiding Fraction (%) 
Baseline 
305 
129 
305 
91 
228 
82 
77 
1 Year 
base 12mths 
208 
12 8 5 6* 
228 
9 2 114* 
235 224 
75 48* 
79 85** 
Mean 
2 Years 
base 24 mths 
66 
130 6 1 * 
110 
9 3 112* 
254 239 
74 50** 
80 84*** 
3 Years 
base 36 mths 
113 
122 8 1 * 
63 
9 4 119* 
230 216 
62 48** 
80 84 
Significant using the Wilcoxon Matched-Pairs Signed Ranks test (a=0 05) with 
(*p<0 001 ,"p<0 01 ,"*p<0 02) 
Table 3 shows the paired data of improvement from baseline of the main 
indices. After one year there is a 56% reduction in symptom score that gradually 
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declines to 53% and 34% at 2 and 3 years followup respectively Nevertheless, the 
symptomatic improvement remains statistically improved over baseline values 
The improvement in maximum flow stays stable at 24% after one year, and 20% 
and 27% after two and three years followup respectively The improvement in post 
void residual and voiding fraction also remains constant over the three-year period 
of observation, although the improvement in voided percentage over baseline is no 
longer statistically significant at three years followup This may be due to the 
small number of patients that have uroflowmetry data available at this visit 
Table 4 Response rates of mam indices after 1 2 and 3 years in patients only 
treated with TUMT shown as a percentage of available patients 
Madsen score 
1 year 
2 years 
3 years 
Qmax (ml/s) 
1 year 
2 years 
3 years 
Percentual 
< 25% 
19% 
23% 
48% 
54% 
57% 
51% 
improvement from baseline parameter 
>25% <50% 
21% 
15% 
13% 
20% 
20% 
22% 
> 50% 
60% 
62% 
39% 
26% 
23% 
27% 
> 75% 
34% 
26% 
27% 
15% 
14% 
18% 
Stratification of the data of patients treated only with TUMT by the percentage 
change in outcome at 1, 2 and 3 years followup, as a definition of success as 
suggested in the Food and Drug Administration (FDA) guidelines, is shown in 
table 4 The proportion of patients that have 50% or more symptomatic 
improvement remains stable at the first two years and declines to 39% at three 
years followup The proportion of patients that have 50% or more improvement 
of the maximum flow remains durable at 26%, 23% and 27% at one, two and three 
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years followup respectively. Apart from the greater symptomatic improvement at 
one year followup for the English patients, there appeared to be no statistical 
difference between the London and Nijmegen center in the amount of 
improvement of any of the main indices (table 5). At 3 years followup, 133 
patients had undergone only TUMT that corresponds to 133/258=52% of patients 
with available data. In total 80/219=31% underwent an invasive procedure with 
a second TUMT in 8 patients, a transurethral resection of the prostate in 45 
patients, an incision of the prostate in 3 patients, a laser prostatectomy in 17 
patients, a suprapubic prostatectomy in 5 patients and finally one patient 
underwent a radical prostatectomy after diagnosis of prostate cancer. In total 
60/258 = 23% of patients were not satisfied with the result of TUMT and changed 
to medical therapy. Of these patients, 42 used α-blockers, 5 patients began 5a-
reductase treatment and 12 patients started with anticholinergic drugs. One patient 
started treatment with flutamide when prostate cancer was diagnosed. Sixteen of 
these were not content with the medical therapy, and finally underwent surgical 
intervention. 
Figure 1 illustrates the Kaplan-Meier plot of early termination of the study due to 
starting medication and an invasive procedure. Patients waited at average 1.4 ± 0.8 
years (range 0.5 - 2.9) before initiating medical therapy and 1.5 ± 0.8 years (range 
0.25 - 2.9) before having a surgical procedure when they were dissatisfied with the 
result of the TUMT treatment. 
No statistical difference in any of the baseline parameters could be found 
between patients who at 3 year followup after TUMT had a response rate of 50% 
or more in either symptom score or maximum flow and patients who underwent 
retreatment by either medication or invasive procedure. After treatment 82 patients 
(82/305=27%) needed a transurethral catheter due to urinary retention. In the 
majority of patients this catheter could be removed one week after treatment. 
Three patients (3/258=1.2%) developed recurrent urinary tract infections for which 
antibiotic treatments were necessary. Eight patients (8/258=3.1%) experienced 
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prolonged macroscopic hematuria. One patient ( 1/258=0.4%) developed a urethral 
stricture. Four patients (4/258=1.6%) developed urge-incontinence. Finally, four 
patients were diagnosed with prostate cancer by prostate biopsies (n=2) and by 
histology of resected tissue after TURP (n=2). 
Table 5. Difference in improvement of baseline parameters between the 
Mean ± SD 
Madsen score 
1 year 
2 years 
3 years 
Qmax (ml/s) 
1 year 
2 years 
3 years 
London 
9 2 ± 4 6 
8 5 ± 5 8 
5 9 ± 6 2 
2.7 + 3 8 
1 6 ± 3 8 
1 7 ± 7 2 
Nijmegen 
6 5 ± 4 9 
5 8 ± 5 7 
3 8 ± 5 9 
2 0 ± 3 7 
1.9±43 
2 6 ± 4 0 
p-value 
0 001* 
0 065 
0 210 
0.249 
0 701 
0 560 
* Significant using T-test for independent samples (a = 0 05) 
DISCUSSION 
The aim of any treatment in patients with LUTS and ΒΡΕ is to achieve 
symptomatic relief with a corresponding reduction of bladder outlet obstruction. 
Symptomatic improvement is determined by a decrease in symptom scores. 
Traditionally, symptomatic treatment efficacy in TUMT is evaluated with the 
Madsen-Iversen symptom score that at the time of the first trials (1991) was the 
only commonly used symptom score. Reduction of bladder outlet obstruction is 
usually evaluated by increased urinary flow rate since urodynamic pressure-flow 
studies are not usually applied. A treatment outcome can be expressed either as 
mean changes of the parameters, or by a percentage improvement of the 
parameters. Short term results using these methods of treatment evaluation, and 
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morbidity of TUMT have been extensively reported 6. However, data as to the 
durability of this treatment and the retreatment rate is limited to only few 
publications91516. 
The 56% improvement at one year followup in the present study appears lower 
than the approximately 70% improvement reported in literature. The same 
accounts for the objective maximum flow improvement of 2.2 ml/s (or 24%) that 
is also slightly less comparable with data from literature that report around 3-4 
ml/s (or approximately 35%) improvement in maximum flow. Finally, the 36% 
reduction of post void residual urine seems more comparable although data are 
limited and with reports varying from a 22 - 69% improvement6. On the other 
hand, the percentage improvement over baseline of the main outcome indices, 
using the FDA stratification guidelines, appears to be very similar to earlier 
papers. The present study reports 50% or more improvement in symptom scores 
and maximum flow in 60% and 26% of patients respectively. Data from literature 
notes 50% or more improvement in symptoms and maximum flow in 62% and 
36% of patients respectively 8. Furthermore, the present study shows that the 
achieved improvement in both symptoms and urinary performance remains durable 
and more or less stable over a three-year observation period. This is in accordance 
with Dahlstrand et al. who reported on two and three years followup data in a 
randomized study of TUMT versus TURP 6 9 . Nevertheless, one should 
acknowledge that there appears to be a trend toward a deterioration of the 
symptoms with the duration of the followup and that at three years followup the 
mean Madsen symptom score is 8.1 which is just above the entry level of this 
study, especially when taking into account that the patients who at three years 
followup are still without additional treatment, represent the best responders. 
So where should TUMT-treatment be positioned among all the available 
treatment options for patients with LUTS and ΒΡΕ? The objective improvement 
after lower-energy TUMT is not comparable to what is achieved after a surgical 
resection of the prostate as has been shown in the study of Dahlstrand et al 9 . The 
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magnitude of improvement in urinary performance seems more in the ranges 
achieved with medical therapy. Stoner reported a significant improvement over 
baseline values of 2.4 ml/s in maximum flow of patients (n=156) treated with 
finasteride in an open extension North American study after 36 months after 
initiation of the treatment '. Lepor published similar changes in 103 patients, 
which were treated with terazosin after three years followup. The improvement in 
maximum flow ranged from 2.3-4.0 ml/s above baseline value between 3 months 
and 42 months followup with 30% or more improvement in flow in 40-59% of 
patients 2. However, patients who are still using medication at three years of 
followup should also be considered as the best responders that inherently skews 
the data. Table 3 and 4 show similar improvements from TUMT after three years 
followup, with an improvement in flow of 2.5 ml/s with a 25% or more 
improvement in 49% of patients. Also, the symptomatic improvements of the 
alternative treatment options seem more or less comparable. Since the studies 
reporting on long term followup use different symptom scores to evaluate 
treatment outcome, the only way to compare these studies is by using the relative 
or percentage improvement. Lepor documents a 30% or greater improvement in 
symptom score in 62-77% of patients in a 3-42 months observation period. Stoner 
reports a mean reduction in symptom score of 3.6 points after 36 months in the 
extended study of finasteride. However, although the improvement is significant 
compared with baseline values and to the placebo control group, it only accounts 
for about a 18% improvement. The present study on TUMT shows that the 
symptomatic improvement after three years is 4.1 points that account for 34% 
improvement over baseline. Furthermore, a 25% or more improvement is achieved 
in 52% of patients (table 3). 
Another point that needs to be addressed in the evaluation of TUMT treatment 
is the retreatment rate. Every treatment option for LUTS and ΒΡΕ has its failure 
rate. In the case of initial surgical treatment, a further surgical intervention occurs 
because either of complications (urethral stricture/ bladder neck sclerosis) or for 
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recurrent disease. Table 2 shows that retreatment with an invasive therapy after 
initial TUMT treatment occurs in 24/287=8% of patients that have available data 
at 1 year followup, in 32/224=14% and 24/173=14% of patients after two and 
three years followup respectively. This accounts for a total of 80/258=31% 
retreatment rate over three years. The U.S. Prostatron TUMT group recently 
presented the long-term results of their FDA Study at the 91s' AU A Annual 
Meeting in Orlando '7. In contradistinction to the present study, they reported a 
significant lower retreatment rate of 11% with a TURP procedure. However, 29% 
reported to have changed to some medical treatment. These differences are likely 
to be explained by difference in department policy. In the present study a large 
number of patients were retreated with laser prostatectomy due to several 
protocols that were conducted with this modality at that time. Whereas in the U.S. 
it appeared that medication was the treatment of first choice when patients didn't 
experience improvement after their TUMT treatment. Nevertheless, both the U.S. 
and the present study report comparable and significant improvement in 52% and 
51% of patients at three and four year followup respectively. Available data in 
literature on retreatment rates after a surgical resection of the prostate has some 
flaws since the reported 1.8-15.5% retreatment mainly depends on the observation 
period l8. The largest documented retrospective study is the study by Roos et al, 
who documented 50.000 patients undergoing a TURP between 1963-1985. The 
retreatment rate for a second prostatectomy amounts to 2.3-4.3%), 8.9-9.7%) and 
12.0-15.5% after 1, 5 and 8 years respectively l9. In this respect the U.S. long-term 
results appear to be quite comparable. And since none of the TURP studies 
reported a retreatment by medication, the overall retreatment rate after TUMT or 
TURP might actually be quite similar. Unfortunately, neither the finasteride nor 
the terazosin studies report on the fate of the patients who were considered a 
treatment failure. 
The retreatment rate in the present study of patient treated with TUMT is 
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Figure 1 Kaplan-Meier plot presenting early termination of the study. Each individual line 
represents the cumulative percentage of drop outs of patients 
( = invasive retreatment, = medication retreatment) 
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higher than after TURP. However, a price has to be paid in terms of morbidity. In 
this respect TUMT seems favorable. The present study only reports a minor 
complication rate of TUMT, except for the TUMT treatment related retention rate 
of 27% that appears much higher than the reported 6.5% after surgical 
intervention20. Since TUMT is an invasive transurethral procedure, a urethral 
stricture rate of 0.4% (1/258) can be considered small compared with surgery that 
report a 2-20% incidence 2 l . No patient reported development of stress-
incontinence yet four patients (1.6%) experienced urge-incontinence after TUMT 
possibly from detrusor instability. Finally, the incidence of prostate cancer in only 
four patients (4/258=1.6%) appears low in comparison with available data on 
prostatectomy studies. This may be explained by the fact that patients were 
screened before entry into the study and that only 50/258=19% of patients actually 
have histology data from resected tissue available. 
The present study, like several other clinical papers on TUMT, has shown that 
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there is a great inter-individual difference in treatment outcome of objective and 
subjective parameters. This has led many investigators to search for selection 
criteria that could predict clinical outcome. A multi center study of responders 
versus nonresponders to TUMT concluded that none of the baseline clinical 
parameters could predict treatment outcome22. The present study supports this 
conclusion since no difference in the main treatment indices was found between 
the patients that could be considered good responders at three years followup and 
the patients that were actually treatment failures. Until now, the only predictive 
factor for treatment outcome can be obtained from urodynamic studies with 
pressure-flow analysis as demonstrated by Tubaro et al. in a European multi center 
study. Patients with the presence of a constrictive urodynamic obstruction showed 
favorable improvement in both symptoms as voiding parameters over patients who 
have a predominantly compressive obstruction23. 
Furthermore, thermometry studies have shown that not all prostates reach the 
maximum temperature intended, because the thermoregulation of the tissue in 
every individual patient differs significantly24. In addition, the correlation between 
the achieved intra prostatic temperature and treatment outcome suggest that the 
higher the intra prostatic temperature, the better the clinical results25. This has led 
to modification of the treatment software by increasing rectal threshold 
temperature and energy levels, resulting in fewer interruptions during treatment 
and a mean increase of 40% of total energy delivered to the prostate 2f'. First 
clinical experience in Phase II studies with high energy TUMT treatments (using 
Prostasoft® version 2.5), has indeed shown an increased objective improvement 
with comparable symptomatic improvement 26,2?. The relieve of urodynamic 
bladder outlet obstruction and the presence of a cavity on transrectal ultrasound 
of the prostate three months after the high energy TUMT treatment, might also be 
indicative for an improved efficacy and durability on the long term. 
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CONCLUSION 
Lower energy transurethral microwave thermotherapy results in significant 
symptomatic improvement in 52% of patients, while the objective improvement 
is in the range of 3 ml/s at three years followup The short and long term morbidity 
is acceptably low 
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RESULTS OF THE EUROPEAN BPH STUDY GROUP 
SUMMARY 
We documented the results of high energy transurethral microwave thermotherapy 
in the treatment of benign prostatic hyperplasia. We evaluated 116 patients 
following transurethral microwave thermotherapy according to symptom scores, 
transrectal ultrasound, fi-ee voiding and pressure-flow study parameters. 
Significant improvement was noted in all objective and subjective parameters. 
Moreover, cavities in the prostatic urethra were observed in almost 40% of the 
patients. High energy transurethral microwave thermotherapy is an effective 
therapy for benign prostatic hyperplasia. Patients with larger prostates and 
moderate to severe bladder outlet obstruction seem to be the best candidates for 
this higher energy thermotherapy protocol, although morbidity is increased. 
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INTRODUCTION 
Bladder outlet obstruction in men has been a clinical problem throughout medical 
history. As early as the 17lh century it was suggested that benign prostatic 
hyperplasia (BPH) could result in mechanical obstruction of the bladder outlet 
tract, which may eventually cause lower urinary tract symptoms, inefficient 
bladder emptying with poor urinary flow and/or post-micturition residual urine'. 
At this juncture the patient usually seeks medical advice either because of 
troublesome symptoms or complaints secondary to the worsened voiding, for 
example recurrent urinary tract infections. 
Presently, transurethral resection of the prostate is the gold standard therapy for 
BPH, affording excellent results in the hands of the experienced operator. The 
success of transurethral resection of the prostate is defined by the immediate 
removal of obstructing prostatic tissue resulting in the formation of cavities. Long 
lasting improvement in symptoms and voiding parameters is achieved within a few 
days of treatment. However, this operation is not to be taken lightly. Although the 
mortality rate has decreased to 0.5%,2 the morbidity rate after transurethral 
resection of the prostate is still 18% and has not altered significantly within the 
last 15 years. Consequently, despite the proved safety and efficacy of this 
procedure, its morbidity as well as its relatively high cost and invasive nature have 
led many investigators to search for an alternative treatment. 
Many techniques that minimize the physiological effects associated with 
prostatic surgery are currently being assessed, including use of prostatic stents, 
transurethral needle ablation, high intensity focussed ultrasound, transurethral 
microwave thermotherapy and laser therapy?'7 The question as to which technique 
is appropriate in any individual is answered largely by knowing the outcome of 
each of these therapies. Despite the encouraging results claimed by all of the new 
techniques, transurethral resection of the prostate continues to surpass its 
competitors. However, the results of high energy thermotherapy seem to shed a 
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new light on this discussion. 
The results reported with lower energy thermotherapy using Prostasoft® 2.0 
(Technomed Medical Systems, Lyon, France) in the treatment of BPH are 
promising. Overall symptomatic improvement has been reported in the majority 
of patients in conjunction with improvement of voiding parameters8"10. The 
Madsen symptom score decreased from a mean of 13 before treatment to about 4 
after treatment, while mean maximum flow change ranged from 2 to 3 ml/s. It has 
been suggested that the placebo response with this modality may contribute 
considerably to treatment outcome. However, 5 sham controlled studies have 
demonstrated that the effect of transurethral microwave thermotherapy is greater 
than can be accounted for by either the associated urethral instrumentation or by 
any placebo effect." The re-treatment after transurethral microwave thermotherapy 
using Prostasoft® 2.0 was reportedly 0.5% to 11% at one year followup.910·12 
An increase in thermal dose can be seen with the evolution of thermal treatment 
modalities. The elevation of intraprostatic temperatures as measured by invasive 
thermometry during transurethral microwave thermotherapy using version 2.0 
operating software has been shown to be broadly correlated with clinical 
outcome.13 Program version 2.0 was modified to provide more power at a 
maximum of 70 Watts and uses a higher rectal threshold leading to an increase in 
the energy delivered to the prostate. This new version of the operating software 
known as Prostasoft® version 2.5 is currently under evaluation. In contrast to 
earlier reports on results achieved with lower energy thermotherapy, the results 
with these higher energy levels seem to be excellent, and in a subgroup of patients 
they are even comparable to those of surgical therapy. We present the results of 
a multicenter study using high energy thermotherapy for the treatment of BPH. 
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PATIENTS AND METHODS 
Patients recruited for the study had a Madsen symptom score of 8 or more, 
maximum flow rate of 15 ml/s or less, post-void residual volume of 350 ml or less 
and voided volume of 100 ml or more. Assessment of these patients included 
history with symptom scores, physical examination with digital rectal examination, 
biochemistry investigations including prostate specific antigen, urinalysis, urine 
culture, transrectal ultrasonography of the prostate, uroflowmetry, post-void 
residual volume measurement and a urodynamic investigation including pressure-
flow studies. The results of high energy thermotherapy in 116 men with lower 
urinary tract symptoms and BPH were evaluated, and outcome was correlated with 
prostate size, International Prostatic Symptom Score (I-PSS), Madsen symptom 
score, free flow voiding parameters and grade of bladder outlet obstruction. 
Followup was performed at 4, 12, 26 and 52 weeks after treatment. 
We used the Prostatron device with a COO treatment catheter consisting of a 
microwave dipole antenna positioned 10 mm below the Foley balloon and 
mounted in a water cooled transurethral probe. Version 2.5 of the high energy 
operating software provides power at a maximum of 70 watts with a rectal 
threshold set at 43.5°C. Transurethral microwave thermotherapy has been 
described previously.14 
Uroflowmetry was performed, and the post-voiding residuals were determined 
by transabdominal ultrasound using the ellipsoid formula. Urodynamic 
investigations were performed with a transurethral catheter equipped with an 
intravesical microtip pressure sensor for bladder pressure recordings. The 
abdominal pressure was recorded intrarectally with a microtip sensor catheter. 
Commercially available equipment was used to record the pressure and flow data. 
The digitally stored data were translated to a urodynamics analysis computer 
program developed at our department. To provide objective and precise grades of 
obstruction, pressure-flow study graphs were fitted to a passive urethral resistance 
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relation curve. The minimal urethral opening pressure and theoretical urethral 
lumen were calculated automatically.15 The urethral resistance factor was 
computed to enable the classification of patients on a continuous, 1 parameter 
scale of obstruction.16 We also added a nonparametric analysis of obstruction using 
a classification according to the linear passive urethral resistance relation pressure-
flow study nomogram.17 
RESULTS 
Between April 1993 and July 1994 a total of 116 patients were treated with 
high energy transurethral microwave thermotherapy using the Prostasoff0 2.5 
software. Patient age at baseline ranged from 50 to 87 years (mean 66.6) and 
average prostate volume plus or minus standard deviation was 51 ± 21 cm3 (range 
20 to 154). Madsen symptom score ranged from 8 to 23 (mean 13.6 ± 3.6). 
Uroflowmetry parameters show a maximum flow rate of 3 to 15 ml/s (mean 9.6 ± 
3.3), voided volume 100 to 697 ml (mean 227 ± 127), and post-void residual 0 to 
350 ml (mean 73 ± 79). An average of 147 ± 44 kJ (range 28 to 209) of microwave 
energy were administered during treatment. 
Of the patients 67 have reached a 1 year followup, while 105 were followed 26 
weeks. Among the 11 patients who were not seen at 26 weeks 2 died of 
nontreatment related causes ( 1 of terminal hart failure 4 months after treatment and 
1 of pulmonary failure due to αϊ-antitrypsin deficiency), 3 underwent transurethral 
resection of the prostate, and 6 were lost to follow up. Mean Madsen symptom 
score at baseline was 13.6 and improved to 9.4 at 4 weeks, 6.0 at 12 weeks, 5.5 at 
26 weeks and 4.9 at 52 weeks of followup (figure la). The I-PSS showed a similar 
pattern, with improvement from a mean of 17.5 at baseline to 13.9 at 4 weeks, 8.2 
at 12 weeks, 7.9 at 26 and 7.1 at 52 weeks of followup (figure lb). Maximum flow 
rate improved from 9.6 ml/s at baseline to 9.8 ml/s at 4 weeks, 15.2 at 12 weeks 
and 14.1 at 26 weeks followup. These improvements were sustained to 52 weeks 
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with a maximum flowrate of 14.5 ml/s (figure lc). The voided volume during 
follow up increased slightly (figure Id), while the post void residual decreased 
significantly from 73 ml at baseline to 40 ml at 4 weeks, 27 at 12 weeks, 33 at 26 
and 25 at 52 weeks followup, respectively (figure le). Mean duration of 
transurethral drainage was 14.3 ± 15.2 days (range 0 to 105 days). 
Transrectal ultrasonography at 3 months followup identified a cavity in 37% 
of the patients (figure 2). There appeared to be a good statistical correlation 
between the presence of cavities and uroflowmetry improvement (p=0.003). 
Maximum flow rate improved from 9.7 ml/s at baseline to 17.9 ml/s in patients 
with a cavity on TRUS and from 9.6 ml/s to 13.6 ml/s in those without a cavity. 
Currently, data for 83 patients are available for urodynamic analysis. At 6 months 
after transurethral microwave thermotherapy, a statistically significant improve-
ment was noted for all parameters, which is also clearly illustrated in the Abrams-
Griffith nomogram (figure 3 and table 1). 
Baseline parameter stratification versus treatment outcome showed that 
particularly patients with larger prostates and moderate to severe bladder outlet 
obstruction respond best to high energy transurethral microwave thermotherapy 
(table 2). These patients showed a significant improvement in objective and 
subjective parameters. The relationship between maximum flow rate at baseline 
and treatment outcome was much less. There appeared to be no relation between 
treatment outcome and the Madsen symptom score at baseline. 
High energy thermotherapy treatment resulted in considerable morbidity. 
Irritative voiding complaints were noted in a large number of patients for up to 2 
to 4 weeks, and transient hematuria was present in most patients during the first 
days after treatment. Finally, retrograde ejaculation was documented in a third of 
the patients who had antegrade ejaculation before treatment. 
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Figure 1a. Improvement in Madsen score at baseline, 4, 12, 26 and 52 after treatment. 
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Figure 1 b. Improvement in l-PSS at baseline, 4, 12, 26 and 52 after treatment. 
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Figure 1 с. Improvement in maximum How at baseline, 4, 12, 26 and 52 after treatment. 
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Figure 1d. Improvement in voided volume at baseline, 4, 12, 26 and 52 after treatment. 
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Figure 1e. Improvement in post-void residual at baseline, 4, 12, 26 and 52 after treatment. 
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Table 1. Changes in pressure-flow study parameters 
before and 6 months after treatment 
Mean ± SD 
pd e tatQmax (cmH 2 0) 
linPURR 
URA (cmH 2 0) 
Pmuo ( c m H 2 0 ) 
A lheo(mm2) 
Before 
64 ±23 
2.9 + 1.3 
41 ±15 
33 ±17 
2.8 ±1.3 
6 months 
39 ±16 
1.3 ± 1.1 
23 ±11 
16 + 9 
6.2 ±5.1 
DISCUSSION 
It is generally believed that enlargement of the prostate results in bladder outlet 
obstruction, leading to clinical manifestations of BPH. The term BPH describes 
histopathological abnormalities of the prostate. However, it is usually used to 
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Table 2 Outcome of main indices at 3 months stratified according to baseline values 
Qmax (ml/s) 
> 12 
< 12 
Prostate vol 
>40 
<40 
ImPURR 
>3 
<3 
N 
36 
80 
(ml) 
77 
39 
52 
31 
Madsen score 
Before 
1 3 8 ± 3 7 
1 3 5 ± 3 6 
1 3 4 ± 3 6 
1 3 8 ± 3 7 
1 3 7 ± 3 5 
1 4 2 ± 3 9 
3 months 
5 0 ± 4 9 
6 5 ± 4 4 
5 8 ± 4 3 
6 4 ± 5 0 
5 7 ± 4 4 
8 0 ± 4 6 
Mean ± SD 
Qmax 
Before 
13 5 ± 1 2 
7 9 ± 2 2 
9 8 ± 3 4 
9 3 ± 3 0 
9 5 ± 3 4 
91 ± 3 1 
(ml/s) 
3 months 
1 8 3 ± 5 9 
14 0 ±6 4 
1 6 5 ± 7 1 
1 3 2 ± 4 6 
16 9± 7 1 
1 4 0 ± 6 5 
pdelatQmax (cmH20) 
Before 
67 ±21 
62 ±24 
68 ±21 
53 ±24 
78 ±15 
40 ±10 
3 months 
37 ±17 
39 ±15 
38 ±16 
41 ±15 
42 ±17 
33 ±13 
describe a condition that can be characterized by nonhistological criteria such as 
voiding symptoms, an enlarged prostate and bladder outlet obstruction.18 The 
majority of elderly men will eventually experience some voiding symptoms and 
will seek therapy.19 The only generally accepted treatment for BPH is transurethral 
or open prostatectomy. Since men with BPH arc often of advanced age with 
cardiopulmonary diseases and high operative risks, a minimally invasive treatment 
has been sought, including medication2021 and instrumentation.3"7 With the concept 
of transurethral microwave thermotherapy as an outpatient and anaesthesia-free 
procedure, and the encouraging clinical results achieved to date, much effort has 
been concentrated on developing this treatment modality. 
Application of higher energy levels using Prostasoft® 2.5 was first reported by 
Devonec6 and de la Rosette" et al, who demonstrated clinically significant 
improvement. Our present multicenter study confirms these results. The changes 
in subjective parameters using the high energy Prostasoft® 2.5 software, is similar 
to the improvement noticed in patients treated with the Prostasoft® 2.0 version.6 
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Figure 2 Ultrasonograms of the prostate identifying a cavity 3 months after TUMT 
(a, longitudinal, b, transverse section) 
However, when comparing the objective parameters, a significantly better outcome 
in terms of urinary peakflow change was noted. A statistically significant increase 
in maximum flow was found of 9.6 to 15.2 ml/s was noted at 12 weeks after 
transurethral microwave thermotherapy, which was sustained to at least one year. 
Mean post void residual values also improved significantly from 73 to 27 ml at 12 
weeks and 25 ml at one year. This objective improvement in uroflowmetry results 
was much more pronounced than in patients treated with the lower energy 
software. Transrectal ultrasound imaging of the prostate identified a cavity in 37% 
of the patients at 3 months after treatment (figure 2). A positive correlation 
between the presence of such a cavity and urinary flow rate improvement was 
observed. One may conclude that more energy delivered to the prostate seems to 
result in greater improvement in objective parameters, which may be explained by 
the creation of cavities within the prostate. However, when such a cavity is absent 
the treatment should not be regarded as a failure because uroflowmetry may 
improve independent of cavity formation. 
Although flowmetry is an excellent method documenting the act of micturition, 
and it may indicate whether an abnormality is present, its role in defining the grade 
of obstruction is limited.22 For transurethral microwave thermotherapy to be 
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Figure 3. Abrams-Griffiths nomogram of obstruction of patients before TUMT (9) 
and 6 months after TUMT (A) 
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regarded as proper therapy for BPH, it must be able to relieve the outlet 
obstruction. Advanced urodynamics, including pressure-flow study analysis, are 
considered the best methods to document changes in the grade of obstruction.22 
The changes in pressure-flow study parameters were only moderate with the lower 
energy Prostasoft® 2.0 software. We concluded that only a certain type of 
obstruction responded favorably to thermotherapy.23'24 In general, however, severe 
obstruction is not cured following low energy thermotherapy. Analysis of the 
urodynamic data at 6 months after transurethral microwave thermotherapy using 
Prostasoft® 2.5 showed that 80% of obstructed patients appeared to be cured 
(Abrams-Griffiths nomogram, figure 3). A significant decrease in all obstruction 
parameters was noted overall (table 1). One can conclude that transurethral 
microwave thermotherapy using Prostasoft® version 2.5 is able to relieve bladder 
outlet obstruction. 
From an earlier study we learned that no single clinical parameter could predict 
which patients would respond best to low energy thermotherapy.25 Using high 
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energy thermotherapy it appears that patients with more severe outlet obstruction 
and larger prostates will respond best. Further studies are required to explain this 
phenomenon. A possible explanation for the favorable outcome of treatment of 
larger prostates is a difference in tissue composition and tissue perfusion. It is well 
known that stromal tissue responds different to heat than glandular tissue.26 Larger 
prostates may have a different distribution of stromal and glandular tissue and 
consequently they may respond differently to thermotherapy. We also know that 
the temperature increase in the prostate depends strongly on the tissue perfusion, 
and that perfusion is known to increase with temperature during thermotherapy.27 28 
One can speculate that in larger prostates the tissue perfusion is less efficient than 
in smaller prostates, and that perhaps as a consequence higher temperatures can 
be achieved resulting in necrosis with formation of a cavity. Current 
thermotherapy systems do not consider the effect of tissue perfusion on the 
efficacy of the treatment. 
Although urine flow is improved, the morbidity caused by high energy 
transurethral microwave thermotherapy is increased compared to lower energy 
protocols. The high energy treatment is well tolerated by the patients but pain 
medication must be administered before or during therapy in most cases. On a trial 
and error basis, 30 mg morphine sulfate administered 2 hours before therapy 
resulted in an almost complaint-free treatment. If requested, patients also were 
given either 10 mg diazepam and/or 0.10 mg fentanyl during treatment. Perception 
of discomfort during transurethral microwave thermotherapy may vary from a mild 
feeling of perineal warmth and a mild urge to urinate to significant discomfort. 
However, the morbidity is clearly lower with transurethral microwave 
thermotherapy than with transurethral resection of the prostate. Transurethral 
microwave thermotherapy can still be performed as an outpatient procedure 
without general anaesthesia, and is particularly well suited for patients in poor 
health. Occasionally, hematuria and tissue slough are noted, and urinary retention 
is expected in almost all patients. Catheterization interval averaged 14.3 days 
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(range 0 to 105), and patients with larger prostates required longer catheterization 
periods than those with smaller prostates. The findings of retrograde ejaculation 
in a third of our patients is in contrast to those documented with lower energy 
thermotherapy, in which antegrade ejaculation was unchanged in the majority of 
patients.1Ч 
No bladder neck contraction or urethral strictures have been noted to date. 
Treatment with transurethral resection of the prostate was repeated in 3 patients 
because they where not satisfied with the result. From the long-term followup data 
using Prostasoft® 2.0 we have learned that re-treatment rate at 1 year is estimated 
up to I0%, 1 0 while 3 year follow up data by de Wildt and de la Rosette,27 and 
Dahlstrand et al 3 ' indicate that clinical benefit is sustained for this period. One 
may expect that the results achieved with the higher energy software are at least 
as good. 
CONCLUSION 
High energy transurethral microwave thermotherapy shows significant subjective 
and objective improvement. The best candidates are patients with moderate to 
severe bladder outlet obstruction and larger prostates. Formation of cavities after 
treatment correlated well with better clinical outcome. 
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1 YEAR FOLLOWUP OF 
HIGH ENERGY THERMOTHERAPY 
SUMMARY 
High energy transurethral microwave thermotherapy (TUMT) was developed to 
increase treatment efficacy over former low energy treatment protocols as an 
outpatient-based, anesthesia-free procedure for patients with benign prostatic 
obstruction A Phase IIstudy was conducted to evaluate treatment outcome and 
to enlighten possible prognostic factors Eighty-five patients with lower urinary 
tract symptoms were included m the study A Madsen symptom score of 8 or more, 
a maximum flow less than 15 ml/s and a postvoid residual urine volume (PVR) of 
under 350 ml were the mam requirements for entry Eleven patients were lost to 
followup, making 74 patients évaluable at one year followup Significant 
improvement was noticed in all indices the Madsen symptom score improved 58% 
from baseline, the maximum flow rate improved from 9 4 to 14 9 ml/s, with a 
decrease in PVR of 80 ml to 25 ml, bladder outlet obstruction could be relieved 
in 78% of patients, and prostate volume decreased by 20% , with cavity formation 
in 42% Patients with bigger prostates (greater than 40 cm3) and patients with 
more severe bladder outlet obstruction appeared to be the best responders Post-
treatment morbidity consisted of a prolonged need for transurethral catheter 
drainage (mean 16 days), with correlated irritative voiding complaints for an 
average of 2 to 3 weeL· Overall improvement of high energy thermotherapy now 
shows comparable results to surgical resection of the prostate 
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INTRODUCTION 
Benign prostatic obstruction (BPO) is a common disease in men that is creating an 
increasing demand on the health care system. It is estimated that eventually one 
third of all males will require an operation for relief of lower urinary tract 
symptoms (LUTS) due to BPO.' 
For more than 50 years, the treatment for BPO has been decreasing gland volume. 
The surgical removal of prostate tissue is still considered the reference standard. 
Besides being the most commonly performed surgical procedure in elderly males, 
it comprises a large part of the urologist's workload.2 Complications and side 
effects include infection, incontinence, retrograde ejaculation, urethral stricture, 
and impotence. In addition, some patients have a severe medical illness that 
increases anaesthetic and surgical risk, which may predispose them to 
postoperative sepsis or a cardiovascular event.'4 
Currently, the management of BPO is under evaluation. Medical treatment is 
becoming an increasingly important option in patients with moderate LUTS.5 б In 
addition several minimally invasive treatment options have been tested. The use 
of heat (applied by different heat generators such as ultrasound, radio-frequency, 
laser and microwave-devices) appears to be the most promising alternative.78910 
Of these different applications, microwave energy has been most extensively 
investigated. Continuous developments have led to transurethral microwave ther-
motherapy (TUMT) that makes it possible to obtain high temperatures deep inside 
the prostate lateral lobes while still preserving the urethral mucosa; 1296 MHz 
microwave radiation is applied from a transurethral antenna, and the mucosa is 
simultaneously cooled by circulating fluid within the applicator (Prostatron device, 
Technomed Medical Systems, Lyon, France). This concept allows an outpatient-
based, anesthesia-free procedure. Significant symptomatic improvement and 
increase in objective parameters such as maximum flow rates and postvoid 
residual urine volume (PVR) are reported.'° The clinical improvement has been 
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shown not to be due to a placebo effect or the result of the associated urethral 
instrumentation in randomized trials of TUMT versus sham." '2 Although in a 
randomized TUMT versus transurethral resection of the prostate (TURP) trial the 
symptomatic improvement is similar to improvement seen after TURP, the 
objective improvement is less pronounced and the durability of the treatment is 
unclear.13 Interstitial thermometry studies during TUMT treatments have shown 
that there is a strong correlation between the treatment outcome and the obtained 
temperatures within the prostate.14 This has led to the development of a new 
software protocol that operates the Prostatron unit (Prostasoft® 2.5), enabling 
higher energy levels (intraprostatic temperatures up to 75°C) with an average 
increase of total energy delivered to the prostate of 40%, thus creating tissue 
necrosis and cavity formation within the prostate; this is termed thermo-
ablation.1516 
We conducted a Phase II study using this high energy protocol. Besides 
documenting treatment outcome, we will also try to determine possible prognostic 
factors that contribute to the better results. 
MATERIAL AND METHODS 
Between October 1993 and August 1994, 85 patients were treated with the 
Prostasoft® 2.5 protocol approved by the hospital's ethical committee. All 85 men, 
aged 50 to 85 years (mean: 64.7 ± SD 8.6), had LUTS related to BPO and, in 
principle, were candidates for either (TURP) or an open prostatectomy. Inclusion 
and exclusion criteria are mentioned in table 1. 
Twelve patients (14%) were in poor cardiac or pulmonary health (ASA 3 to 4). At 
baseline, all patients underwent the following investigations: general history; 
complete physical examination with digital rectal examination (DRE); estimations 
of full blood count, blood urea and creatinine; and urine microscopy and culture. 
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Urine cytology and prostate specific antigen (PSA: Hybritech, Texas) levels were 
always measured to exclude coexisting malignancy. Upper urinary tract dilation 
and renal pathology were excluded by ultrasound investigation. Prostate 
configuration was assessed by performing transrectal ultrasound (TRUSP), volume 
being calculated by a planimetrie technique (Kretz Combison 330 with a 7.5 MHz 
transrectal probe; multi 3-D VRW 77 AK). In case of an abnormality detected by 
DRE, PSA level, or TRUSP, ultrasound-guided prostate biopsies were performed. 
Flexible urethrocystoscopy (Storz) was carried out to judge the patency of the 
(prostatic) urethra for the presence of strictures or an isolated obstructing prostatic 
middle lobe and to exclude intravesical pathology. 
Table 1 Inclusion and exclusion criteria for high energy TUMT 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Age > 45 years Acute prostatitis or urinary tract 
Prostatic urethra measured by Prostate carcinoma 
flexible cystoscopy > 2.5 cm Isolated obstructed prostatic middle 
Madsen symptom score > 8 Diabetes mellitus 
Qmax < 15 ml/s Intravesical pathology 
Postvoid residual volume < 350 ml Neurological disorders 
Voided volume > 100 ml Drugs influencing bladder function 
Patient symptoms were evaluated using a physician-guided Madsen symptom score 
allowing comparison with previous studies reporting on TUMT.17 In addition the 
self-administered International Prostate Symptom Score (I-PSS) was used.18 
A Dantec Urodyn 1000 flowmeter was used to register the maximum flow 
rates (with corrections for flow artefacts using the two second method) and voided 
volume. Post-void residual volume (estimated by suprapubic ultrasound with an 
ellipsoid technique), and voiding percentage (that is, [voided volume/(voided 
volume + postvoid residual volume)] χ 100 as a measure of voiding efficiency, 
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were also recorded. 
To quantify the grade of bladder outlet obstruction, urodynamic investigation 
with pressure-flow (PQ) analysis was performed. Intravesical and rectal pressures 
were recorded using 8F catheters mounted with microtip-sensors (MTC, Dräger, 
Germany), and detrusor pressure was calculated as the difference between both. 
The digitally stored pressure and flow-data were analyzed by a program developed 
at our department (UIC/BME Research Center, Department of Urology, Nijmegen, 
The Netherlands). The following parameters derived from the PQ-analysis were 
used: detrusor pressure at maximum flow (Pdelat Qmax in cmH20), maximum flow 
rate PQ-Qmax in ml/s), and the linPURR (obstruction grading according to 
Schäfer).19·20 A patient is considered urodynamically obstructed when Pdetat Qmax 
falls into the obstructed area of the linPURR nomogram when the linPURR is 3 
or greater. 
After correct positioning of the urethral heat applicator and rectal-temperature 
probe, a 60 minute microwave treatment was performed. A more extensive 
description of such a treatment has been reported elsewhere.21 Two hours before 
treatment a 20-40 mg dose of morphine sulphate was administered orally. If neces-
sary, additional intravenous sedation with a combination of diazepam and fentanyl 
was given when patients experienced major discomfort during treatment; this was 
mostly expressed as an intense urge to void, sometimes in combination with an 
urge to defecate. Initial experience showed urinary retention in nearly all patients; 
therefore, all patients were given a urethral catheter with leg-bag directly after 
treatment. Patients were seen 1, 4, 12, 26 and 52 weeks after treatment. 
Uroflowmetry with PVR volume, symptom scores and blood analysis, and 
urinalysis were repeated at each visit. Ultrasonography of the prostate was 
repeated at 12 and 52 weeks. Finally, the urodynamic investigation was repeated 
26 weeks after treatment. Statistical analysis was done with the Student's t-test 
(cc=0.05) and the Wilcoxon signed-rank test (a=0.05). Correlations were tested 
using the Pearson correlation (a=0.05) 
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RESULTS 
At baseline 85 patients entered the study. At a 1-year followup, 74 patients were 
available for analysis. The followup scheme is presented in table 2. 
Table 2. Followup of the 85 patients at 3, 6 and 12 months from baseline 
Number of patients 
Baseline 3 months 6 months 1 year 
85 
1 TURP elsewhere 
1 died of terminal 
heart failure non 
treatment related 
83 81 
1 died of pulmonary 
failure due to 
a1-antitrypsine 
deficiency 
1 refused further 
visits to out-
patient clinics 
underwent TURP 
because of un-
satisfactory result 
refused further visits 
to outpatient clinics 
died of metastasized 
gastrointestinal 
tumor 
1 underwent laser 
prostatectomy 
74 
Treatment 
In 40 patients (47%) additional intravenous sedation was necessary during 
treatment. None of the treatments had to be stopped before 60 minutes nor did the 
energy level have to be reduced. The total amount of energy delivered to the 
prostate ranged from 50.0 kJ to 208.9 kJ (mean: 154.7 kJ ± SD 36.4). In 3 patients 
(5%), it was not possible to insert a transurethral catheter immediately after 
treatment, so a suprapubic catheter was inserted. 
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Figure 1. Mean improvement of main indices at baseline, 4, 12, 26 and 
52 weeks after treatment 
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FOLLOW UP IN WEEKS 
Subjective results (symptom scores) 
The complete group showed significant changes in both symptom scores. The 
mean Madsen symptom score decreased by 58% at 12 months followup. With an 
initial improvement from a mean 13.9 ± SD 3.6 at baseline to a mean of 6.7 ± SD 
4.6 at 3 months, stabilizing occurred at 5.7 ± SD 4.6 at 6 months and 5.8 ± SD 4.7 
at one year followup. Comparable changes were noticed in the I-PSS scores. The 
mean I-PSS at baseline of 17.6 ± SD 6.0, decreased to 9.2 ± SD 6.4 at 3 months, 
8.5 ± SD 6.5 at 6 months and 8.0 ± SD 5.8 at a year followup indicating a mean 
I-PSS decrease by 55% at 1 year (figure 1). 
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Objective results 
voiding parameters 
For the complete group the mean maximum flow rate showed significant 
improvement from 9.4 ± SD 3.3 ml/s at baseline to 15.8 ± SD 7.0 ml/s at 3 months 
followup and remained stable at 14.4 ± SD 6.7 ml/s at 6 months and 14.9 ± SD 6.7 
ml/s at 1 year followup. 
Figure 2. Changes in p^fltQmax (cmH20) before (Ш) and 6 months after TUMT (A) 
in the linPURR-nomogram for obstruction 
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Similar improvements were noticed in the post void residual urine and voided 
percentage. A mean PVR of 80 ± SD 88 ml at baseline improved to 26 ± SD 44 
ml/s at 3 months, stabilizing at 28 ± SD 75 ml at 3 months and further improving 
to 25 ± SD 35 ml after l year. The voided percentage improved from a mean of 77 
± SD 18% at baseline to 92 ± SD 10% at 3 months, 93 ± SD 13% and 92 ± SD 
11% after 1 year followup (Figure 1). 
121 
Urodynamic investigation with pressure flow studies 
At baseline, two investigations were excluded because pressure-flow analysis was 
not available due to unreliable recording of the voiding phase; therefore the 
urodynamic data of 83 patients were available. After 26 weeks the urodynamic 
investigation was repeated in 71 patients. In total, 8 patients refused a second 
investigation, the remaining 4 patients were the ones who were lost to followup 
(table 2). The urodynamic parameters significantly improved: the pdelatQmax 
improved from a mean of 63.6 ± SD 22.7 cmH20 at baseline to 38.9 ± SD 15.7 
cmH20 at 26 weeks; the PQ-Qmax improved from a mean of 6.3 ± SD 2.3 ml/s at 
baseline to 11.0 ± SD 5.4 ml/s at 26 weeks; the linPURR improved from a mean 
of 2.9 ± SD 1.3 at baseline to 1.3 ± SD 1.0 at 26 weeks. 
Figure 2 gives a graphical representation of changes in detrusor pressure at 
maximum flow rate (pdet atQmax) before and 6 months after TUMT using the 
linPURR-nomogram for obstruction. At baseline, 46 patients (65% of 71) could 
be considered obstructed with a linPURR of 3 or more. Using the linPURR 
classification for obstruction, 36 of these 46 patients (78%) can no longer be 
considered obstructed 6 months after treatment. 
Trans rectal ultrasound imaging of the prostate 
At baseline, the mean prostate volume on ultrasonographic investigation was 
measured at 53.9 ± SD 22.8 ml (range 30 to 154). The repeated measurement at 3 
months showed an average volume of 45.1 ± SD 19.1 ml (range 21 to 122 ml) thus 
indicating a significant volume reduction of 8.8 ± SD 12 ml (p < 0.001). This 
reduction was confirmed at 52 weeks with a mean prostate volume of 43.4 ± SD 
19.3 ml (range 15 to 119). Furthermore, in 35 patients of the available patients at 
3-month followup (42% of 83) a cavity could be observed (Figure 3). The presence 
of a cavity was positively correlated with improvement in urinary performance and 
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relief of outlet obstruction. The difference in Qmax improved was significant 
(p=0.02): the mean improvement in Qmax is 8.5 ± SD 7.3 ml/s (from 9.4 to 17.9 
ml/s) in patients with a cavity and 4.8 ± SD 5.4 ml/s in patients without a cavity 
(from 9.7 to 14.5 ml/s). In accordance there is greater relief of outlet obstruction 
in patients with a cavity (p=0.002): the mean pdelatQmax improves 36.8 ± SD 27.1 
cmH20 (from 70.4 to 33.6 cmH20) in patients with a cavity and 17.7 ± SD 25.6 
cmH20 (from 59.3 to 41.6 cmH20 ) in patients without a cavity. 
PSA levels 
The mean PSA level at baseline was 5.0 ± SD 3.3 ng/ml (range 0.5 to 14), and it 
increased to a mean 40.8 ± SD 28.3 (range 1.8 to 120), 1 week after treatment. It 
ended below baseline level of 4.0 ± SD 2.9 after 12 weeks, 4.0 ± SD 2.6 at 6 
months and 4.3 ± SD 2.7 at the I year followup. The amount of prostate volume 
reduction is significantly correlated with the decrease below baseline of the PSA-
levels (Pearson correlation coefficient of 0.51 and ρ < 0.001). 
Sexual function 
Of the 85 patients at baseline 77 indicated being sexually active. Prior to treatment 
already 35 of these 77 patients (45%) had already reported a decrease in erectile 
function, and 14 of the 77 (18%) had diminished or absent ejaculation. At least 3 
months after treatment, none of the 41 remaining patients with normal erectile and 
ejaculatory function reported erectile dysfunction, 18 of the 41 (44%) claimed a 
retrograde ejaculation, and 6 of the 41 (15%) experienced diminished ejaculatory 
volume at evaluation. 
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Response criteria 
Analysis of the 3- month followup data shows different response rates when taking 
some of the baseline parameters into account. Table 3 shows the response rates in 
percentage and mean improvement as expressed by Madsen and I-PSS symptom 
scores, Qmax and pdelatQmax, given the stratification of some baseline parameters. 
Regarding this table, it seems that patients with bigger prostates and urodynamic 
obstruction are the best responders to high energy TUMT. 
Table 3 Mean value and % improvement 3 months after treatment of stratified baseline 
Baseline 
N 
Madsen score 
% 
% and Mean ± SD 
l-PSS score Qmax 
% % 
pdetatQmax 
% 
Madsen score 
< 15 
> 15 
Qmax (ml/s) 
> 12 
< 12 
Prostate vol 
>40 
<40 
ImPURR 
>3 
<3 
hnPURR>3 
and pros vol 
51 
34 
26 
59 
(ml) 
62 
23 
52 
31 
48 
56 
64 
45 
54 
43 
58 
40 
>40 ml 
56±44 40 67±73 88 65±70 32 27 1 ± 27 7 
98±51 48 110 ±84 69 56±66 31 215±28 4 
95±48 59 113±63 39 53±55 36 23 4±29 9 
63±50 36 72±84 99 66±73 30 25 3 ± 27.5 
77±50 45 86±72 84 67±73 39 29 5± 28 9 
62±53 38 80±99 72 49±52 13 13 5± 22 1 
8 1 ± 4 6 50 94±71 98 7 3 ± 7 3 44 36 5 ± 24 8 
62±57 33 71±93 53 45±58 9 63±17 3 
40 62 8 6 ±4 3 53 9 9 ±6 3 102 8 0 ± 7 4 46 39 0 ± 26 4 
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Post treatment morbidity 
At the first visit (1 week after treatment) micturition had been restored 
satisfactorily in 57% of the patients and the transurethral catheter could be 
removed. The mean catheter placement time was 16 days, with a prolonged 
catheter time necessary in 10% of patients (range 30 to 105 days). This mainly 
concerned patients with bigger prostates and patients with severe outlet 
obstruction. The most common complaints noted during the time of an indwelling 
catheter were bladder spasms with urine leakage past the catheter in 25%, perineal 
discomfort in 7%, and hematuria in 76% After removal of the catheter, 60% of 
patients experienced temporary irritative complaints of urgency and frequent 
micturition. These irritative complaints could successfully be treated with 
anticholinergic medication (oxybutinin) sometimes (in combination) with anti-
inflammatory drugs (diclofenac). All patients received systemic antibiotic 
prophylaxis (Cotrimoxazol) prior to treatment and was continued for 5 days. In 
29% of patients the antibiotics were resumed either because of positive culture or 
empirically in the case of substantial complaints. Six patients (7%) developed 
epidydimitis after treatment. On average the treatment-related complaints ended 
2 to 3 weeks after treatment. In total 18 of 85 (21%) patients were using 
anticoagulants of whom 5 (6%) coumarin derivatives. One of these patients had 
to be admitted to the urology ward for bladder rinsing because of blood clot 
retention due to dysregulated anticoagulant medication. 
DISCUSSION 
Transurethral resection or open prostatectomy in the treatment of BPO still results 
in the best symptomatic improvement and urinary performance. Various new 
surgical techniques are comparable in their results.7,8'9 The major drawback of 
125 
most of these treatments is that hospital admission and anesthesia are still 
necessary. Although TUMT does not result in TURP-like objective improvement, 
the question was raised if it was necessary to reach "supranormal" flow rates 
achieved with TURP since age-matched asymptomatic patients appear to have a 
flow rate (13 ml/s) more comparable to that of TUMT.22 It appeared that the 
mechanism of action using this lower energy thermotherapy is substantially 
different from the volume reduction and cavity formation obtained with TURP. 
However, this most likely contributes most to the durable effect of TURP in the 
long term. Although this study does not concern a randomized study of TURP 
versus TUMT, it is the first report that shows that it is indeed possible to achieve 
TURP-like results with an anesthesia-free procedure without major post-treatment 
morbidity. 
The symptomatic improvement obtained using TUMT in this study, expressed as 
the Madsen symptom score, is in agreement with ranges previously reported. The 
entry level score is usually around 13 and the expected outcome around 4, with an 
overall improvement of around 65%.I0 The present study is comparable to these 
data with an average improvement of Madsen symptom score from 13.9 at baseline 
to 5.8 at week 52, representing an overall improvement of 58%. Improvements in 
I-PSS score show a similar decrease when compared with other studies of 
minimally invasive treatment for BPO. These studies represent an entry level 
I-PSS of around 20 with improvement to around 7 at the 12-month followup, 
representing an improvement of 65%.23 The present study shows comparable 
results with a mean I-PSS of 17.7 at baseline and improvement to 8.0 at week 52, 
with an overall improvement of 55%. 
The improved efficacy of high energy TUMT compared with former low 
energy protocols is mainly expressed in a significantly better outcome in all 
objective parameters. The far better urinary performance is expressed in changes 
in uroflowmetry, which demonstrates a substantial increase in maximum urinary 
flow rate with reduction of PVR and an increase of voiding percentage. 
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Improvements in maximum flow rate are now in the range that are usually seen in 
patients treated with TURP or open prostatectomy.2"25 Such an improvement can 
only contribute to a more durable effect in the long term if this is indeed based on 
relief of outlet obstruction. Previous studies on urodynamic changes after TUMT 
with low energy levels, reported little change in urodynamic obstruction 
parameters. This was not comparable to urodynamic changes seen after TURP, but 
seemed to be founded on an increased elasticity of the prostatic urethra.26 On the 
contrary, high energy TUMT can achieve TURP-like urodynamic relief of 
obstruction, which in the present study is evidently shown in the improvement of 
the mentioned urodynamic obstruction parameters. In 78% of patients who could 
be considered obstructed at baseline, outlet obstruction is relieved. This substantial 
improvement is best illustrated with the changes in pre-treatment and post-
treatment detrusor pressure at maximum flow using the linPURR-nomogram 
(figure 2). It shows a general trend from the obstructed pre-treatment region 
towards the unobstructed region after treatment, although some patients remain 
obstructed. This shift is comparable to the changes found in patients who are 
treated with TURP.27 
Further evidence of the substantial effect on prostate tissue produced by the 
high energy TUMT, is shown in the significant reduction of prostate volume at 1 
year by a mean of 10.5 ± SD 12 cm3 which represents an overall reduction of a 
mean 19.4 ± SD 21.8%. Available studies on prostate volume decrease after TURP 
show a higher amount of tissue (around 60%) removal.28 
Changes in PSA levels shortly after TUMT have always been associated with the 
amount of effect that microwave energy causes on prostate tissue. In TUMT versus 
sham studies, no rise of PSA was seen in the sham-arm, whereas the TUMT group 
showed increase to a mean of 25 ng/ml.2'J In a retrospective responder versus 
nonresponder study it was shown that responders to TUMT had a significantly 
higher rise of PSA 1 week after treatment when compared to nonresponders.30 In 
the present study, the PSA levels rose to mean levels of around 40 ng/ml. 
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Interestingly, the present study shows a significant correlation between the 
decrease of PSA below baseline level and the amount of prostate volume reduction 
that is achieved, which is in accordance with what is found after TURP.11 Tissue 
damage not only can result in prostate volume reduction but also in cavity 
formation. Previous studies with lower energy TUMT failed to show this effect on 
the prostate. In contradistinction, the present study notes a cavity, comparable to 
cavities that can be seen after TURP, in 42% of patients (figure 3). The absence 
of a cavity does not, however, necessarily imply worse treatment outcome. 
Although the mean improvement of several parameters might be less, the standard 
deviations indicate moderate amount of variation. Therefore, good response can 
also be seen on an individual basis. 
However, there is a price to be paid in terms of morbidity. The present trial 
showed that there is an increased morbidity mainly consisting of a prolonged 
catheterization time and irritative complaints after treatment. Whereas patients 
treated with lower energy TUMT are reported to have a retention rate after 
treatment of around 20%, all patients treated with the high energy protocol needed 
a catheter for at least 1 week. Although irritative complaints - such as frequency, 
urgency, dysuria and hematuria - were also reported with lower energy TUMT 
treatments, they are more frequent and pronounced during the First 2 to 4 weeks 
in patients with high energy treatments. Nevertheless, the high energy treatments 
are still possible on an outpatient basis in a single 1 hour session without the need 
for anesthesia. Moreover, in the present study with 74 patients followed up for at 
least 1 year, there were no urethral strictures, no bladder neck contractures, and no 
stress incontinence. 
As a consequence of a more effective treatment, the effect on ejaculatory 
performance is substantially changed. Patients treated with low energy TUMT 
report a 5% to 10% retrograde ejaculation after treatment; in the present trial, this 
occurred in 44%, with an additional 15% of patients reporting a diminished 
ejaculatory volume. These results indicate that the high energy TUMT is also 
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Figure 3 Ultrasonograms of the prostate 3 months after treatment identifying a cavity 
(a, transverse, b, longitudinal section) 
capable of changing the bladder neck function, which, besides causing retrograde 
ejaculation, is probably responsible for better urinary performance and reduction 
of bladder outlet obstruction. Finally, one also has to keep in mind that a large 
number of patients who are unfit for surgery because of poor physical health, 
profit from this ambulatory anesthesia-free therapy. In this study, the twelve 
patients in ASA 3 to 4 group all responded favorably. 
Although the objective and subjective improvement all point to TURP-like 
results, not all patients experienced equal response. Previous clinical results of low 
energy TUMT showed clear separation between patients who respond favorably 
in both subjective and objective terms and patients who do not respond at all. In 
a retrospective multicenter study of responders versus nonresponders, it was 
concluded that none of the baseline parameters (such as prostate volume, 
uroflowmetry results, or symptom scores) were able to define the ideal patient for 
treatment and to predict the result of the treatment.30 In another multicenter study 
using urodynamic parameters, it was concluded that, with pressure-flow study 
parameters, it was possible to identify the patients who would respond favorably.32 
Data analysis with stratification of baseline parameters in the present study, shows 
favorable results in patients with moderate to severe bladder outlet obstruction and 
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bigger prostates (table 3). Nevertheless, there still is considerable difference in 
treatment outcome among individual patients. The clinical benefit appears to be 
related to the achieved ¡ntraprostatic temperatures, that result from a complex 
interaction between the biologic response to microwaves and the pattern of energy 
provided during treatment in any individual.1'' This interaction is probably greatly 
depending on prostate vascularization and tissue composition of the prostate.33·3'' 
Further research should, therefore, be directed towards gaining better insight in 
these matters. 
CONCLUSION 
High energy TUMT results in improved objective outcome with comparable 
subjective response when compared to low energy TUMT treatments that were 
reported previously. Overall, the improvement now attains results that are 
comparable with surgical resection of the prostate and bladder outlet obstruction 
is similarly relieved. Nevertheless, stratification of baseline data showed improved 
efficacy in patients with bigger and urodynamically obstructed prostates. However, 
post treatment morbidity is substantial and should be given more attention in 
future prospective randomized trials. 
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PRESSURE-FLOW STUDY ANALYSES AND 
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Based on: 
JJMCH de la Rosette, MJAM de Wildt, К Höfner, SStC Carter, FMJ Debruyne, 
A Tubaro. 
Pressure-flow study analyses in patients treated with high energy 
Thermotherapy 
Journal of Urology, in press 
SUMMARY 
We evaluated the urodynamic changes after high energy microwave 
thermotherapy in patients with lower urinary tract symptoms and benign prostatic 
enlargement. A total of 120 patients was available for analysis with urodynamic 
investigation and pressure-flow studies before and 6 months after treatment. 
Several obstruction parameters were used to evaluate treatment outcome. A 
significant decrease (p < 0.001) in all obstruction parameters was noted. Mean 
detrusor pressure at maximum flow decreased from 64.7 cmH20 to 39.1 cmH20, 
urethral resistance factor from 41.8 cmH20 to 23.5 cmH20 and linear passive 
urethral resistance relation from 3.0 to 1.4. Analysis of subgroups showed better 
results in patients with greater grades of obstruction. High energy thermotherapy 
results in significant and substantial decrease of bladder outlet obstruction. 
136 
INTRODUCTION 
Presently, there is no agreement on the role of urodynamic studies in assessment 
of patients with lower urinary tract symptoms and benign prostatic hyperplasia 
(BPH).12 Most urologists agree that the main feature of the enlarging prostate is 
bladder outlet obstruction, eventually resulting in lower urinary tract symptoms. 
Most surgical therapies attempt to decrease obstruction and relieve symptoms. 
Since the results of surgery for BPH are generally favorable, there has been little 
enthusiasm for use of resource consuming investigations, such as advanced 
urodynamic studies. 
However, an increasing number of urologists are becoming aware of the 
additional benefit of urodynamic studies with pressure-flow analysis in 
assessment and followup of patients with lower urinary tract symptoms and BPH. 
It is well-known that 25 to 30% of patients treated surgically do not have bladder 
outlet obstruction.35 Although postoperative results are impressive and the 
procedure is reasonably safe, the morbidity of the operation is still considerably 
great.' Furthermore, the outcome in patients with minimal obstruction is less 
favorable,3'5'7 and most urologists will agree that a treatment designed to relieve 
obstruction in patients without bladder outlet obstruction is unjustified. Also, 
during the last decade many alternatives to prostatectomy have surfaced, ranging 
from the pharmacological approach to numerous procedural alternatives.8"13 While 
none of these alternatives have reached subjective and objective results 
comparable to those noted postoperatively, morbidity is significantly decreased 
and one may question whether transurethral prostatectomy-1 ike results always must 
be obtained to achieve a good outcome. Urodynamic studies can also be useful in 
the selection of patients who are candidates for alternative treatment.1415 
For the last 5 years, we performed transurethral microwave thermotherapy 
in the treatment of patients with lower urinary tract symptoms and BPH. Although 
subjective improvements using the lower energy protocol (Prostasoft® 2.0; 
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Technomed Medical Systems, Lyon, France), objective improvements are less 
pronounced. Urodynamic studies have been used to investigate the 
pathophysiology of BPH and evaluate the clinical outcome of various treatments. 
From a urodynamic viewpoint, only patients with a particular type of obstruction 
responded favorably using the lower energy using the lower energy protocol.14 
Recently, a higher energy software version has been introduced to improve the 
outcome of this procedure, and a significant improvement in all objective and 
subjective parameters was observed. In a subgroup of patients, the results even 
seemed competitive with surgical therapy.9 We report on the urodynamic results 
of this high energy thermotherapy in patients with lower urinary tract symptoms 
and BPH. We used pressure-flow study parameters to describe the power of this 
high energy thermotherapy to relieve obstruction, and compared this method to 
other (alternative) therapy options. We also studied which patients improved the 
most with this new thermotherapy protocol and to identified specific urodynamic 
selection criteria. 
MATERIAL AND METHODS 
Since April 1993, patients with lower urinary tract symptoms and BPH were 
included in a prospective study of TUMT using the high energy thermotherapy 
protocol. Inclusion criteria were Madsen symptom score of 8 or more, maximum 
flow rate of 15 ml/s or less, post void residual volume of 350 ml or less, and 
voided volume of 100 ml or more. All patients underwent screening with physical 
examination (including digital rectal examination), blood chemistry studies 
(including prostate specific antigen with the Hybritech assay), urinalysis and urine 
culture. Transrectal ultrasound of the prostate was performed with planimetrie 
measurement of prostate volume. All patients underwent urethrocystoscopy to 
measure prostate length, and assess the size of the middle and lateral lobes. In 
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cases of a suspicious digital rectal examination, transrectal ultrasound or elevated 
prostate specific antigen, prostate biopsies were obtained to exclude malignancy. 
We used the Prostatron device with a treatment catheter consisting of a 
microwave dipole antenna with the hot point positioned just below the Foley 
balloon. The catheter was mounted in a water cooled transurethral probe. The high 
energy operating software (Prostasoft® 2.5) provides a maximum power of 70 W 
with a transrectal threshold set at 43.5°C. Transurethral microwave thermotherapy 
generally has been described previously.16 
Urodynamic investigations were performed with an 8F transurethral lumen 
catheter with an intravesical microtip pressure sensor, and abdominal pressure was 
recorded intrarectally with an 8F microtip sensor catheter. Before cystometry, the 
bladder was emptied through the lumen of the transurethral catheter, and filled 
with sterile saline at room temperature and a filling speed of 50 ml per minute with 
the patient supine. Pressure and flow data were recorded with commercially 
available equipment. The digitally stored data were translated to a urodynamic 
analysis computer program, developed at our department. Precise fitting of the 
automatically computed passive urethral resistance relation curves to the pressure-
flow plot, with correction for artefacts, was done by hand. Patients with detrusor 
failure or chronic urinary retention were excluded from this study. Several 
different parameters were used to document obstruction, including detrusor 
pressure at maximum flow ( pdel at Qmax in cmH20 ) with grading according to the 
Abrams-Griffiths nomogram17, intersection of the quadratic urethral resistance 
relation with the pressure axis (URA in cmH20)18, parameters calculated from the 
passive urethral resistance relation (pmuo = minimal computer derived detrusor 
pressure with ongoing flow in cmH20, and AIheo= theoretical cross-sectional area 
of the urethra during voiding in mm2)'9 and, finally, linear passive urethral 
resistance relation (HnPURR) which is an approximation of the resistance relation 
by means of a straight line through minimal voiding pressure and detrusor pressure 
at maximum flow rate with grading according to the Schäfer nomogram20. 
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Our patients were evaluated at baseline and at 26 weeks. To evaluate subjective 
parameters, patients had to complete international prostatic (I-PSS) and Madsen 
symptom score questionnaires. Objective parameters were evaluated by free 
urinary flow rate using a uroflowmeter and urodynamic studies with pressure-flow 
study analysis. 
Student's t-test was used for statistical comparison of preoperative and 
postoperative data of the entire group. The Wilcoxon matched pairs signed ranks 
test and the Kruskal-Wallis test were used to compare improvement in the 
different stratified groups. 
Table 1. Changes of mean baseline symptomatic, uroflowmetry and 
urodynamic parameters with standard deviation SD (n=120) 
Symptoms 
Madsen score 
IPSS score 
Uroflowmetry 
Maximum flow (ml/s) 
Post-void residual (ml) 
Voided volume (ml) 
Urodynamics + 
pd8, at Qmax (cmH20) 
Qmax (ml/s) 
URA (cmH20) 
pmu0 (cmH20) 
A,heo (mm 2 ) 
linPURR 
Mean 
Baseline 
13.9 ±3.6 
17.7 ±6.0 
9.4 ±3.1 
72 ±86 
222 ±127 
64.7 ±23.4 
6.1 ±2.6 
41.8 ±15.4 
33.6 ±16.6 
2.7 ±1.4 
3.0 ±1.3 
±SD 
6 Months 
5.3 ± 4.5 
8.0 ± 6.0 
14.1 ±6.2 
29.2 ± 78 
296 ±134 
39.1 ±17.1 
10.5 ±5.3 
23.5 ±11.7 
16.1 ±10.4 
6.1 ±5.2 
1.4 ±1.2 
p-value* 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
<0.001 
* all parameters significant according to Student's t test (a=0.05) 
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RESULTS 
A total of 120 patients with repeated urodynamic investigations was available for 
analysis. Only 15% of the initially treated patients had no second urodynamic 
evaluation because of difficulty to introduce the microtip catheter or because the 
patient refused another study. There was no difference in outcome between these 
patients and the 120 studied. Mean patient age plus or minus standard deviation 
was 67.0 ± 8.8 years (range 45 to 89). The average prostate volume was 58.1 ± 
25.0 cm3 (range 30 to 154). Symptomatic, uroflowmetric and urodynamic pressure-
flow parameters at baseline and 6 months after treatment demonstrated highly 
significant and substantial improvement (table 1). 
Figure 1. Detrusor pressure at maximum flow (pdel at Qmax) before ( · ) and 6 months after 
treatment (A) of 120 patients in an Abrams Griffiths nomogram of obstruction. 
Abrams Griffiths nomogram 
120 -
0 5 10 15 20 25 30 
Qmax (ml/s) 
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Depending on what obstruction parameter was used, the incidence of pretreatment 
urodynamic obstruction ranged from 66 to 78%. Of the 120 patients 79 (66%) 
were considered obstructed according to linPURR of 3 or more, 81 (68%) 
according to the Abrams Griffiths nomogram and 93 (78%) according to URA of 
more than 29 cmH20. After treatment 18 to 30% of the patients still had 
obstruction: 21 (18%) according to the linPURR classification, 23 (19%) 
according to the Abrams Griffiths nomogram and 36 (30%) according to URA. 
Figure 1 shows the pretreatment and posttreatment values of detrusor pressure at 
maximum flow using the Abrams Griffiths nomogram of obstruction. 
When stratifying the patients according to the grade of obstruction at 
baseline, the changes and mean improvement in objective parameters showed 
Table 2. Improvement in parameters stratified according to baseline obstruction grade 
Symptoms 
Madsen score 
l-PSS score 
Uroflowmetry 
Qmax (ml/s) 
Post-void res. (ml) 
Urodynamics 
pdelatQmax 
Qmax (ml/s) 
URA (cmH20) 
Pmuo ( c m H 2 0 ) 
Α,,,βο ( m m 2 ) 
linPURR 0/1 
before 
12.9±2.9 
16.5±6.7 
9.6±2.8 
53±83 
33±9 
7.8±4.1 
22±4 
15±5 
4.211.7 
after 
5.3±4.1 
8.4±5.8 
13.3±5.5 
83±7 
28±13 
10.2±4.7 
18±8.1 
12±7.5 
6.9±4.6 
Mean ± SD 
linPURR 2/3 
before 
14.6±3.5 
18.6±5.9 
10.1 ±3.3 
64±94 
55±14 
6.4±1.8 
35±11 
28±14 
2.9±0.6 
after 
6.5±3.7 
9.9±4.1 
12.4±7.0 
33±81 
40±19 
9.9±6.0 
24±13 
16±11 
5.8±0.6 
NnPURR4/5/6 
before 
13.7±3.5 
17.3±5.9 
8.7±3.3 
87±94 
86±14 
5.2±1.8 
55±11 
46±14 
1.9±0.6 
after 
4.3±3.7 
6.1±4.1 
15.9±7.0 
35±81 
43±19 
11.1 ±6.0 
25±13 
18±11 
6.1±5.5 
p-value 
0.23 
028 
0.002* 
0.70 
<0.001* 
0.056 
<0.001* 
<0.001* 
0.07 
' significant according to Kruskal Wallis test for independent samples 
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Figure 2. The mean value of detrusor pressure at maximum flow before and after 
treatment stratified according to obstruction class. 
Non/mild: HnPURR 0/1; moderate: linPURR 2/3; severe: HnPURR 4/5/6 
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120 J 
Abrams Griffiths nomogram 
linPURR 
0/1 -*- 2/3 — 4/5/6 
10 15 
Qmax (ml/s) 
different results (table 2). There was a statistically significant improved efficacy 
in the majority of the objective parameters in patients with severe obstruction 
(linPURR of 4 or more) compared to those without or with moderate obstruction 
(linPURR of 3 or less). There appeared to be no significant difference in 
subjective parameters in patients with different grades of obstruction. Furthermore, 
analysis of mean changes in pdetatQmax in these 3 subgroups is best expressed with 
the Abrams Griffiths nomogram (figure 2). One can appreciate that patients with 
severe obstruction had the most impressive changes. Nevertheless, on an 
individual basis, those without obstruction showed good improvement but 
generally the changes were moderate. The same finding accounts for patients with 
moderate obstruction, although mean improvement was more pronounced. 
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[f the achieved decrease in outlet obstruction is considered a stratification criterion 
and is compared to baseline subjective parameters, it is confirmed again that the 
greater degree of outlet obstruction at baseline, the better the objective 
improvement. No prognostic value could be identified in uroflowmetry parameters 
nor symptom scores (table 3). 
Table 3. Mean baseline parameters and SD in correlation with urodynamic 
Symptoms 
Madsen score 
l-PSS score 
Uroflowmetry 
Qmax (ml/s) 
Post-void res. (ml) 
Urodynamics 
pdetatQmax 
Qmax (ml/s) 
URA (cmH20) 
linPURR 
< 0 classes 
η = 30 
14.0 ±3.8 
17.9 ±6.1 
10.2 ±2.8 
71 ±91 
49.0 ±23.2 
6.6 ± 2.4 
32.3 ±13.2 
2.0 ±1.3 
Mean ± SD 
1 - 2 classes 
η = 57 
14.4 ±3.5 
17.6 ±5.8 
9.1 ±2.8 
65 ±79 
61.2 ±19.1 
6.3 ±3.1 
39.5 ±13.5 
2.9 ±1.2 
> 3 classes 
η = 33 
13.0 ±3.3 
17.6 ±6.2 
9.2 ± 3.6 
85 ±93 
85.0 ±15.1 
5.3 ±1.7 
54.2 ±12.3 
4.2 ± 0.6 
p-value 
0.23 
0.98 
0.24 
0.48 
o.oor 
0.09 
<0.001* 
<0.001* 
significant according to Kruskal Wallis test for independent samples 
DISCUSSION 
Urologists have recently renewed their interest in the treatment of symptomatic 
BPH because of the availability of less invasive methods. However, to compare 
these alternative therapies to the gold standard of transurethral resection, previous 
reports have questioned which method is the best for describing the individual 
physiological problem. The pathological triad of symptoms, prostate size and 
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obstruction described by Hald et al is well recognized, and it is also acknowledged 
that the 3 variables are independent.21 It is important to know whether new 
treatments have the same effect on each variable as does the classic transurethral 
resection of the prostate. If there are differences in the way that a new treatment 
affects patients, it is possible that this information could be used to select patients 
for less invasive therapies. The main question is whether heat treatments such as 
transurethral thermotherapy, high intensity focused ultrasound or laser therapy 
truly offer an alternative to classic ablative operations such as transvesical 
enucleation or transurethral resection of the prostate. 
Changes in symptoms scores, prostate size and flow rate are the most 
commonly cited evidences of efficacy for alternative treatments. However, at best 
there is only questionable evidence to support an association between these 
parameters and obstruction as defined by urodynamic studies.22'24 The latter has 
always been accepted as the only diagnostic method for determination of lower 
urinary tract obstruction, although the use of routine urodynamics has yet to be 
established.25 Alternative treatments are able to relieve subjective symptoms but 
the question remains whether the objective improvements in obstruction 
parameters as documented by pressure-flow studies are changed. An effective 
decrease in outlet resistance as shown by pressure-flow measurements has been 
documented for transurethral resection of the prostate, indicating the efficacy of 
the procedure in the elimination of specific mechanical obstruction in BPH.26 
A promising minimally invasive, anaesthesia-free, alternative treatment 
options is transurethral microwave thermotherapy. Large series of patients have 
been treated, using the Prostatron unit with different types of treatment catheters 
and energy levels.9 Regardless of the vast experience, it is still not precisely clear 
how low energy thermotherapy affects the objective and subjective symptoms of 
patients with BPH. It has been assumed that a potential effect of this form of 
thermotherapy on decreasing outlet obstruction resistance may be caused by 
shrinkage of tissue due to tissue necrosis, leading to expansion of the urethral 
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lumen in the prostatic urethra. Subjective symptoms may be influenced by this 
decrease of bladder outlet obstruction or the evident effect on the autonomic 
nervous system.N2? 
Recently we investigated to what extent low energy transurethral microwave 
thermotherapy as a nonablative procedure is able to decrease the outlet resistance. 
It appeared that transurethral microwave thermotherapy exerts a specific effect on 
outlet obstruction that cannot be compared quantitatively with surgical removal of 
the prostate. Transurethral microwave thermotherapy only influences the flow-
controlling area significantly, which is expressed in changes in the PURR 
curvature (and thus an increase in theoretical cross-sectional area A,heo) without 
affecting the PURR footpoint (equivalent to an unchanged pmu0).28 Although low 
energy transurethral microwave thermotherapy is comparable to transurethral 
resection of the prostate with regard to improvement of subjective symptoms, 
outlet obstruction is changed little. Therefore, low energy transurethral microwave 
thermotherapy would prove to be an optimal choice for patients with BPH and 
lower urinary tract symptoms and low grade bladder outlet obstruction. 
To improve outcome after thermotherapy, high energy levels have been 
applied. Simple clinical analysis of the outcome by peak flow rate and Madsen 
symptom scores demonstrates a substantial advantage of Prostasoft® 2.5 over the 
earlier version. We concluded that "the great change in flow rate we have seen in 
patients receiving the 2.5 software treatment cannot be explained by anything 
other than a decrease of urodynamic obstruction, assuming the same 
contractility".9 Our present study shows that symptomatic improvement is in the 
same range as is reported in previous studies on low energy thermotherapy.29 The 
Madsen symptom score usually shows a baseline value of approximately 13 with 
an expected outcome of approximately 4. Our study is comparable with a mean 
improvement from 13.9 at baseline to 5.3, 6 months after treatment. The same 
degree of improvement may be seen in I-PSS. Our study shows improvement from 
17.7 at baseline to 6.0 after 6 months, which is comparable to available data on 
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other minimally invasive treatments for BPH that use the I-PSS for subjective 
evaluation.10 Furthermore, analysis of the stratified data shows that, except for the 
urodynamic parameters, neither subjective nor uroflowmetric parameters could be 
identified as prognostic factors. This finding agrees with previous studies of low 
energy transurethral microwave thermotherapy.14·31 
The improvements in uroflowmetry results are significantly better 
compared to former low energy transurethral microwave thermotherapy. For the 
entire group, there is an average 50% improvement in maximum flow from 
baseline of 9.4 to 14.1 ml/s after 26 weeks. However, stratified data show that the 
improvement can range from 23 to 38% in the no to moderate obstructed group, 
to 83% in the severe obstruction group. This finding shows that high energy 
transurethral microwave thermotherapy results in almost doubling of the maximum 
flow in severely obstructed cases which is significantly better than results of low 
energy transurethral microwave thermotherapy in the same group, whereas patients 
with no to moderate obstructed patients show improvement, which is still 
comparable with the best results achieved with the low energy protocol. Our study 
demonstrates that improvement in maximum flow is indeed due to decreased 
bladder outlet obstruction as indicated by a significant improvement in all 
obstruction parameters. In addition, it is shown that patients with greater degrees 
of obstruction seem to respond best, showing a substantial decrease of pdet at Qmax 
of 86 cmH20 at baseline to 43 cmH20 after treatment, with a similar improvement 
in maximum flow from 5.2 ml/s before treatment to 11.1 ml/s at 6 months. This 
substantial decrease in bladder outlet obstruction with associated subjective 
improvement might possibly lead to increased durability of this treatment in the 
long term. 
Where should we position high energy thermotherapy in the armamentarium 
of treatment options? As noted earlier, an effective decrease in outlet obstruction 
according to pressure-flow measurements has been documented for transurethral 
resection of the prostate, indicating the efficacy of the procedure in the elimination 
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Figure 3. The mean value of detrusor pressure at maximum flow before and after 
treatment in obstructed patients (HnPURR > 3) 
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of specific mechanical obstruction in BPH. This fact indicates that transurethral 
resection of the prostate is effective because of the tissue ablation involved. For 
comparison of the urodynamic changes after alternative treatments with those 
noted in patients who underwent transurethral resection of the prostate in a 
nonrandomized fashion, a number of patients from Bristol, England were 
evaluated before and after transurethral prostatectomy.32 Furthermore, the 
urodynamic changes after medication (terazosin) are also compared with the 
results of the current study of high energy thermotherapy and are presented as the 
mean changes of pdet at Qmax before and after treatment in a Abrams Griffiths 
nomogram.33 However, when judging and comparing data of the aforementioned 
studies, one should consider that at baseline these were different groups. The 
transurethral resection group mainly consisted of patients with severe obstruction, 
whereas the terazosin group included those with mild-to-moderate obstructed. 
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Therefore, to make the data of these studies more comparable, we selected only 
patients who at baseline had clear obstruction (linPURR of 3 or more), and 
compared these data with those of our present study (figure 3). The improvement 
after transurethral microwave thermotherapy is in the range of what is achieved 
after transurethral resection of the prostate, and significantly greater than noted 
after medication. However, although changes are impressive, one should 
acknowledge that results are not equal to those after transurethral resection of the 
prostate. In this regard, high energy thermotherapy should be positioned between 
medication therapy and operative intervention. Similar conclusions were drawn by 
Devonec et al., who compared symptomatic and objective improvements in 
uroflowmetry parameters of different treatments 34. They also positioned high 
energy transurethral microwave thermotherapy between medication therapy and 
surgical intervention, with ranges noted more towards those achieved with surgery. 
Nevertheless, case selection should identify the most favorable patients for high 
energy thermotherapy to improve further treatment efficacy and finally achieve 
results comparable to those of surgery with lower morbidity. Since patients with 
greater degrees of obstruction respond most favorably to higher energy 
transurethral microwave thermotherapy, they are the best candidates for this 
treatment. Thus, patients with minimal bladder outlet obstruction should 
preferably undergo medical treatment or lower energy thermotherapy, since 
subjective improvements with these treatments are significant with only minimal 
morbidity. However, such an algorithm can be used only if urodynamic studies 
with pressure-flow studies are included in the assessment of patients with BPH. 
In view of the benefit to the patients, when using urodynamic studies with 
pressure-flow analysis as a selection criterion for therapy, we believe it worthwhile 
to include these so-called invasive, time consuming investigations in the 
assessment of patients with BPH. 
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CONCLUSION 
High energy thermotherapy using the Prostatron device with the Prostasofì® 2.5 
operating software results in significant and substantial subjective and objective 
improvement in the majority of patients. Patients with greater degrees of bladder 
outlet obstruction are the best candidates for treatment. 
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Chapter 6 
TRANSURETHRAL MICROWAVE 
THERMOTHERAPY: A REVIEW 
Based on 
MJAM de Wildt and JJMCH de la Rosette 
Review Transurethral microwave thermotherapy an evolving technology 
in the treatment of benign prostatic enlargement 
British Journal of Urology, 76 531-538, 1995 

HISTORY 
The use of heat in treatment of prostatic diseases has been advocated for over a 
century. In 1866 Busch showed that malignant tissue was especially susceptible 
to heat.1 Since then, many different and ingenious methods for the beneficial 
application of heat have been described. 
In prostatic tissue there are several temperature thresholds: below 40°C cells 
are affected little; between 41 and 45°C malignant cells are more susceptible to 
permanent damage than benign tissue and this effect is termed hyperthermia; in the 
range of 45-60°C cell death can occur and is defined as thermotherapy. Thermal 
treatment in excess of 70°C destroys all human living tissue and is termed 
thermoablation.2 
Hyperthermia was first introduced in the early 1980s, initially to treat 
prostate carcinoma.1 The alleviation of symptoms of prostatism and the reduction 
of tumor bulk seen in patients treated with hyperthermia also led to application of 
hyperthermia in patients with benign prostatic hyperplasia (BPH).4 Many studies 
have been published on the use of hyperthermia in treatment of BPH. Although 
they reported significant symptomatic relief, the effect on objective improvement 
was very limited. Moreover, in a multicentre study transrectal hyperthermia was 
shown to be ineffective when compared with sham treatment,5 transurethral 
hyperthermia is still under investigation as has proved to be more effective than 
the transrectal route and better than sham treatment.6-7 The results achieved with 
hyperthermia suggested that higher temperatures would be more effective. Trans-
urethral microwave thermotherapy (TUMT) was designed to apply microwave 
energy deep within the lateral prostatic lobes whilst simultaneously cooling the ur-
ethral mucosa. Currently the application of high energy thermotherapy in the 
treatment of BPH is being evaluated. 
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MICROWAVE TISSUE INTERACTION. 
The applicability and outcome of microwave treatment is influenced by the 
microwave frequency used, the tissue composition and vascularization, and 
patient's tolerance of the heat treatment. 
The appropriate electromagnetic spectrum comprises microwaves in the 
range from 300 to 3000 MHZ, but the two frequencies most commonly used are 
915 MHZ and 1296 MHZ. When applied transurethrally, the isothermic field of 
the latter shows a concentric heat distribution more or less following the 
anatomical borders of the transition zone of the prostate and not reaching 
maximum temperature in the rectal mucosa; this frequency thus seems best fitted 
for the treatment of prostatic diseases. The effects of microwaves on tissue 
depends on tissue composition and water content. Penetration is greater in fat, 
which has a high water content, than in muscle which has a lower water content. 
The depth of penetration also depends on the microwave frequency: the higher the 
frequency of the microwaves, the less the penetration. However, penetration is also 
influenced by tissue temperature and refraction, reflection and dispersion of the 
microwaves in heterogenous tissue. Furthermore, heat conduction and convection 
are influenced by perfusion of the tissue causing spatial differences in tissue 
temperatures. 
Cell death is achieved when temperatures exceed the cytotoxic threshold, 
which depends on the cell type; In prostate adenomatous tissue the thermal 
threshold is 45°C for 30 minutes. Therefore when heterogenous tissue is treated, 
not all cells within the treated area will die. Furthermore, small capillaries are 
thrombosed whereas larger vessels are spared because they are cooled by blood 
flow. Thus, the size of the necrotic area is not only determined by the tissue 
composition but also by tissue vascularization.2 
To allow treatment with no anesthesia, heating of the urethral mucosa, 
which is rich in pain receptors, should be avoided because 45°C is not only the 
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thermotoxic level but also the thermal pain threshold. The transition zone of the 
prostate has fewer nociceptors and can therefore be heated to more than 45°C. 
Urethral obstruction associated with BPH arises from anatomical compression by 
the periurethral adenomatous tissue from the bladder neck to the verumontanum, 
and partly by a dynamic obstruction resulting from the tone of the prostatic smooth 
muscle.8 Theoretically, the optimal treatment is the one that spares the urethral 
mucosa, heats the periurethral prostate tissue to above cytotoxic temperatures, and 
spares the adjacent rectal mucosa. Thermotherapy with urethral cooling allows not 
only the delivery of increased energy, but higher temperatures, up to 70°C, deep 
inside the lateral prostatic lobes resulting in tissue coagulation, necrosis and even 
tissue ablation. Not all patients reach the maximum temperature intended, because 
the thermoregulation of the tissue differs.9 Studies correlating the achieved intra-
prostatic temperatures and outcome of treatment, suggest that the higher the intrap-
rostatic temperature, the better the clinical results.10 
Thus the clinical benefit and tolerability of TUMT must be related to the 
achieved intraprostatic temperature, which results from a complex interaction 
between the biological response to microwaves, the pattern of energy provided 
during the treatment and the incorporation of urethral cooling. 
CLINICAL RESULTS 
Many thermotherapy devices have been developed for the treatment of BPH, 
including the Urowave (Dornier Medical Systems, Germering, Germany), ECP 
(Prof. H. Wiksell, Stockholm, Sweden), Prostalund (Dantec Medical A/S), T3 
(Urologix, Minneapolis, USA), TURAPY (Direx Medical Sytems, Petah Tiqvah, 
Israel) and the Prostatron device (Technomed Medical Sytems, Lyon, France). The 
latter has been most widely used and reported on and the authors have experience 
with over 600 patients treated using this device. Therefore, in the following section 
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reports this experience with the Prostatron device and compares the results with 
those available from the other devices and with transurethral resection of the 
prostate (TURP). 
The Prostatron has been used with three software programs which have 
different features, mainly in controlling the amount of energy applied while 
ensuring maximum safety for the patient with no need for anesthesia: Prostasoft 
Version 1.0 (temperatures < 50°C); Version 2.0 (temperatures from 50-60°C) and 
Version 2.5 (temperatures < 70°C). Version 2.0 is the most widely used and 
Version 2.5 is currently under investigation. The procedure for the TUMT 
treatment itself has been described extensively elsewhere."12 
The results of Prostatron treatment are discussed below. 
TUMT using Prostasoft" 2.0 
Currently, over 25.000 patients with BPH have been treated with the Prostatron 
device using Prostasoft® 2.0. The first clinical data was presented by Devonec et 
al. and Carter et al. in 1991."13 The results achieved for symptomatic improve-
ment and changes in urinary performance were encouraging and impressive. 
The overall symptomatic changes, using the total Madsen-Iversen physician-
guided symptom score, showed a considerable improvement.14 The mean entry 
level is usually 13 (range 11-16) and the expected outcome at 3 months is about 
4 (range 2-6) showing an overall improvement of around 70% (Table 1). Similar 
symptom scores were found in asymptomatic elderly men.15 
Urinary peak flow rates (Qmax)were also improved, although less 
pronounced. Mean Qmax at baseline was about 9 ml/s (range 8.2-10.4), improving 
by 3-4 ml/s after 3 months, representing a mean improvement of 35% over baseli-
ne. Unlike those occurring after TURP, improvement in Qmax occurred gradually. 
Improvement had occurred by 4 weeks after treatment and was more pronounced 
after 3 months. The final improvement of urinary flows occurred between 6 to 12 
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Table 1. Improvement in main treatment indices before, 3 and 12 months after TUMT 
using Prostasoft® 2.0 
No. of Symptom score Qmax (ml/s) Post-void residual (ml) 
patients Baseline 3 mths 1 yr Baseline 3 mths 1 yr Baseline 3 mths 1 yr 
37 13 
19 11 
37 35 
60 36 
1 7 3 7 
130 38 
1 2 8 3 9 
140 40 
140 41 
818 42 
1154 3 
12 
12 
8.5* 
13.9 
16.5 
12.9 
11.3 
11.7* 
23.7* 
13.3 
15.7 
8 
2.8 
4.5 
4.8 
-
5.9 
2.1 
4.9 
10.6 
5.7 
3 8 
-
1.4 
-
-
6 9 
6 4 
-
4.2 
11.6 
3 5 
2.6 
8 4 
8.2 
10.3 
8.9 
7.2 
10.4 
9.2 
9.0 
10.1 
8 8 
9.8 
10.8 
14.3 
11.5 
13.1 
-
11.5 
14.9 
12.6 
12.3 
13.0 
13.3 
-
14.3 
-
-
10.7 
11.8 
-
13.3 
12.4 
12.6 
13.7 
109 
64 
-
-
39 
54 
100 
135 
98 
-
108 
50 
41 
-
-
-
49 
43 
81 
69 
-
33 
-
58 
-
-
17 
42 
-
41 
76 
-
22 
* Symptom score other than Madsen-lversen symptom score 
months after TUMT and was sustained at the followup 3 years later.'6'7 Post-void 
residual volume (PVR) also decreased significantly; large initial PVR's were 
reduced, but better results are found in patients with a PVR of < 200 ml. 
The variability in objective outcome between the different centres was conside-
rable. Although the results of TUMT using Prostasoft® 2.0 are very promising, the 
degree and significance of the a possible placebo effect remained to be evaluated. 
Sham treatment versus TUMT using Prostasoft" 2.0 
All treatments contain possible 'placebo' effects and thus a precise and general 
definition of 'placebo' is difficult. Broadly, the placebo effect could be defined as 
a single, unknowable nuisance variable which is inactive and specific in its effect. 
To apply this definition to the effect of surgical intervention is a daring concept. 
There are several controlled studies, using sham treatment, of the clinical use of 
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thermotherapy for BPH.18"23 The majority of which show a significant effect of 
TUMT on both subjective and objective parameters with no significant placebo 
component (Table 2). 
Table 1. Improvement in main indices before , 3 and 12 months after TUMT using Prostasoff 2.0 
No Symptom score Qmax (ml/s) Post-void residual (ml) 
Type pat. Baseline 3 mths 1 yr Baseline 3 mths 1 yr Baseline 3 mths 1 yr 
Sham 1S 
TUMT 
Sham ,9 
TUMT 
Sham 20 
TUMT 
Sham 22 
TUMT 
Sham23 
TUMT 
Control 
19 
21 
24 
24 
36 
75 
44 
46 
40 
40 
40 
14.2 
14.5 
12.1 
13.2 
14.9 
13.9 
12.9 
13.7 
17.5* 
19 0* 
18.0* 
12.8 
4.3 
8.2 
5.9 
10.7 
6.3 
10.4 
4.7 
9.5 
9.5 
17.0 
-
-
9.1 
3.3 
-
-
8.2 
4.2 
-
-
. 
8.6 
85 
9.7 
96 
7.4 
7.3 
96 
9.2 
9.4 
88 
88 
92 
13.0 
95 
13.0 
9.5 
11.5 
9.7 
13.4 
9.5 
99 
8.5 
-
-
11.3 
140 
-
-
10.5 
13.4 
-
-
. 
118 
147 
-
-
-
-
85 
94 
97 
86 
86 
171 
12 
-
-
-
-
104 
34 
106 
86 
83 
-
-
-
-
-
-
56 
50 
-
-
. 
* American Urological Association - 7 symptom score 
In addition, the changes in prostate-specific antigen (PSA) levels, seen only after 
TUMT,1920 are further prove that the mechanism of action of TUMT is related to 
the thermal damage of prostatic tissue and not to the mechanical effect of a single 
catheterization. 
However, to be considered an alternative to surgical therapy in (a 
subgroup of) patients with BPH, TUMT should be compared with TURP. 
TUMT using Prostasoft* 2.0 versus TURP 
To evaluate the clinical utility of TUMT, Dahlstrand et al have randomized 
TUMTagainst the 'gold standard' TURP.17 Their study showed a statistically 
identical symptomatic improvement of symptom scores in patients treated with 
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Table 3. Results of a randomized controlled study of TUMT vs TURP17 
Madsen 
TUMT 
TURP 
Qmax (ml/s) 
TUMT 
TURP 
PVR (ml) 
TUMT 
TURP 
Baseline 
12.1 ±3.0 
13.6 ±3.9 
8.4 ±2.6 
8.3 ±3.2 
97 ±78 
104 ±95 
3 months 
2.6 ±2.6 
1.1 ±2.8 
11.5 ±4.2 
18.1 ±7.1 
51 ±51 
34 ±32 
Meant SD 
12 months 
2.3 ± 2.4 
0.6 ±1.4 
12.3±4.1 
18.9 ±6.0 
55 + 65 
23 ±18 
24 months 
2.3 ±2.9 
1.2 ±1.8 
12.3 ±4.4 
17.6 ±5.9 
47 ±43 
27 ±32 
36 months 
3.0 ±2.9 
2.3 ±3.7 
11.9 ±3.4 
18.6±7.1 
42 ±51 
45 ±27 
(TUMT η = 38; TURP η = 32) 
TUMT or TURP. This effect was sustained for at least 3 years of followup. The 
mean Madsen score in those patients undergoing TUMT improved from a baseline 
of 12.1 to 3.0 after three years of followup and from 13.1 to 2.3 in those 
undergoing TURP. TUMT had less effect on voiding parameters; the mean Qmax 
improved from a baseline 8.4 ml/s to 12.8 ml/s 3 years after treatment in those 
treated with TUMT, whereas those undergoing TURP improved from 8.3 ml/s to 
18.6 ml/s. The PVR decreased similarly in both groups, from a baseline 97 to 47 
ml after 3 years in the TUMT group, and from 104 to 43 in the TURP group (Table 
3). It was concluded that the objective improvements with TUMT were not equal 
to those with TURP, but the subjective improvement were more or less 
comparable. The need for TUMT to achieve Qmax seen with TURP was 
questioned, because asymptomatic age-matched patients only have a mean Qmax 
of 13 ml/s.24 
It is clear that the mechanism of action of TUMT, using the Prostasoft® 2.0 
software, is substantially different to that which produces the volume reduction 
and cavity formation obtained with TURP. Clinical outcome could possibly be 
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enhanced with higher temperatures, resulting in thermoablation and thus cavity 
formation. 
Prostasoft" 2.5 
Modifications to the operating software have provided more power at a maximum 
of 70 Watt and a higher rectal threshold temperature, resulting in fewer interrupti-
ons during treatment and a mean increase of 40% in the total energy delivered to 
the prostate.25 
Changes in subjective parameters using (high energy) Prostasoft® 2.5 were 
similar to those in patients treated using Prostasoft® 2.0. The mean Madsen 
symptom score improved from a baseline of 14, to 6 at the 3-month followup. 
However, when objective improvement was compared, there was a significantly 
better outcome in the changes in Qmax (Table 4).25·26 Indeed, after high energy 
thermotherapy, values of Qmax were greater than those of patients in the same age 
group but with no voiding symptoms.24 The improvements in Qmax were in the 
range that is observed after TURP, from a mean baseline of 9 ml/s to almost 16 
ml/s by 3 months after treatment. Transrectal ultrasonography of the prostate, 
performed 3 months after treatment, identified a cavity in more than 40% of the 
patients. There was a positive correlation between the presence of such a cavity 
and the improvement in Qmax. 
Thus, more energy delivered to the prostate seems to result in greater improvement 
in objective parameters possibly because cavities are created in the prostate. 
However, the price is an increase of incidence of morbidity. Whereas patients 
treated with the Prostasoft® 2.0 were reported to have a urinary retention rate after 
treatment of about 20%, using high energy Prostasoft® 2.5 a catheter was needed 
in all patients for at least 1 week. Although irritative complaints such as frequency, 
dysuria and hematuria were also reported after low energy TUMT treatments, they 
were more frequent and pronounced during the first 2-4 weeks in patients 
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Table 4. Some results obtained using high energy thermotherapy devices 
compared with those using Prostasoff 2.5 
Prostasoft®2.54426 
TURAPY7045 
Prostalund 46 
T3 System47 
No. of 
patients " 
116 
72 
72 
91 
103 
Qmax (ml/s) 
Before 
9.6 
92 
5.8 
8.5 
94 
After 
15.7 
15.2 
12.3 
10.2 
14.3 
Symptomatic 
improvement 
(%) 
59 
62 
53 
38 
62 
receiving the high energy treatment. Nevertheless, the high energy treatments are 
still possible on an outpatient basis in a single one hour session with no need for 
anesthesia. 
SELECTION CRITERIA 
The clinical results of TUMT show a clear separation between patients who 
respond favorably to TUMT in both subjective and objective parameters and 
patients who do not respond at all. Consequently, many investigators have 
searched for selection criteria to predict clinical outcome. Because high energy 
TUMT is under clinical evaluation, no selection criteria are yet available and the 
following study was initiated in patients treated with Prostasoft® 2.0. 
Responders versus nonresponders 
Data of 292 patients from 17 centres were analyzed retrospectively.27 Using data 
obtained at the 6-month followup, patients were divided into responders, defined 
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as having a Madsen symptom score of 3 or less, or 50% or more decrease, a Qmax 
of 15 ml/s or more, or 50% or more improvement, and a PVR of 50 ml or less, or 
50% or more improvement, and nonresponders defined as those with a Madsen 
symptom score of 8 or more, or 50% or less improvement, a Qmax of 10 ml/s or 
less, or 20% or less improvement, and a PVR of 200 ml or more, or 50% or less 
decrease. There were no differences in any of the baseline clinical parameters (i.e. 
age, prostate volume, symptom scores, Qmax and PVR) between the groups and 
it was concluded that none of the baseline parameters used in this study were able 
to define the 'ideal' patient for treatment or to predict the result of treatment. 
However, compared to nonresponders, the responders had significantly different 
curves of the urethral and rectal temperatures during treatment, possibly because 
there was a better energy absorption by the prostate tissue. This absorption 
eventually causes tissue damage, which may be reflected in change of PSA level. 
Indeed, the responders showed a significantly greater increase of PSA level I week 
after treatment when compared to that of nonresponders, suggesting a more 
pronounced effect of treatment on prostatic tissue. 
There has been increased interest in urodynamic investigation, using pressure 
flow analysis (PFA), in the assessment of patients with voiding complaints. In the 
aforementioned study,27 urodynamic studies with PFA were not performed. 
Therefore, a multicentre, retrospective urodynamic study was conducted to 
evaluate the role of PFA in TUMT treatment to determine whether it predict the 
clinical outcome of TUMT treatment.28 
The role of pressure flow analysis 
Urodynamic studies have been used to investigate the pathophysiology of benign 
prostatic disease and to evaluate the clinical outcome of various treatment 
modalities. 
The (change of) elasticity of the prostatic urethra seems to play an important 
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role in treatment of BPH using TUMT.29"31 If TUMT is able to modify elasticity 
of the prostatic urethra, patients suffering from reduced elasticity should be ideal 
candidates for study. This hypothesis was tested in a retrospective analysis of a 
large European multicentre study,28 which showed that no single subjective or 
objective parameter was significantly correlated with clinical outcome after 
TUMT. However, there was a trend towards a better outcome in patients with less 
obstruction. Schäfer defined two types of obstruction, constrictive and 
compressive.12 When the patients were divided according to this definition, both 
groups were still comparable at baseline but differed significantly after treatment. 
The severity of symptoms of BPH was significantly modified in both groups, with 
a greater decrease in severity in patients with constriction than in those with 
compression. The change in objective parameters after treatment also differed 
significantly in both groups; those with predominantly constrictive obstruction had 
a greater improvement in voiding parameters, than did those with compressive 
obstruction. It was concluded that PFA may be used to identify the patients who 
respond favorably using Prostasoft® 2.0. 
DISCUSSION 
Since 1990, TUMT using Prostasoft® 2.0 has been used for the treatment of men 
with lower urinary tract symptoms. There are several advantages of the minimally 
invasive approach in TUMT; patients are treated on an ambulatory basis, com-
plications are extremely rare and patients suffer minimal discomfort, which arises 
mainly from the 20%, who need catherization for about I week after treatment. 
The results of TUMT treatment have been encouraging, but there has been 
some scepticism as to the place of TUMT in the urological options available for 
the treatment of BPH. Several studies have demonstrated that there is significant 
clinical effect, with a reduction in symptom scores. However, the changes in Qmax 
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Figure 1. Ultrasonograms of the prostate with color Doppler mapping using the 
Hitachi EUB555 with a transrectal probe (V33W; 6.5 MHz multipurpose 
endoprobe), before (a, longitudinal and b, transverse) and immediately after 
TUMT (c, longitudinal and d, transverse). 
are less impressive and do not attain those achieved after TURP. The advocates of 
TUMT treatment have argued that thermotherapy eventually results in changes of 
voiding parameters after treatment comparable to those in asymptomatic elderly 
men. In this respect, TURP could even be considered as an 'over treatment' in 
achieving a supra-normal Qmax after surgery. 
In contrast to surgical therapy, the clinical results after TUMT treatment show 
a wide range in outcome variables. Recent results have produced a better 
understanding of how microwave heating of the prostate can achieve clinical 
benefits and suggest better selection criteria which may allow us to take advantage 
of the undoubted benefits of a less-invasive treatment. The clinical benefit seems 
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to be related to the achieved intraprostatic temperature, which results from a 
complex interaction between the biological response to microwaves and the 
pattern of energy provided during the treatment in any individual.910 This interacti-
on depends on the heat-sink, formed by the veins of the Santorini's plexus, and on 
the heterogeneity of each individual's prostatic structure. Overall, in unselected 
patients, there is a 60% improvement in subjective and a 30% improvement in 
objective variables after 1 year. Unless predictive factors can be identified and/or 
the efficacy of TUMT treatment is improved, opponents of TUMT treatment will 
not accept this minimally invasive therapy as a valuable alternative for treatment 
ofBPH. 
The outcome of TUMT may be closely related to the vascularization and tissue 
composition of the prostate. Tubaro et al. showed that TUMT significantly 
changed intraprostatic blood perfusion." Color Doppler flow analysis performed 
immediately after treatment showed a mean 12.5-fold increase in the number of 
visible vessels within the prostate. This effect appeared to be restricted to the 
adenomatous area (Figure 1). Presently, there are few published studies concerning 
the vascularization of the prostate. Because it has a major impact on treatment 
outcome, this subject demands further investigations, as does the influence of com-
position of the prostate. 
Thermotherapy relies on a predictable zone of heating within homogenous 
prostatic tissue; however, it is well known that prostatic tissue is heterogeneous. 
Because glandular and stromal tissue respond differently to heat, it is obvious that 
thermotherapy will have a different impact on individual prostates. Studies to test 
this hypothesis and provide selection criteria based on histological variables are 
under way. Complications after TUMT are minimal and patients tolerate the 
treatment well. Many patients who are unfit for surgery, because of poor physical 
health, may profit from this ambulatory anesthesia-free therapy. The re-treatment 
rate 1 year after TUMT using Prostasoft® 2.0, is acceptable and ranges from I to 
13%.u To determine the durability of response, a longer followup is necessary and 
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Figure 2. Ultrasonograms of the prostate showing cavity formation 3 months after TUMT 
using the Prostatron and Prostasoff 2.5 (a, transverse, to, longitudinal section) 
the three years followup results of Dahlstrand et al., are very encouraging.17 
To improve the treatment outcome, high energy software and devices have 
been developed (Prostasoft® 2.5; TURAPY 70; Prostalund; T3 System). The early 
results of these high energy thermotherapies are very promising and more compa-
rable with the results of TURP. Indeed, the efficacy of increased heating has 
improved and the conclusion 'the hotter the better' seems correct (Table 4). 
Cavities are frequently detected by ultrasonography after treatment (Figure 2), 
which may account for the improvements found so far. Larger prostates with 
moderate to severe bladder outlet obstruction seem to be best candidates for the 
higher energy thermotherapy treatment. However, there is an increased morbidity, 
mainly arising from prolonged catherization and irritative complaints after 
treatment. From these preliminary results it seems obvious that high energy 
thermotherapy is the way forward.25 
Therefore, we conclude that the objective must be to determine the thermal 
dose which will maintain a safe treatment with clinically significant improvements 
in objective and subjective variables, whilst causing minimum morbidity after 
treatment. Moreover, a maximum benefit will be guaranteed only when proper 
selection criteria are identified and applied. 
168 
REFERENCES 
1 Busch W Über den einfluss welchen heftiger erysipeln zuweilen auf organisierten 
neubildungen ausüben Verhandl Naturh Preuss, Rhein Westphal 23 28,1866 
2 Devonec M, Ogden C, Pernn P, Carter SStC Clinical response to transurethral 
microwave thermotherapy is thermal dose dependent Eur Urol, 23: 267-274, 1993 
3 Yerushalmi A, Servadlo С, Leib Ζ, Fislelowitz E, Rakowsky E, Stein JA Local 
hyperthermia for treatment of carcinoma of the prostate a preliminary report Prostate 
3 623-630, 1982 
4 Lindner A, Golomb Y, Siegel Y and Lev A Local hyperthermia of the prostate gland 
for the treatment of benign prostatic hyperthrophy and urinary retention A preliminary 
report Br J Urol, 60 567-571, 1987 
5 Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia 
(BPH) Pans 1993 Ed Cockett ATK, Khoury S, Aso Y et al 453-506,1993 
6 Stawarz В, Smigielski S, Ogrodnik J, Astrahan M, Petrovich Ζ A comparison of 
transurethral and transrectal microwave hyperthermia in poor surgical risk benign 
prostatic hyperplasia patients J Urol, 146 353-357, 1991 
7 Bdesha AS, Bunce CJ, Kelleher JP, Snell ME, Vukusic J, Witherow RO Transurethral 
microwave treatment for benign prostatic hyperthrophy a randomized controlled 
clinical trial BMJ, 306: 1293-1296, 1993 
8 Caine M The present role of alpha-adrenergic blocker in the treatment of benign 
prostatic hyperthrophy J Urol, 132 474-479, 1986 
9 Devonec M, Berger Ν, Fendler JP, Joubert P, Nasser M, Pemn Ρ Thermoregulation 
during transurethral microwave thermotherapy Experimental and clinical fundamen­
tals Eur Urol, 23 (Suppl 1) 63-67, 1993 
10 Carter SStC and Ogden CW Intraprostatic temperature versus clinical outcome in 
TUMT Is the response heat-dose dependent9 J Urol, 151 416A, 756, 1994 
11 Carter SStC, Patel A, Reddy P, Royer Ρ, Ramsey JWA Single-session transurethral 
microwave thermotherapy for the treatment of benign prostatic obstruction J 
Endourol, 5 137-144, 1991 
12 Laduc R, Bloem FAG, Debruyne FMJ Transurethral microwave thermotherapy in 
symptomatic benign prostatic hyperplasia Eur Urol, 23 275-281, 1993 
13 Devonec M, Berger Ν, and Pemn Ρ Transurethral microwave heating of the prostate-
169 
or from hyperthermia to thermotherapy J Endourol, 5 129-135, 1991 
14 Madsen OM, Iversen Ρ A point system for selecting operative candidates In "Benign 
Prostatic Hyperthrophy" Hinman F (Jr) ed New York, Springer-Verlag 763, 1983 
15 Chute CG, Panser LA, Girman CJ, Oesterhng JE, Guess HA, Jacobsen SJ, Lieber 
MM The prevalence of prostatism population-based survey of urinary symptoms J 
Urol, 150 85-89, 1993 
16 Ersev D, llker Y, Kuyumcuoglu U, Akdas A Two years followup in 112 patients 
treated by transurethral microwave thermotherapy Xlth Congress of the EAU, Berlin 
643 A, 1994 
17 Dahlstrand C, Walden M, Geirsson G Petterson S Transurethral microwave thermo­
therapy versus transurethral resection for symptomatic benign prostatic obstruction Br 
J Urol, 76 614, 1995 
18 Ogden CW, Reddy P, Johnson H, Ramsay JWA, Carter SStC Sham versus transur­
ethral microwave thermotherapy in patients with symptoms of benign prostatic bladder 
outflow obstruction Lancet, 341 14-17,1993 
19 de la Rosette JJMCH, de Wildt MJAM, Alivizatos G, Froeling FMJA, Debruyne FMJ 
Transurethral microwave thermotherapy (TUMT) m benign prostatic hyperplasia 
Placebo versus TUMT Urology, 44 58-63, 1994 
20 Blute ML, Patterson DE, Segura JW, Hellerstein DK, Tornera KM Transurethral mi­
crowave thermotherapy vs SHAM a prospective double blind randomized study J 
Urol, 151 752A, 1994 
21 French study group French urological association meeting, Novemberl7-l9, 1993 
22 de Wildt MJAM, Hubregtse M, Ogden CW, Carter SStC, Debruyne FMJ, de la Rosette 
JJMCH A 12 month study ofthe placebo effect in TUMT Br J Urol, 77 221-7, 1996 
23 Nawrocki JD, Bell TJ, Lawrence WT, Ward JP A randomised controlled study of 
thermotherapy Abstract of paper presented at BAUS 29th June 1994 
24 Girman CJ, Pansar LA, Chute CG, Oesterling JE, Barrett DM, Chen CC, Arrighi HM, 
Guess HA, Lieber MM Natural history of prostatism Urinary flow rates in a 
community-based study J Urol, 150 887-892,1993 
25 de la Rosette JJMCH, Tubaro A, Hofner K, Carter SStC Transurethral microwave 
thermotherapy past, present and future World J Urol, 12 352-356, 1994 
26 Devonec M, Carter SStC, Tubaro A, de la Rosette JJMCH, Hofner K, Perrnn Ρ 
Microwave therapy Current Opinion in Urology, 5 3-9, 1995 
170 
27 Berg С, Choi Ν, Colombeau Ρ et al Responders versus non-responders to 
thermotherapy in BPH A multicenter retrospective analysis of patient and treatment 
pronies J Urol, 149 I49A, 1993 
28 Tubaro A, Carter S, de la Rosette J, Hofher K, Trucchi A, Ogden C, Miano L, Valenti 
M, Jonas U, Debruyne FMJ The prediction of clinical outcome from transurethral 
microwave thermotherapy by pressure-flow analysis A European multicenter study 
J Urol, 153 1526-1530, 1995 
29 Rosier PFWM, de Wildt MJAM, ν Kerrebroeck PhEVA, de la Rosette JJMCH, 
Debruyne FMJ, Wijkstra H Urodynamic results of transurethral microwave 
thermotherapy treatment of prostatism Neurourol Urodyn, 12 41A 378-379,1993 
30 Homer K, Tan Η-K, Kramer A, Kuczyk M, von Dalwig-Nolda D, Jonas U Changes 
in outflow obstruction in patients with benign prostatic hyperthrophy (BPH) after 
transurethral microwave thermotherapy (TUMT) Neurourol Urodyn, 12 40A 376-
377, 1993 
31 Porru D, Scarpa RM, Delisa A, Usai E Urodynamic changes in benign prostatic 
hyperplasia patients treated with transurethral microwave thermotherapy Eur Urol, 26 
303-308, 1994 
32 Schafer W Principles and clinical application of advanced urodynamic analysis of 
voiding function Urol Clin N Am, 17 553-566, 1990 
33 Tubaro A, Paradiso Galatioto G, Vicentini С, et al The impact of transurethral 
microwave thermotherapy on prostate blood perfusion A color flow doppler 
sonography study SIU 23rd Congress, Sydney abstract 608, 1994 
34 de Wildt MJAM, de la Rosette JJMCH, and Debruyne FMJ Retreatment rate In 'E-
ORTC Genitourinary group monograph 12 Benign Prostatic hyperplasia Recent 
progress in clinical research and practice' Editor Kurth, K, and Newling, DWW 
Wiley-Liss, Ine 597-613 
35 Baba S, Ohigashi Τ, Tazaki H, Imai Y Transurethral microwave thermotherapy for 
benign prostatic hyperplasia J Endourol, 6 371-376, 1992 
36 Blute ML, Tornera KM, Hellerstein DK, McKiel Jr CF, Lynch JH, Regan JB, Sankey 
NE Transurethral microwave thermotherapy for management of benign prostatic 
hyperplasia results of the United States Prostatron cooperative study J Urol, 150 
1591-1596, 1993 
37 Homma Y, Aso Y Transurethral microwave thermotherapy for benign prostatic 
171 
hyperplasia A 2 year followup study J Endourol, 7 261-265, 1993 
38 de la Rosette JJMCH, Froeling FMJA, Debruyne FMJ Clinical results with 
microwave thermotherapy of benign prostatic hyperplasia Eur Urol, 23 (Suppl 1) 68-
71, 1993 
39 Van Cauwelaert RR, Castillo OC, Aquirre CA, Azocar GH, Medina FI Transurethral 
microwave thermotherapy for the treatment of benign prostatic hyperplasia Prelimi-
nary experience Eur Urol, 23 282-284, 1993 
40 Tubaro A, Paradiso Galatioto G, Trucchi A, Begani A, Stoppacciaro A, Trucchi E, 
Begani Provenciah R, Furbetta A, Laurenti C, Albanese R, Miaño L Transurethral 
microwave thermotherapy in the treatment of symptomatic benign prostatic hyperpla-
sia Eur Urol, 23 285-291, 1993 
41 Kirby RS, Grant Williams, Witherow R, Milroy EJG, Philp Τ The Prostatron transur­
ethral microwave device in the treatment of bladder outflow obstruction due to benign 
prostatic hyperplasia Br J Urol, 72 190-194,1993 
42 Devonec M, Tornera К and Perrin Ρ Review Transurethral microwave thermotherapy 
in benign prostatic hyperplasia J Endourol, 7 255-258,1993 
43 Marteinsson VT, Due J Transurethral microwave thermotherapy for uncomplicated 
benign prostatic hyperplasia Scand J Urol Nephrol, 28 83-89, 1994 
44 de la Rosette JJMCH, de Wildt MJAM, Hofner K, Tubaro A, Carter SStC, Debruyne 
FMJ High energy TUMT (Prostasoft 2 5) in the treatment of BPH Results of a 
European BPH study group Abstract AU A annual meeting, Las Vegas, 1995 
45 Hournez LA, Peltier A, Vanden Bossche M et al High temperature radiofrequency 
thermal ablation of the prostate (TURAPY) SIU 23rd congress Sydney 611A, 1994 
46 Roos DA, Pedersen J Transurethral microwave thermotherapy in patients with 
symptoms of benign prostatic hyperplasia using the Prostalund system SIU 23rd 
congress Sydney 605A, 1994 
47 Miller PD, Parsons K, Ramsey EW et al The Urologix T3 prostatic thermal ablation 
system A multicentre study. Abstract AU A annual meeting, Las Vegas, 1995 
172 
SUMMARY AND FUTURE PERSPECTIVES 

SUMMARY 
For many decades, the only solution for male bladder outlet obstruction has 
been the surgical removal of prostate tissue. In the past sixty years, the 
transurethral resection of the prostate has been perfected to the extent that it is now 
an acceptably safe procedure. However, the morbidity and costs involved with the 
procedure and the patients demands for non-surgical treatment, has led to 
development of numerous medical and procedural alternatives that aimed to reduce 
the burden on both the patient and the health care expenses. 
Nearly all procedural modalities are based on the application of some form 
of heat to the prostate aiming at destruction and consequent removal of tissue. 
Although many different heat applicators are available, the use of microwaves has 
been most extensively investigated and reported on. This thesis reports on several 
clinical trials that have been conducted using Transurethral Microwave 
Thermotherapy or TUMT for the treatment of elderly men with lower urinary tract 
symptoms and benign prostatic enlargement. Furthermore, we enlighten 
improvements of this technique and possible predictive factors and subjects for 
future research efforts. 
Early experience and the first reports on TUMT results, showed significant 
subjective improvement. However, the objective improvement was less 
pronounced and not comparable to results achieved with surgical intervention. To 
investigate the role of a possible placebo effect, we conducted a randomized 
controlled study of Sham versus TUMT treatment. Chapter 1 shows that although 
a placebo response indeed is present, compared to the genuine treatment the 
improvement seen after sham accounts for little of the observed benefit. 
Nevertheless, the TUMT results demonstrated a high variability between 
patient's response in both subjective and objective variables. In chapter 2 we 
discuss possible factors that might predict or enhance treatment outcome based on 
data derived from a retrospective trial in 292 patients at 17 centers worldwide. We 
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demonstrated that responders to thermotherapy had a significant higher total 
energy dose administered with significant higher urethral temperatures and fewer 
rectal alarms. Furthermore, the PSA levels after treatment, as an indirect measure 
of intraprostatic temperature, were measured significantly higher in the responder 
group. However, none of the baseline variables used within our study was able to 
define the ideal patient for and predict the result of treatment. 
The durability of response of thermotherapy is discussed in chapter 3. We 
report on a retrospective study on 305 patients that underwent TUMT in two 
European centers. After 3 year follow-up, a total of 133 patients that only had 
TUMT treatment were available. We showed that the improvement in symptom 
score and urinary performance stayed stable over this observation period, with a 
slight symptomatic deterioration after three years. The retreatment rate amounts 
to 48% in 3 years: 80 patients underwent an invasive treatment, and 45 patients 
turned to medical therapy. We reported only little morbidity on short and long term 
follow-up. 
In order to improve treatment efficacy, changes in the treatment protocol 
were made to enable application of higher energy levels. Chapter 4 reports on a 
Phase II multi center study in 116 patients that were treated with this new protocol. 
We showed that the subjective improvement remained comparable with the results 
of former lower-energy protocols. On the other hand, the objective improvement 
was now in the ranges that can be attained after surgical resection of the prostate. 
In the majority of patients, further proof of increased efficacy was shown by a 
significant reduction in bladder outlet obstruction based on urodynamic 
investigations with pressure-flow studies analyses before and 6 months after 
TUMT treatment. The presence of a prostate cavity, 3 months after TUMT in 
almost 40% of patients, also contributes to this. The high energy treatments were 
still possible without anaesthesia and on an outpatient basis. Nevertheless, the post 
treatment retention rate of 100% with a mean catherization time of two weeks in 
combination with irritative complaints during the first 2 to 3 weeks, induced an 
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increased treatment morbidity. 
The initial results of high energy thermotherapy showed that the grade of 
outlet obstruction and the size of the prostate, might be indicative for better 
treatment outcome. We further elaborate on these findings in chapter 5. The 
changes in pressure-flow study parameters in 120 patients that underwent high 
energy TUMT, are discussed. For the total group there appeared to be a substantial 
and clinically relevant reduction in bladder outlet obstruction, that after treatment 
is no longer present in 72% of patients. Further analysis of the stratified baseline 
variables, identified that patients with a prostate volume of more than 40 grams 
with moderate to severe bladder outlet obstruction appeared to be the best 
responders. 
Finally, chapter 6 gives a review on thermotherapy with reiteration and 
comparison of the results of the abovementioned studies with the available data in 
literature. With regard to the results achieved with high energy thermotherapy and 
the probable predictive factors for improved treatment efficacy, we bring up some 
possible answers. The fact that bigger prostates respond better to TUMT might be 
explained by a different composition and vascularization of prostatic tissue. 
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FUTURE PERSPECTIVES 
In chapter 4 and 5 we showed that the efficacy of thermotherapy could be 
enhanced by applying higher energy levels to increase the intraprostatic 
temperature. The results of high energy thermotherapy showed significantly better 
objective improvement over former lower energy protocols with similar subjective 
outcome. However, although the results in subgroup of patients were comparable 
to the results achieved with surgical resection of the prostate, there still was a 
significant group of patients that did not respond favorably. It became apparent 
that the size of the prostate and the grade of bladder outlet obstruction were 
indicative for treatment outcome. This variability might be explained by the 
heterogeneity of the prostatic tissue. The difference in tissue composition and in 
particular the vascularization of the prostate in each individual patient, are likely 
the most important contributing factors. Therefore, to further enhance treatment 
outcome future research efforts should be focused on gaining better insight in 1) 
prostate vascularization, 2) tissue composition, and 3) temperature mapping 
of the prostate which may lead to possible adaptions to the treatment protocol 
and/or devices. Finally, this should be tested in prospective clinical trials based on 
proper 4) selection criteria. 
Prostate vascularization 
Little is known about the difference in vascularization in each individual prostate 
and it's correlation in the response to heat treatment. Tubaro et al. demonstrated 
that there was an enormous increase in prostatic blood flow directly after TUMT 
treatment.' They tried to quantify the amount of increase in blood flow by using 
color Doppler imaging. They concluded that there appeared to be a 12.5 fold 
increase in blood flow mainly in the adenomatous part of the prostate. However, 
presently color Doppler imaging still lacks high reproducibility and quantification 
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is difficult. Therefore, also other ways for visualization and quantification should 
be investigated. Possible solution might be the use of intravascular ultrasound 
contrast agents.2 The ideal contrast contains micro bubbles that are inert, have the 
size of red blood cells with identical velocity profiles and physiologic transit 
times, do not cause systemic hemodynamic effects, and do not alter the bloodflow. 
It therefore can be applied to determine bloodflow, volume and/or perfusion. The 
most important property of ultrasonic contrast agents is their capacity to enhance 
the backscattered signal. This first of all results in images with greater clarity with 
better visualization of the blood vessels. Furthermore, additional digital 
substraction techniques might also be applied to further enhance and to make three 
dimensional imaging possible.1 Different contrast agents are currently being tested. 
Were the first research efforts conducted in the field of cardiology, future research 
may also allow application in prostate imaging. 
Tissue composition 
Imaging of the vascularization of the prostate implies a dynamic process. Whereas 
the determination of the tissue composition of the prostate relies more on a static 
condition. 
The prostate is composed from smooth muscle, fibrous tissue, epithelium and 
glandular lumen. However, the proportion of the various components differs for 
each individual prostate and depends on the prostate size as on the location in the 
prostate.4 This heterogeneity of tissue, with different reactions to microwaves of 
each component, might partly explain the variety of treatment outcome since the 
TUMT theory is essentially based on the application of heat to homogenous tissue. 
Therefore, to correlate treatment outcome with prostate composition, histology is 
necessary. Hefty et al. showed that a there was difference in the stromal-epithelial 
ratio of the transition zone of the prostate between patients who failed and who 
were successful to treatment with laser.5 The specimens for histology were derived 
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from pretreatment prostatic biopsies. Similar studies to correlate treatment 
outcome after TUMT are currently being conducted. Drawback of these studies is 
the invasive way to obtain histology with consequent risks,6 and the number and 
positions in the prostate from which the biopsies can be taken are limited. 
Therefore, possible noninvasive methods that can cover the complete prostate 
would be ideal. Presently, computerized analysis of ultrasound images is superior 
to conventional interpretation of transrectal ultrasound imaging of the prostate in 
the detection of prostate carcinoma. An image analysis technique based on the 
correlation of statistical texture descriptions computed from ultrasound prostate 
images with the histopathology of the tissue imaged (AUDEX), makes 
differentiation between benign and malignant prostate tissue possible.7 Possibly, 
similar techniques can be applied when assessing the stromal-epithelial ratio to 
enable prostate tissue mapping. 
Temperature mapping 
The abovementioned methods that might give insight in the dynamic and static 
properties of the prostate composition, do not elucidate the actual effect that heat 
has on prostatic tissue. Possibly temperature mapping contributes to a better 
understanding. 
The ideal treatment protocol would be the one that continuously measures the 
intraprostatic temperature at multiple levels in the prostate to form a feedback 
system with the energy delivery system to regulate the determined temperatures. 
Thermometry studies have been performed by applying intraprostatic temperature 
sensors by the perineal route.89 Major drawback is the invasive nature of this 
procedure which limits the amount of sensors. Furthermore, they only measure the 
temperature at predetermined sensor locations, which might not correspond to the 
actual tissue location of interest. Hence, a non-invasive temperature feedback 
method should be investigated that can cover the whole prostatic region. 
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Ultrasound is capable to depict tissue temperature changes by measuring shifts in 
the reflected signals that are proportional to the change in tissue temperature.1" 
Therefore, the theory to combine transrectal ultrasound temperature mapping of 
the prostate with the heat delivery system to establish a feedback system, offers 
unique opportunities to greatly enhance treatment efficacy. 
Selection criteria 
Major research efforts should be aimed at achieving insight in the fundamental 
dynamic and static properties of the prostate to make adaptions to either the 
treatment protocol and/or devices and initiation of clinical trials with proper 
selection criteria possible. 
The present thesis has shown that from all the baseline parameters, prostate size 
and bladder outlet obstruction were indicative for treatment outcome. However, 
although transrectal ultrasound of the prostate is a common assessment tool in 
patients with benign prostatic hyperplasia, the use of urodynamic investigations 
with pressure-flow studies is still a matter of debate due to the invasive character 
of the procedure, the costs and the availability of the equipment and personnel." 
Therefore, future clinical trials in thermotherapy could greatly benefit from any 
noninvasive and easy accessible assessment tools, like the options which have 
been discussed in the above paragraphs, that are able to distinguish between 
patients and are predictive for treatment outcome. 
We close with the observation that the objective for further studies must be to 
determine the thermal dose that will still maintain a safe treatment with clinically 
significant improvement in subjective and objective parameters, whilst causing 
minimum morbidity after treatment. Only by identifying and applying the proper 
selection criteria, maximum benefit of thermotherapy can be achieved. 
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SAMENVATTING EN TOEKOMSTPERSPECTIEVEN 

SAMENVATTING 
Decennia lang is de chirurgische verwijdering van prostaatweefsel de enige 
oplossing voor blaasuitgangsobstructie bij mannen geweest. De laatse zestig jaar 
is de transurethrale resectie van de prostaat zodanig geperfectioneerd, dat het 
hedentendage een veilige ingreep is. Echter de met deze ingreep samenhangende 
morbiditeit, het kostenaspect, alsmede de vraag van patiënten naar niet operatieve 
alternatieven, hebben geleid tot de ontwikkeling van diverse minder invasieve als 
ook medicamenteuze behandelingsvormen. 
Vrijwel alle alternatieve minimaal invasieve technieken maken gebruik van 
warmte die op verschillende manieren kan worden toegediend. Het uiteindelijke 
doel van deze warmtetoediening is de destructie en de verwijdering van 
prostaatweefsel. Diverse technieken zijn beschikbaar, echter het gebruik van 
microgolven wordt het meest toegepast. Dit proefschrift beschrijft diverse 
klinische studies met betrekking tot een nieuwe behandelingsvorm voor oudere 
mannen met mictieklachten en een goedaardige prostaatvergroting, de zogenaamde 
TUMT-behandeling (Transurethrale Microgolf Thermotherapie). Verder is 
geprobeerd verbeteringen van deze techniek, mogelijke prognostische factoren, 
toekomstverwachtingen en onderwerpen voor verder onderzoek, te verduidelijken. 
De eerste resultaten van TUMT lieten weliswaar duidelijke symptomatische 
verbeteringen zien, echter de objectieve verbetering was minder uitgesproken en 
niet te vergelijken met resultaten die werden bereikt met een operatief ingrijpen. 
Om uit te zoeken of een mogelijk placebo-effect een rol speelde, is een placebo 
gecontroleerde en gerandomiseerde studie uitgevoerd. Hoofdstuk 1 maakt duidelijk 
dat een er inderdaad een placebo effect aanwezig is. Echter in vergelijking met een 
daadwerkelijke thermotherapie behandeling, draagt het placebo effect slechts 
weinig bij tot het uiteindelijk verkregen resultaat. 
Desalniettemin vertoonden de resultaten een grote interindividuele 
variabiliteit in de mate van symptomatische en objectieve verbetering. 
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Hoofdstuk 2 beschrijft een retrospectieve studie van 292 patiënten uit 17 
internationale centra, waarin werd gepoogd mogelijke predictieve parameters te 
identificeren die het behandelingsresultaat konden verbeteren of voorspellen. Het 
bleek dat patiënten die goed reageerden op behandeling een significant hogere 
totale hoeveelheid energie hadden toegediend gekregen waarbij hogere urethrale 
temperaturen en minder rectale triggers gevonden werd. Tevens bleek dat de PSA-
stijging na behandeling, wat indirect een maat is voor het bereikte effect in de 
prostaat, significant hoger was bij patiënten waarbij de behandeling succes had. 
Echter geen van de basis-parameters was in staat de ideale patient te identificeren. 
Noch was het mogelijk om hiermee het behandelingsresultaat van thermotherapie 
te voorspellen. 
De lange termijn resultaten en duurzaamheid van de thermotherapie, worden 
behandeld in hoofdstuk 3. Hierin wordteen retrospectieve studie van 305 patiënten 
beschreven die een TUMT behandeling hadden ondergaan in twee Europese 
centra. Na 3 jaar waren 133 patiënten beschikbaar die alleen een TUMT 
behandeling hadden gehad. De subjectieve en objectieve verbetering bleef 
gedurende deze periode min of meer stabiel, hoewel er een geringe 
symptomatische verslechtering optrad 3 jaar na behandeling. In totaal werd 49% 
van de patiënten herbehandeld. Bij 80 patiënten werd alsnog een operatieve 
behandeling uitgevoerd en 45 patiënten stapten over op een medicamenteuze 
behandeling. De morbiditeit van thermotherapie op zowel korte als lange termijn, 
bleek gering te zijn. 
Om het behandelingsresultaat te verbeteren, werd het TUMT-protocol 
aangepast om behandeling op een hoger energie niveau mogelijk te maken. 
Hoofdstuk 4 beschrijft een fase 2 studie van 116 patiënten die behandeld werden 
met dit nieuwe hoge energie protocol. De symptomatische verbetering bleef 
vergelijkbaar met eerdere protocollen. De objectieve verbetering daarentegen liet 
nu resultaten zien die te vergelijken waren met de resultaten van een chirurgische 
interventie. De meerderheid van de patiënten liet een significante daling van de 
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blaasuitgangsobstructie zien. Dit werd duidelijk gemaakt met blaasdrukmetingen 
die voor en 6 maanden na behandeling werden uitgevoerd. Het vinden van een 
caviteit in de prostaat bij echografisch onderzoek bij bijna 40% van de patiënten, 
is een verdere aanwijzing dat de behandeling effectiever is. Deze hoge energie 
TUMT behandelingen zijn nog steeds mogelijk zonder narcose en op poliklinische 
basis. Daarentegen is er sprake van een toegenomen morbiditeit die zich met name 
uit in de noodzaak om na de behandeling een transurethrale catheter te plaatsen bij 
alle patiënten. Gedurende gemiddeld twee weken dient deze catheter te blijven 
zitten en de patient kan in de eerste 2 tot 3 weken irritatieve klachten ondervinden 
die van voorbijgaande aard zijn. 
De eerste resultaten van de hoge energie behandelingen lieten zien dat de 
grootte van de prostaat en de mate van blaasuitgangsobstructie bepalend waren 
voor een beter behandelingsresultaat. In hoofdstuk 5 gaan we verder in op deze 
bevindingen. De verbeteringen in blaasdrukmeting van 120 patiënten die werden 
behandeld met hoge energie TUMT, worden hier beschreven. De gehele groep laat 
een aanzienlijke en klinisch significante vermindering van de blaasuitgangs-
obstructie zien, waar bij 72% van de patiënten na behandeling geen obstructie 
meer aanwezig is. Verdere analyse van de basis parameters laat zien dat patiënten 
met een prostaatvolume van meer dan 40 cm1 en matig tot ernstige blaasuitgangs-
obstructie het best reageerden op hoge energie TUMT behandelingen. 
In hoofdstuk 6 wordt een overzicht gegeven van de literatuur met betrekking 
tot thermotherapie en worden de resultaten van de in dit proefschrift vermelde 
studies vergeleken met reeds eerder uitgevoerde onderzoeken. Verder wordt 
ingegaan op het feit dat het betere behandelingsresultaat van hoge energie TUMT 
behandelingen bij patiënten met grotere prostaten verklaard zou kunnen worden 
door een verschil in bloedvoorziening en samenstelling van het prostaatweefsel. 
In het laatste hoofdstuk wordt vervolgens ingaan op de toekomst-
perspectieven. Er zal fundamenteel onderzoek verricht moeten worden naar 
diverse dynamische en statische eigenschappen van prostaatweefsel met 
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betrekking tot de reactie op door microgolven gegenereerde warmte. De 
belangrijkste dynamische factor ¡s de bloedvoorziening van de prostaat. 
Kwantificatie van de vascularisatie met color Doppler behoort tot een van de 
mogelijkheden. Wellicht kan de toediening van intraveneus echocontrast hier 
eveneens tot bijdragen. De samenstelling van de prostaat kan middels echogeleide 
prostaatpuncties worden vastgesteld en gecorreleerd worden met het bereikte 
behandelingsresultaat. Andere minder invasieve methoden zoals beeldanalyse 
technieken, behoren wellicht ook tot de mogelijkheden. Bij een ideale 
thermotherapie behandeling zou het mogelijk moeten zijn een directe 
terugkoppeling te verkrijgen met de in de prostaat gemeten temperatuur. De 
temperatuur in de prostaat kan bepaald worden met behulp van in de prostaat 
geplaatste optische thermosensoren. Nieuwe ontwikkelingen in de echografie, 
maken het wellicht ook mogelijk op een niet invasieve wijze de temperatuur te 
meten. 
Toekomstige klinische studies kunnen zeker profiteren van de hierboven 
genoemde technieken. Het zal patientenselectie mogelijk maken en behandelings-
resultaat kunnen voorspellen. Om het maximale effect van thermotherapie te 
realiseren, zal het uiteindelijke doel moeten zijn de juiste energiedosis te vinden 
die een veilige behandeling garandeert met een zo gering mogelijke morbiditeit en 
die tevens een klinisch relevante verbetering in zowel subjectieve als objectieve 
parameters laat zien. 
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Stellingen behorende bij het proefschrift 
Transurethral Microwave Thermotherapy 
an evolving technology ¡η the treatment of 
benign prostatic enlargement 
door 
Michel J.A.M. de Wildt 
Nijmegen, 24 september 1996 
1 De wonderlijke combinatie van stralingswarmte en koude-
geleiding vormt de basis van het thermotherapie principe. 
Dit proefschrift 
2 Zonder twijfel is thermotherapie meer dan alleen placebo. 
Dit proefschrift 
3 Hoe groter de prostaat, des te beter het resultaat. 
Dit proefschrift 
4 Het urodynamisch onderzoek lijkt vooralsnog alleen bij 
thermotherapie van prognostische waarde te zijn voor het 
te bereiken behandelingsresultaat. 
Dit proefschrift 
5 De hoogte van de individuele symptoom score is noch voor 
de patient noch voor de uroloog van enige waarde. 
Dit proefschrift 
6 Gezien de goede resultaten van thermotherapie bij BPH rijst 
de vraag of de transurethrale resectie van de prostaat nog 
wel als 'gouden standaard' moet worden beschouwd. 
Dit proefschrift 
7 Nog steeds geldt dat de numerus fixus voor de studie 
Geneeskunde met name gebaseerd is op kans en niet op de 
mate van intelligentie. 
8 Specialisatie leidt tot artsen die steeds meer weten over 
steeds minder. 
9 Hoe lager de frequentie, des te dieper de penetratie, is niet 
alleen een fysisch verschijnsel. 
10 De behandelend arts van de prostaat-magnetron is net als 
een chefkok bij het braden met boter: voor het beste resultaat 
dient hij 'er wel even bij te blijven'. 
11 Het als dokter promoveren tot doctor in de Medische 
Wetenschappen betekent niet per definitie dat de 
geneeskunde ook ten volle wordt beheerst. 
12 'Even at the center of fire there is cold' ( by *¥* ) 

